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 i 
Abstract 
 
     Accumulating evidence suggest that Bcl-xL, an anti-apoptotic member of the Bcl-
2 family, also functions in cell cycle progression and cell cycle checkpoints. To further 
understand Bcl-xL regulation and function in cell cycle progression, we first expressed a 
series of single-point Bcl-xL cDNA phospho-mutants, including Thr41Ala, Ser43Ala, 
Thr47Ala, Ser49Ala, Ser56Ala, Ser62Ala and Thr115Ala in human cancer cell lines and 
investigated their impact on cell cycle progression.   
     Analysis of this series of phosphorylation mutants reveals that cells expressing 
Bcl-xL(Ser62Ala) mutant are less stable at the G2 checkpoint and enter mitosis more 
rapidly than cells expressing wild type Bcl-xL or Bcl-xL phosphorylation mutants, 
including Thr41Ala, Ser43Ala, Thr47Ala, Ser56Ala and Thr115Ala. Dynamic 
phosphorylation and location studies on phospho-Bcl-xL(Ser62) in unperturbed, 
synchronized cells and during DNA damage-induced G2 arrest revealed that phospho-
Bcl-xL(Ser62) translocates into nucleolar structures in VP16-exposed cells during G2 
arrest. Using in vitro kinase assays, pharmacological inhibitors and specific siRNAs 
experiments, we found that Polo kinase 1 and MAPK9/JNK2 are major protein kinases 
involved in Bcl-xL(Ser62) phosphorylation and accumulation into nucleolar structures 
during the G2 checkpoint. In nucleoli, phospho-Bcl-xL(Ser62) binds to and co-localizes 
with CDK1(CDC2), the key cyclin-dependent kinase required for entry into mitosis. 
These data indicate that, during G2 checkpoint, phospho-Bcl-xL(Ser62) stabilizes G2 
arrest by timely trapping CDK1(CDC2) in nucleolar structures to slow mitotic entry. It 
also highlights that DNA damage affects the dynamic composition of the nucleolus, 
which now emerges as a key event in the DNA damage response. 
 In a second study, we describe that cells expressing Bcl-xL(Ser62Ala) are also more 
stable at a sustained spindle-assembly checkpoint (SAC) after exposure to taxol than cells 
expressing wild-type Bcl-xL or other mutants, an effect that appears to be independent of 
its anti-apoptotic activity. Bcl-xL(Ser62) is strongly phosphorylated by PLK1 and 
MAPK14/SAPKp38α at prometaphase, metaphase and the anaphase boundary, while it is 
dephosphorylated at telophase and cytokinesis. Phospho-Bcl-xL(Ser62) localizes in 
centrosomes with γ-tubulin, along the mitotic spindle with dynein motor protein and in 
cytosol with SAC signaling components. In taxol-exposed cells, phospho-Bcl-xL(Ser62) 
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binds to the CDC20/MAD2/BUBR1/BUB3 complex, while Bcl-xL(Ser62Ala) does not. 
The data indicate that during SAC, Bcl-xL(Ser62) phosphorylation accelerates SAC 
resolution and cell entry into anaphase, even in the presence of unattached or misaligned 
chromosomes. Silencing Bcl-xL expression also leads nocodazole-exposed cells to 
tetraploidy and binucleation, consistent with a Bcl-xL function in SAC and genomic 
stability. 
     In the third study, the functional analysis of a Bcl-xL phosphorylation mutant 
series has revealed that cells expressing Bcl-xL(Ser49Ala) mutant are less stable at G2 
checkpoint after DNA damage and enter cytokinesis much more slowly after microtubule 
poisoning than cells expressing wild-type Bcl-xL. These effects of Bcl-xL(Ser49Ala) 
mutant seem to be distinct from Bcl-xL function in apoptosis. Bcl-xL(Ser49) 
phosphorylation is cell cycle-dependent. In synchronized cells, phospho-Bcl-xL(Ser49) 
appears during the S phase and G2, whereas it disappears rapidly in early mitosis during 
prometaphase, metaphase and early anaphase, and re-appears during telophase and 
cytokinesis. During DNA damage-induced G2 arrest, an important pool of phospho-Bcl-
xL(Ser49) accumulates in centrosomes which act as essential decision centers for 
progression from G2 to mitosis. During telophase/cytokinesis, phospho-Bcl-xL(Ser49) is 
found along microtubules and at midbody with dynein motor protein. In a series of in 
vitro kinase assays, specific small interfering RNA and pharmacological inhibition 
experiments, polo kinase 3 (PLK3) was implicated in Bcl-xL(Ser49) phosphorylation. 
These data indicate that during G2 checkpoint phospho-Bcl-xL(Ser49) is another 
downstream target of PLK3, acting to stabilize G2 arrest. Bcl-xL phosphorylation at 
Ser49 also correlates with essential PLK3 activity and function, enabling cytokinesis and 
mitotic exit.  
 
Key words: Bcl-xL, phosphorylation, cell cycle, G2 checkpoint, spindle-assembly 
checkpoint. 
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Resumé 
     Quelques évidences suggèrent que Bcl-xL, un membre anti-apoptotique de la 
famille Bcl-2, possède également des fonctions au niveau du cycle cellulaire et de ses 
points-contrôle. Pour étudier la régulation et fonction de Bcl-xL au cours du cycle 
cellulaire, nous avons généré et exprimé dans des cellules humaines une série de mutants 
de phosphorylation incluant Thr41Ala, Ser43Ala, Thr47Ala, Ser49Ala, Ser56Ala, 
Ser62Ala et Thr115Ala. 
     L'analyse de cette série de mutants révèle que les cellules exprimant Bcl-
xL(Ser62Ala) sont moins stables au point-contrôle G2 du cycle cellulaire comparées aux 
cellules exprimant le type sauvage ou les autres mutants de phosphorylation incluant 
Thr41Ala, Ser43Ala, Thr47Ala, Ser56Ala et Thr115Ala. Les études de cinétiques de 
phosphorylation et de localisation de phospho-Bcl-xL(Ser62) dans des cellules 
synchronisées et suite à l'activation du point-contrôle en G2 médié par l'étoposide 
(VP16), nous indiquent que phospho-Bcl-xL(Ser62) migre dans les corps nucléolaires 
durant l'arrêt en G2 dans les cellules exposées au VP16. Une série d'expériences incluant 
des essais kinase in vitro, l'utilisation d'inhibiteurs pharmacologiques et d'ARN 
interférant, nous révèlent que Polo kinase 1 (PLK1) et MAPK9/JNK2 sont les protéines 
kinase impliquées dans la phosphorylation de Bcl-xL(Ser62), et pour son accumulation 
dans les corps nucléolaires pendant le point-contrôle en G2. Nos résultats indiquent que 
durant le point-contrôle en G2, phospho-Bcl-xL(Ser62) se lie et se co-localise avec 
CDK1(CDC2), le complexe cycline-kinase qui contrôle l'entrée en mitose. Nos résultats 
suggèrent que dans les corps nucléolaires, phospho-Bcl-xL(Ser62) stabilise l'arrêt en G2 
en séquestrant CDK1(CDC2) pour retarder l'entrée en mitose. Ces résultats soulignent 
également que les dommages à l'ADN influencent la composition des corps nucléolaires, 
structure nucléaire qui émerge maintenant comme une composante importante de la 
réponse aux dommages à l'ADN.  
 Dans une deuxième étude, nous décrivons que les cellules exprimant le mutant de 
phosphorylation Bcl-xL(Ser62Ala) sont également plus stables au point-contrôle de 
l'assemblage du fuseau de la chromatine (SAC) suite à une exposition au taxol, 
comparées aux cellules exprimant le type sauvage ou d'autres mutants de phosphorylation 
de Bcl-xL, incluant Thr41Ala, Ser43Ala, Thr47Ala, Ser56Ala. Cet effet est indépendent 
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de la fonction anti-apoptotique de Bcl-xL. Bcl-xL(Ser62) est fortement phosphorylé par 
PLK1 et MAPK14/SAPKp38α à la prométaphase, la métaphase et à la frontière de 
l'anaphase, et déphosphorylé à la télophase et la cytokinèse. Phospho-Bcl-xL(Ser62) se 
trouve dans les centrosomes avec γ-tubuline, le long du fuseau mitotique avec la protéine 
moteure dynéine et dans le cytosol mitotique avec des composantes du SAC. Dans des 
cellules exposées au taxol, phospho-Bcl-xL(Ser62) se lie au complexe inhibiteur 
CDC20/MAD2/BUBR1/BUB3, alors que le mutant Bcl-xL(Ser62Ala) ne se lie pas à ce 
complexe. Ces résultats indiquent que durant le SAC, la phosphorylation de Bcl-
xL(Ser62) accélère la résolution du SAC et l'entrée des cellules en anaphase. Des 
expériences bloquant l'expression de Bcl-xL révèlent ègalement un taux très élevé de 
cellules tétraploïdes et binuclées après un traitement au nocodazole, consistant avec une 
fonction de Bcl-xL durant la mitose et dans la stabilité génomique.  
 Dans la troisième étude, l'analyse fonctionnelle de cette série de mutants de 
phosphorylation indique également que les cellules exprimant Bcl-xL(Ser49Ala) sont 
moins stables durant le point-contrôle G2 et entre en cytokinèse plus lentement dans des 
cellules exposées aux inhibiteurs de la polymérisation/dépolymérisation des tubulines, 
composantes des microtubules. Ces effets de Bcl-xL(Ser49Ala) sont indépendents de sa 
fonction anti-apoptotique. La phosphorylation de Bcl-xL(Ser49) est dynamique au cours 
du cycle cellulaire. Dans des cellules synchronisées, Bcl-xL(Ser49) est phosphorylé en 
phase S et G2, déphosphorylé à la prométaphase, la métaphase et à la frontière de 
l'anaphase, et re-phosphorylé durant la télophase et la cytokinèse. Au cours du point-
contrôle G2 induit par les dommages à l'ADN, un pool important de phospho-Bcl-
xL(Ser49) se trouve aux centrosomes, un site important pour la régulation de l'entrée en 
mitose. Durant la télophase et la cytokinèse, phospho-Bcl-xL(Ser49) se trouve le long des 
microtubules avec la protéine moteure dynéine et dans le cytosol mitotique. Finalement, 
nos résultats suggèrent que PLK3 est responsable de la phosphorylation de Bcl-
xL(Ser49), une protéine kinase impliquée pour l'entrée des cellules en mitose et pour la 
progression de la mitose jusqu'à la division cellulaire.  
 
Mots-clé: Bcl-xL, phosphorylation, cycle cellulaire, point-contrôle G2, mitose. 
 v 
Contents 
 
Abstract..................................................................................................................     i 
Résumé...................................................................................................................    iii 
Contents..................................................................................................................    v 
List of Figures.........................................................................................................   viii 
Abbreviations..........................................................................................................     x 
Acknowledgements.................................................................................................   xiii 
 
 
1.Introduction..........................................................................................................    1
 1.1  Cell cycle and the cyclin/CDK complexes....................................................     3 
 1.2  Cell cycle checkpoints...................................................................................    5 
 1.3  Regulatory networks controlling the G2 cell cycle checkpoint.....................    7 
   1.3.1  CyclinB1/CDK1(CDC2) complex..........................................................   7 
   1.3.2  The ATR-CHK1 and ATM-CHK2 network pathways..........................    8 
   1.3.3   MAPK14/SAPKp38α signaling pathway.............................................    9 
 1.4  The spindle assembly checkpoint..................................................................    10 
   1.4.1  The anaphase promoting complex /cyclosome and CDC20..................    10  
   1.4.2 MAD2- and BUBR1-bound CDC20 inhibitory complexes ...................    12 
   1.4.3 Dismantling the SAC..............................................................................    16 
 1.5  The mitotic exit signaling network................................................................    17 
 1.6  Bcl-xL function in apoptosis.........................................................................    20  
   1.6.1 p53-dependent and -independent activation...........................................    23 
 1.7  Bcl-2 family members and cell cycle ...........................................................    24 
 
2.  Rationale of the thesis........................................................................................    26 
 2.1 Goal, hypothesis and specific objectives........................................................    26 
 2.2 Presentation of the appended manuscripts......................................................    27 
 2.3 Contribution of co-authors..............................................................................    27 
 
3.  Phospho-Bcl-xL(Ser62) plays a key role at the G2 checkpoint.........................    28 
  3.1 Abstract..........................................................................................................    29 
  3.2 Introduction...................................................................................................    30 
 vi 
  3.3 Results...........................................................................................................    31 
  3.4 Discussion.....................................................................................................    35 
  3.5 Materials and Methods..................................................................................    39 
  3.6 Acknowledgement.........................................................................................    41 
  3.7 References.....................................................................................................    42 
  3.8 Figures...........................................................................................................    45 
  3.9 Supplemental Data........................................................................................    55 
 
4. Phospho-Bcl-xL(ser62) in spindle assembly checkpoint  
    and mitosis progression......................................................................................    69 
  4.1 Abstract.........................................................................................................    70 
  4.2 Introduction...................................................................................................    71 
  4.3 Results...........................................................................................................    72 
  4.4 Discussion.....................................................................................................    77 
  4.5 Materials and Methods..................................................................................    79 
  4.6 Acknowledgement.........................................................................................    81 
  4.7 References.....................................................................................................    82 
  4.8 Table..............................................................................................................    87 
  4.9 Figures...........................................................................................................    88 
 4.10 Supplemental Data.......................................................................................  100 
 
5.  Bcl-xL phosphorylation on Ser49 by polo kinase 3 during G2  
  and cytokinesis..................................................................................................  113 
  5.1Abstract..........................................................................................................  114 
  5.2 Introduction...................................................................................................  115 
  5.3 Results...........................................................................................................  117 
  5.4 Discussion.....................................................................................................  121 
  5.5 Materials and Methods..................................................................................  123 
  5.6 Acknowledgement.........................................................................................  125 
  5.7 References.....................................................................................................  126 
  5.8 Figures...........................................................................................................  131 
 vii 
 5.9 Supplemental Data..........................................................................................  139 
 
6. Discussion...........................................................................................................  144 
 6.1 Bcl-xL and its unstructured flexible loop domain..........................................  144 
 6.2 Bcl-xL phosphorylation and the cell cycle.....................................................  145 
   6.2.1 Bcl-xL and the MAPK family................................................................  145 
   6.2.2 Bcl-xL and polo kinase family...............................................................  147 
   6.2.3 Bcl-xL and CDK1(CDC2) kinase..........................................................  148 
 6.3 Phospho-Bcl-xL(Ser62) and (Ser49) location................................................  149 
   6.3.1 Phospho-Bcl-xL(Ser49) and (Ser62)  and centrosomes.........................  149 
   6.3.2 Phospho-Bcl-xL(Ser62) and nucleoli.....................................................  150 
   6.3.3 Phospho-Bcl-xL(Ser62) and Cajal bodies..............................................  150 
   6.3.4 Phospho-Bcl-xL(Ser49) and (Ser62) and microtubules.........................  151 
 6.4 Bcl-xL, cell survival  and genomic stability...................................................  151 
 
7. Conclusion..........................................................................................................  154 
 7.1 Major findings................................................................................................  154 
 7.2 Future directions.............................................................................................  155 
 
8. Bibliography........................................................................................................  158 
 
 viii 
List of Figures 
 
1. Introduction 
 
  Figure 1  Bcl-xL structure and putative phosphorylation sites within the  
         unstructured flexible loop domain......................................................     2 
  Figure 2  Illustration of the 4 phases of the cell cycle.......................................     3 
  Figure 3  A) Expression of human cyclins through the cell cycle.....................     4 
         B) Major CDK/cyclin complexes during cell cycle progression..... ..      5   
  Figure 4  Schematic view ell responses to DNA damage.................................      6 
   Figure 5  The G2/M cell cycle checkpoint........................................................    10 
   Figure 6  Signaling network during the SAC....................................................    13 
   Figure 7  Model of APC/C-CDC20 regulation at the SAC...............................   16 
   Figure 8  Kinetics of CDK1(CDC2) activity through mitotic progression.......    18 
   Figure 9  The Bcl-2 family members................................................................    20 
   Figure 10  The mode of action of Bcl-2 family members................................ ..    22 
   Figure 11 Bcl-2, Mcl-1, Bid and Bcl-xL on cell cycle progression...................    24 
 
   
3.  Phospho-Bcl-xL(Ser62) plays a key role at the G2 checkpoint 
 
  Figure 1  Effect of Bcl-xL and Bcl-xL(Ser62Ala) phosphorylation 
         mutant on DNA damage-induced G2 arrest.....................................    45 
   Figure 2  HA-Bcl-xL(Ser62) phosphorylation and location during  
         DNA damage-induced G2 arrest.......................................................    47 
   Figure 3  Endogenous Bcl-xL(Ser62) phosphorylation and location in  
         unperturbed synchronized cells and during DNA damage- 
         induced G2 arrest...............................................................................    49 
   Figure 4  PLK1 and MAPK9/JNK2 are major protein kinases involved  
         in Bcl-xL(Ser62) phosphorylation.....................................................    51 
   Figure 5  Phospho-Bcl-xL(Ser62) meets CDK1(CDC2) in nucleolar  
         structures during DNA damage-induced G2 arrest............................   53 
 ix 
  Supplemental  Data.............................................................................................   55 
  
4. Phospho-Bcl-xL(Ser62) in spindle-assembly checkpoint and mitosis progression 
 
  Figure 1  Effect of Bcl-xL and Bcl-xL(Ser62Ala) phosphorylation mutant 
         on the stability of the SAC...............................................................   88 
   Figure 2  Bcl-xL(Ser62) phosphorylation and location in synchronized 
         wt HeLa cells at mitosis....................................................................    90 
   Figure 3  Bcl-xL(Ser62) phosphorylation and location in taxol-exposed 
          wt HeLa cells....................................................................................    92 
   Figure 4  Effect of silencing Bcl-xL expression on the stability and  
         resolution of the SAC........................................................................    94 
   Figure 5  PLK1 and MAPK14/SAPKp38α are major protein kinases  
         involved in Bcl-xL(Ser62) phosphorylation at mitosis......................   96 
   Figure 6  Phospho-Bcl-xL(Ser62) interacts with SAC components.................    98 
   Supplemental Data.............................................................................................. 100 
 
 
5.  Bcl-xL phosphorylation on ser49 by polo kinase 3 during G2 and cytokinesis 
 
   Figure 1  Effect of Bcl-xL and Bcl-xL(Ser49Ala) phosphorylation mutant 
          on G2 checkpoint resolution and entry into cytokinesis..................... 131 
   Figure 2  Bcl-xL(Ser49) phosphorylation and location during DNA  
         damage-induced G2 arrest and in unpertubed, synchronized  
         wt Hela cells at interphase.................................................................. 133 
   Figure 3  Bcl-xL(Ser49) phosphorylation and location during  
         mitosis progression............................................................................. 135 
   Figure 4  PLK3 is involved in Bcl-xL(Ser49) phosphorylation........................  137 
  Supplemental Data.............................................................................................. 139 
 
6. Discussion 
 
   Figure 12  Schematic illustration of major findings in these studies................  153 
 x 
Abbreviations 
 
Ala, alanine; 
APC/C, anaphase-promoting complex/cyclosome;  
Asp, aspartic acid; 
ATM, Ataxia telangiectasia mutated (kinase); 
ATR, ataxia telangiectasia and rad-3-related (kinase); 
Bax, Bcl-2-associated X protein; 
Bak, Bcl-2 homologous antagonist-killer; 
Bcl-2, B cell leukemia/lymphoma protein 2;  
Bcl-xL, Bcl-2-related gene X, long isoform;  
BH, Bcl-2 homology domain;  
Bid, BH3 interacting death agonist; 
Bim, Bcl-2-like protein 11; 
BUB, budding uninhibited by benzimidazole protein;  
CDC, cell division cycle (protein);  
CDK, cyclin-dependent kinase;  
CENP, centromere protein ;  
CHK, checkpoint kinase ;  
CLIP170, cytoplasmic linker protein 170;  
CPT, camptothecin 
DAPI, 4',6'-diamidino-2-phénylindole; 
DNA, deoxyribonucleic acid; 
GSK3, glycogen synthase kinase 3;  
 xi 
h, hour; 
H1, histone 1; 
H3, histone 3;  
HA, influenza hemagglutinin epitope tag;  
HEC1; highly expressed in cancer protein 1;  
JNK, Jun N-terminal kinase;  
MAD, mitotic arrest deficient protein;  
MAPK, mitogen-activated protein kinase;  
MAPKAPK2, mitogen-activated protein kinase-activated protein kinase 2;  
Mcl-1, myeloid cell leukemia sequence 1; 
min, minute; 
ml, milliliter; 
mM; millimolar; 
MPS1, monopolar spindle 1 kinase;  
nM, nanomolar; 
PCNA, proliferating cell nuclear antigen; 
PCR, polymerase chain reaction;  
PI, propidium iodide;  
PICH, polo-interacting checkpoint helicase; 
PLK, polo kinase;  
Puma, p53 upregulated modulator of apoptosis; 
Rad-3, radiation gene 3; 
RNA, Ribonucleic acid; 
 xii 
RNAi, RNA interference; 
SAC, spindle-assembly checkpoint;  
SAPK, stress-activated protein kinase;  
Ser, serine; 
siRNA, small interfering RNA;  
Thr, threonine; 
Tyr, tyrosine; 
mg, milligram 
µg, microgram 
mM, micromolar 
VP16, etoposide;  
wt, wild-type. 
 xiii 
 
Acknowledgements 
 
I gratefully thank my supervisor, Dr. R Bertrand, for his support, help, advice and 
discussion during this research program.  I also want to thank other members of the 
laboratory, Myriam, Nicolas and Sandra, and of Estelle Schmitt' laboratory for their 
helpful and resourceful discussion.  The editorial work of Mr. Ovid Da Silva is much 
appreciated. 
 
 
Special though to all my family - mother, father, sisters and brothers - and my friends. 
 
 
I want to thank and mention studentship support from the China Scholarship Council, 
Faculté des études supérieures de l'Université de Montréal and the Fondation de l'Institut 
du cancer de Montréal. This project was funded by Canadian Institutes for Health 
Research. 
  
 1 
 1. Introduction 
  Over the last 15 years, close links between the cell cycle and apoptosis in cancer 
development and tumor reactions to cancer treatment have become eminently apparent 1-
6. In response to cancer chemotherapeutic drugs and radiotherapy, cells rapidly trigger the 
apoptotic program 7-9 or undergo cell cycle arrest 10-15, followed or not by premature 
senescence 16-20. The Bcl-2 family of proteins stands out among the most crucial 
regulators of apoptosis and performs a vital function in controlling whether a cell will 
live or die after cancer chemotherapy and radiotherapy 21-30. In addition, several studies 
have revealed that members of this family also interface with the cell cycle 20, 31-46 and 
DNA repair pathways 47-51, effects that are generally separable from their function in 
apoptosis. 
 Before I started my Ph.D., our laboratory reported that Bcl-xL, an anti-apoptotic 
Bcl-2 family member, in addition to counteracting BH3-only protein-mediated cell death 
signals after cancer chemotherapy, interfaces with the cell cycle checkpoint, stabilizes the 
G2 cell cycle checkpoint and favors the establishment of premature senescence in 
surviving cells after DNA topoisomerase I and II inhibitor treatments 20. We also reported 
that Bcl-xL co-localizes with cyclin-dependent kinase 1 (cell division cycle 2) 
(CDK1(CDC2)) in nucleolar structures and binds to CDK1(CDC2) during the G2 
checkpoint, whereas its overexpression stabilizes G2 arrest and premature senescence in 
surviving cells after DNA damage. Bcl-xL potently inhibits CDK1(CDC2) kinase 
activities. In in vitro kinase assays using recombinant Bcl-xL protein, this effect was 
reversed by a synthetic peptide between the 41st to 60th amino acids, a region rich in Ser- 
and Thr-phosphorylated residues within the flexible loop domain of Bcl-xL. A mutant 
deleted from the region (Bcl-xLΔP3) did not alter the anti-apoptotic function of Bcl-xL, 
but impeded its effect on CDK1(CDC2) activities and on the G2 checkpoint after DNA 
damage 20. The fact that this Bcl-xL region (Figure 1) contains several putative 
phosphorylation sites strongly suggests that Bcl-xL phosphorylation level may govern 
Bcl-xL regulation and function in cell cycle checkpoints.  
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Figure 1. Bcl-xL structure and putative phosphorylation sites within the unstructured 
flexible loop domain. Upper right inset: schematic representation of the 3D structure of 
Bcl-xL (A) and Bcl-xL bound to a BH3 ligand (B) (From Youle and Strasser 52). The 
unstructured flexible loop domain has been added to the illustration. 
 
 During my research program, we generated a series of single-point Bcl-xL cDNA 
phospho-mutants, including Thr41Ala, Ser43Ala, Thr47Ala, Ser49Ala, Ser56Ala, 
Ser62Ala and Thr115Ala, and expressed them in human cancer cell lines. We designed 
experimental assays to measure the stability of etoposide (VP16)-induced G2 arrest and 
microtubule poisoning-induced spindle-assembly checkpoint (SAC) as well as the 
kinetics of cytokinesis entry and mitotic exit. We developed specific anti-phospho-Bcl-
xL antibodies directed against phospho-Bcl-xL sites of interest, phospho-Ser49 and 
phospho-Ser62. A combination of such original experiments allowed us to address the 
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roles of Bcl-xL phosphorylation events during cell cycle progression and checkpoints, 
and identify the specific protein kinases involved in Bcl-xL phosphorylation at Ser49 and 
Ser62. 
 
1.1 Cell cycle and the cyclin/CDK complexes 
 In all living organisms, from the unicellular bacterium to multicellular mammals, 
the only way that new cells can be made is by duplication of their genetic materials and 
division into 2 daughter cells. This duplication and division are known as the cell cycle 
(reviewed in 53-56). A schematic view of the cell cycle is presented in Figure 2.  
 
 
 
 
 
 
 
 
 
Figure 2. Illustration of the 4 phases of the cell cycle (From http://en.wikipedia.org/ 
wiki/File: Cell_Cycle_2.svg) 
 
 The eukaryotic cell cycle is divided into 4 phases: G1 phase (gap phase 1) 
following the M phase (M for mitosis) and before the S phase (S for DNA synthesis) in 
cycling cells or between the G0 phase (gap phase 0) and the S phase in temporarily 
quiescent cells; the G2 phase (gap phase 2) between the S phase and mitosis. G1, S, and 
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G2 together are called the interphase (I), occupying about 23 hours of a 24-hour cycle, 
with 1 hour for mitosis. In the G1 and G2 phases, cells take time to grow and, at the same 
time, monitor external and internal conditions and signals, then make decisions to either 
delay progress through G1 or allow commitment to the S phase, to either delay G2 or 
allow entry into mitosis. Chromosome duplication occurs during the S phase; in the M 
phase, chromosomes segregate and cells divide (reviewed in 53-56).  
 The cell cycle control system is like a programmed clock that triggers essential 
processes of the cell cycle in a relatively fixed amount of time. The central components 
of the cell cycle control system are members of a family of protein kinases known as 
CDKs. The most important CDK regulators are proteins known as cyclins. CDKs are 
dependent on cyclins for their activity. Without cyclins, CDKs are inactive. Cyclins 
undergo a cycle of synthesis and degradation in each cell cycle. These changes in cyclin 
protein levels result in the cyclic assembly and activation of cyclin-CDK complexes, 
which trigger cell cycle events. Cyclin expressions along the cell cycle are shown in 
Figure 3A, and the major cyclins and CDKs in eukaryotic cells are illustrated in Figure 
3B. At the G1 phase, cyclin D/CDK4 and cyclin D/CDK6 are the main cyclin-CDK 
complexes. During G1/S transition, cyclin E/CDK2 is the key regulator. During the S 
phase, cyclin A/CDK2 or cyclin A/CDK1 plays an essential role. During G2/M 
transition, cyclin B1/CDK1 controls the door to mitosis (reviewed in 53-56). In addition to 
dynamic cyclin/CDK interactions, another level of control involves key phosphorylation 
and dephosphorylation events that are explained in sections below.  
 
A)       
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B)  
 
 
 
 
 
 
 
 
Figure 3. A) Expression of human cyclins through the cell cycle. Illustration from 
http://en.wikipedia.org/wiki/File:Cyclin_Expression.svg.   
B) Major CDK/cyclin complexes during cell cycle progression. Illustration from Chin 
and D’Mello 57. 
 
1.2 Cell cycle checkpoints 
         There are 6 major regulatory transitions or checkpoints in the cell-cycle control 
system of most eukaryotic cells: G1 restriction point, G1/S checkpoint, intra-S 
checkpoint, G2/M checkpoint, metaphase-to-anaphase transition or the SAC, and the 
mitotic exit network (MEN). When the cellular and tissue environments are not favorable 
to replicate, cells delay progress through G1 and enter or stay in G0. If the cellular and 
tissue environments are favorable, cells progress through the restriction point near the 
end of G1 and initiate their division cycles 58, 59. The G1 checkpoint is a system that 
monitors DNA integrity before entering the S phase 11-13. The intra-S checkpoint 
monitors replicative stress and DNA single- and double-strand breaks whereas the G2 
checkpoint is a surveillance mechanism ensuring that proper DNA replication is achieved 
without mistakes or damage and/or production of DNA strand breaks 10, 11, 14, 15, 21, 60-64. If 
DNA damage or replication errors are produced, the G2 checkpoint provides more time 
for DNA repair before entering mitosis. The SAC checks the alignment of chromosomes 
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at the equator of the spindle and senses the tension produced by attachment of 
kinetochores to microtubules; if errors occur, the SAC halts mitosis progression at 
metaphase, allowing more time to correct the mistakes 65-70. Finally, the MEN controls 
cytokinesis and mitotic exit  71-75. 
 Depending on their genetic and environmental background, cells respond to DNA 
damage specifically, either by rapidly triggering cell death, primarily by apoptosis or, to a 
much lesser extent, by necrosis or other forms of atypical cell death, or by activating cell 
cycle checkpoints which arrest cell cycle progression at different phases of the cell cycle 
(Figure 4). It is generally believed that these checkpoints allow time to repair DNA 
damage or misaligned and mis-attached chromosomes at mitosis. If repair occurs in a 
satisfactory manner, the cells can resume cell cycle progression. If DNA damage is 
persistent and/or the checkpoint is not resolved, cells could then undergo cell death or 
enter into premature senescence. Cell cycle checkpoints are essential mechanisms that 
maintain genomic integrity, preventing mutations, chromosomal translocations, 
aberrations and aneuploidy, events intimately associated with tumorigenesis 15, 76-82.  
 
 
 
 
 
 
 
 
 
Figure 4. Schematic view of cell responses to DNA damage 
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 Current anticancer drugs and radiotherapy can perturb the orderly progress of 
DNA replication and cell division 14, 15, 77.  In the laboratory, cancer chemotherapeutic 
drugs are deployed to induce cell cycle checkpoints and cell death in experimental 
models consisting of human cancer and variant, genetically-modified cell lines. DNA 
topoisomerase inhibitors, including camptothecin (a DNA topoisomerase I inhibitor) and 
VP16 (a DNA topoisomerase II inhibitor), induce DNA single- or double-strand breaks, 
leading to G2 arrest and/or apoptosis, depending on specific cellular responses and 
genetic background of the cells. Taxol and nocodazole, microtuble dynamic inhibitors, 
activate the mitotic SAC, followed or not by cell death or aberrant or avorted mitosis, 
resulting in aneuploidy, again depending on the specific cellular responses and genetic 
background of the cells. In the next sections, we will focus on molecular networks 
controlling the G2 checkpoint, the SAC and mitotic exit, within the contexts of our 
research program.  
 
1.3 Regulatory networks controlling the G2 cell cycle checkpoint  
    To control the activity of cyclin B1/CDK1(CDC2) complexes 83-85, the G2 
checkpoint is regulated by different pathways, including the classical ATM-CHK2 86-88 
and ATR-CHK1 pathways 89-93 as well as a third pathway initiated by 
MAPK14/SAPKp38α 94-99.   
 
1.3.1 Cyclin B1/CDK1(CDC2) complex 
 By the end of the S phase, cyclin B1 starts to be synthesized due to cell cycle-
regulated transcription in human cells 85, 100, 101. During G2, mammalian cyclin 
B1/CDK1(CDC2) complexes are held in an inactive state by phosphorylation of 
CDK1(CDC2) at 2 negative regulatory sites, Thr14 and Tyr15, when it is bound to its 
cyclin partner, cyclin B1 102-110. Inhibitory phosphorylation is mediated by the kinases 
WEE1 and MYT1. WEE1 is a tyrosine kinase that phosphorylates Tyr15, and MYT1 is a 
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dual-specificity kinase that can phosphorylate both sites, with a tendency toward Thr14 
103-110. CDK1(CDC2)-Tyr15-specific kinase WEE1 has been postulated to be a CHK1 
target 111. Indeed, WEE1 has been shown to be required for CHK1-mediated G2 arrest 
and retention of CDK1(CDC2)-Tyr15 phosphorylation 111.  
 For entry into mitosis, cells need to activate cyclin B1/CDK1(CDC2) complexes 
by dephosphorylating the 2 inhibitory sites. CDC25 phosphatases are responsible for 
these dephosphorylation events. Mammalian cells have 3 CDC25 protein phosphatases, 
CDC25A, B, and C, which appear to have some level of specificity for different 
cyclin/CDK complexes. Studies indicate that CDC25A regulates G1/S and G2/M 
transition, whereas CDC25B and CDC25C are involved in intra-S and G2/M regulation 
112-119. CDC25 phosphatases are responsible for triggering activation of cyclin 
B1/CDK1(CDC2) complexes by dephosphorylating the inhibitory CDK1(CDC2) sites 
Thr14 and Tyr15.  
 Entry into mitosis absolutely requires progressive accumulation of active cyclin 
B1/CDK1(CDC2) complexes in the nucleus. Cyclin B1/CDK1(CDC2) kinase activity is 
time-organized to coordinate and trigger different mitotic events, the initial activation of 
cyclin B1/CDK1(CDC2) complexes occurring about 20 to 25 minutes before nucleolar 
disassembly and nuclear envelope breakdown 120, 121. After these events, cyclin 
B1/CDK1(CDC2) rapidly reaches its maximum activity to promote mitosis 120, 121. 
 
1.3.2 ATR-CHK1 and ATM-CHK2 network pathways 
 In response to DNA damage, activation of ATM and/or ATR kinases elicits 
CHK1 and CHK2 phosphorylation and activation 86-93. In turn, CHK1 and CHK2 are 
important intermediaries of cell cycle arrest and participate in the G2 checkpoint, in part 
by mediating CDK1(CDC2) inactivation through the inhibitory phosphorylation of 
CDC25A(Ser123), CDC25C(Ser216) and CDC25B(Ser230-Ser563) 112-119. Phospho-
rylation of CDC25 phosphatases by CHK1 and CHK2 creates a binding site for 14-3-3 
proteins, which prevents CDC25 from dephosphorylating CDK1(CDC2). These 
phosphorylation events, which also impede the nuclear export of CDC25, then separate 
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CDC25 from cyclin B1/CDK1(CDC2). CDC25 phosphorylation also facilitates its 
association with SCF(β-TRCP) ubiquitin ligase complex, promoting their degradation 122-
128.  
 PLK1 is inactivated in response to DNA damage by ATM/ATR-dependent 
phosphorylation 129, 130. Because PLK1 can phosphorylate cyclin B1 to block its export 
from the nucleus, it is possible that PLK1 inactivation leaves cyclin B1 stranded in the 
cytoplasm, thus contributing to CDK1(CDC2) inactivation and G2 arrest 131-136. However, 
PLK1 also mediates G2/M transition by phosphorylation/activation and evokes CDC25B 
and C translocation at centrosomes and nuclei to locally activate cyclin B1/CDK1(CDC2)  
117, 137-139, indicating that PLK1 inhibition favors G2 arrest. Accordingly, PLK1 activation 
by Aurora A promotes checkpoint recovery and resolution after DNA damage 140-142. In 
addition, PLK1-dependent activation of the transcription factor FoxM1 at G2 provides a 
positive-feedback loop associated with mitotic regulatory expression, including cyclin A, 
cyclin B1, CDC25c and PLK1 itself 143. PLK3, another member of the Polo kinase family, 
negatively regulates CDC25C by phosphorylation on Ser216, thereby creating a binding 
site for 14-3-3 proteins, resulting in protein phosphatase sequestration in the cytoplasm, 
inhibition of CDC25C activity and G2 arrest 144, 145. 
 Although not essential for the G2 checkpoint, the tumor suppressor gene product 
p53, an ATM downstream target, could contribute to G2 arrest by regulating p21, 
GADD45, and 14-3-3 expression, which overall affects the activity of cyclin 
B1/CDK1(CDC2) 146-159. The p53-dependent activation of p21 is, however, mostly linked 
to the G1 checkpoint and it is believed to have  few effects, if any, on the G2 checkpoint 
160-170. 
 
1.3.3 The MAPK14/SAPKp38α  signaling pathway 
  The third pathway involved in the G2 checkpoint is the MAPK14/SAPKp38α-
initiated signaling pathway  94-99. Several findings suggest that, after DNA damage, 
MAPK14/SAPKp38α could mediate the phosphorylation of key target proteins at Ser 
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residues, in a manner similar to those modified by CHK1 and CHK2. Indeed, 
MAPK14/SAPKp38α activates MAPKAPK2, which is directly responsible for CDC25B 
and C phosphorylation associated with 14-3-3 protein binding in vitro and in response to 
DNA damage in mammalian cells 94-98. Thus, in addition to CHK1 and CHK2, 
MAPKAPK2 constitutes a third checkpoint kinase involved in coordinating and 
mediating the DNA damage response and G2 arrest of higher eukaryotic cells. A 
schematic representation of the molecular network involved in the G2 checkpoint is 
presented in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A simplified schematic view of the G2/M cell cycle checkpoint 
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1.4 The spindle-assembly checkpoint  
 The SAC is a surveillance mechanism employed by cells to detect the mis-
attachment and mis-alignment of chromosomes and tension produced by chromosome 
capture at kinetochores by microtubules to prevent premature sister-chromatid separation, 
chromosome mis-segregation and aneuploidy 65-70. The SAC is also active in response to 
cancer chemotherapeutic drugs that poison microtubule dynamics, including the 
clinically-used vinca alkaloids vinblastine and vincristine, tubulin polymerization 
inhibitors, and the taxane-ring molecule taxol, a tubulin depolymerization inhibitor 65, 66, 
69. 
 
1.4.1 The anaphase promoting complex/cyclosome and CDC20  
 The anaphase-promoting complex or cyclosome (APC/C), a multiprotein E3 
ubiquitin ligase, is designed to signal the destruction of specific proteins by transferring 
multiple copies of the small protein ubiquitin, which target these proteins to proteasome-
dependent proteolysis 171. Vertebrate APC/C consists of at least 12 core subunits 
organized into 2 large domains, referred to as the "platform" and the "arc lamp", which 
are flexible relative to each other 67, 172. The original work of Hartwell and coworkers first 
isolated multiple CDC mutants of S. cerevisiae 173. Among the selection of mutants, they 
discovered that yeast harboring the CDC20 mutant arrested cell division in mitosis, and 
failed to initiate anaphase and chromosome segregation 174. Human CDC20 contains 
WD40 repeats, C box, KEN box, MAD2-interacting motif, CRY box, IR motif, and in 
vivo phosphorylation sites. WD40 domains of CDC20 have been suggested to be 
involved in substrate binding. The C box and IR motif have been implicated in binding to 
APC/C 175, 176.  
 The elaborate ubiquitin-conjugating system marks proteins for destruction. E1, as 
an ATP-dependent, ubiquitin-activating enzyme, transfers ubiquitin to ubiquitin-
conjugating enzyme E2, in a complex with E3. By means of the E3 component, E2-E3 
complex recognizes a specific degradation signal on target proteins and covalently adds a 
chain of ubiquitin at the targeted substrate. Once a substrate is marked with the 
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polyubiquitin chain, its translocates into a proteasome core system that will digest it 177-
179. In concert with E1 and E2 components, the E3 ubiquitin ligase APC/C associated 
with CDC20 is the key regulator of metaphase-to-anaphase transition, which catalyzes 
the ubiquitinylation and destruction of 2 major substrate proteins, securin and cyclin B1, 
thus promoting the onset of anaphase and mitotic exit 180-190. Indeed, at metaphase, sister-
chromatid pairs are linked together by cohesin. Securin inhibits separase, a protease 
involved in cohesin proteolysis. APC/C-CDC20 degrades securin to relieve separase 
inhibition 191. Then, active separase cleaves the SCC1 subunit of cohesin complexes and 
triggers sister-chromatid separation mediated by the action of microtubule force 67, 172. By 
promoting the degradation of cyclin B1, APC/C-CDC20 lowers CDK1(CDC2) activity, 
an essential event that resumes mitosis and triggers mitotic exit 192-194.   
 
1.4.2 MAD2- and BUBR1-bound APC/C-CDC20 inhibitory subcomplexes  
 Given the essential role of APC/C-CDC20 evoking entry into anaphase and 
initiating the segregation of chromosomes, APC/C-CDC20 is tightly regulated by the 
SAC, which negatively controls APC/C-CDC20 activity in a highly complex manner, 
mainly by regulating the ability of the limiting subunit CDC20 to activate APC/C, until 
all centromeric chromosomes have achieved bipolar kinetochore-microtubule attachment. 
SAC regulators and kinases are involved in an elaborate network that includes MPS1, 
PLK1, chromosome passenger complex (CPC) containing Aurora B, Survivin, Borealin, 
and INCEN-P as well as mitotic checkpoint complex containing MAD2, BUB1, BUB3 
and BUBR1 (reviewed in 65-70). The kinetochore localization of SAC components is a 
prerequisite for checkpoint signaling and amplification. By recruitment to kinetochores 
that are not, or improperly, captured by microtubules, SAC components are activated and 
generate "stop anaphase signals" that diffuse into the mitotic cytosol 195-201. In these 
hierarchical signaling pathways, MPS1, Aurora B, BUB1 and PLK1 lie at the top, 
whereas BUB3, BUBR1, MAD1 and MAD2 are downstream. A schematic illustration of 
the ordered cascade is illustrated in Figure 6.  
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Figure 6. Signaling network during the SAC 
 
 
 MPS1, one the first kinases to be activated when chromosomes are mis-attached 
and mis-aligned to kinetochores and microtubules, participates in CPC and Aurora B 
activation 202-207. On taxol but not nocodazole treatment, CHK1 also participates in 
Aurora B kinase activation 208, 209. The importance of Aurora B, BUB1 and PLK1 in that 
network has been highlighted in several studies. CPC containing Aurora B with BUB1 
collaborates to recruit and activate PLK1 at the unattached kinetochore 195, 198, 210-221. 
Activated PLK1 then facilitates the kinetochore localization of PICH, MAD1-MAD2, 
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BUBR1-BUB3, and CDC20 200, 222-226. In early mitosis, CDK1 and PLK1 phosphorylate 
Emi1, a pseudo-substrate that inhibits APC/C-CDC20 activity, resulting in its 
ubiquitination and degradation 227-230. PLK1 also phosphorylates and targets PICH to 
kinetochores, which is required for the kinetochore localization of MAD2 231. Other 
protein kinases, including NEK2A and TAO1, are also involved in the kinetochore 
localization of MAD2 197, 232-236.  
 Several models explain how APC/C-CDC20 is inhibited during the SAC. Studies 
by Tang et al. and Vanoosthuyse and Hardwick have indicated that 6 residues of CDC20 
are phosphorylated both in vitro and in vivo in a BUB1-dependent manner, providing a 
catalytic mechanism that negatively regulates APC/C-CDC20 activity 237, 238. 
 Dynamic subcomplexes have been shown to inhibit APC/C-CDC20 activity 
during the SAC. MAD2-CDC20 complex is one of the inhibitory forms of CDC20 
complex 239, 240. MAD2 is known to exist in 2 distinct structural conformations, termed 
"open" (O-MAD2) and "closed" (C-MAD2) 241, 242. MAD2 can stably bind MAD1, which 
recruits MAD2 to kinetochores 243, 244. A "template" model of kinetochore-dependent 
MAD2 activation, a modified version of the "2-state" model, has emerged from recent 
research on purified components of unattached chromosomes in cultured cells 245. It has 
been observed that O-MAD2 can undergo conformational change to C-MAD2 in which 
its carboxyl-terminal "seatbelt" domain encloses either MAD1 or CDC20, thereby 
converting the initial O-MAD2 form to C-MAD2 conformation 245. During SAC 
signaling, MAD2 dimerization status is also modified. Two distinct kinetic forms of 
MAD2 exist at kinetochores, one being the stably-associated MAD1-MAD2 template, 
and the other, rapidly exchanging MAD2. In these models, conformational change of 
MAD2, from O-MAD2 to C-MAD2, is required for its efficient binding to CDC20 246-252. 
 Dynamic BUBR1-bound subcomplexes, including BUBR1-BUB3-MAD2-
CDC20 and BUBR1-BUB3-CDC20, are major inhibitory subcomplexes of APC/C 196, 198, 
253-262. Several studies indicate that these BUBR1-bound subcomplexes are more stable in 
SAC-activated cells. The exact molecular mechanism by which they inhibit APC/C 
activity is, however, not completely resolved. Most studies suggest that these 
subcomplexes act as pseudo-substrates and thus interfere with the ability of APC/C-
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CDC20 to interact with its physiological substrates, primarily securin and mitotic cyclins. 
BUBR1 also contains 2 conserved KEN boxes that appear to regulate CDC20 turnover 
263, and BUBR1-bound CDC20 subcomplexes seem to favor CDC20 autoubiquitination 
and degradation 264-266. Once CDC20 is autoubiquitinated, the reduced CDC20 level 
lowers its bioavailability, which, in turn, amplifies APC/C inhibition 266. However, others 
have suggested the opposite. One consequence of CDC20 autoubiquitination is the 
dissociation of MAD2- and BUBR1-bound CDC20 inhibitory complexes, making APC/C 
available for free-bound CDC20, meaning APC/C-CDC20 activation and SAC 
resolution. Indeed, Reddy et al. showed that overexpression of UBCH10, the UBC that 
supports APC/C-catalyzed ubiquitination reactions, prevents cells from arresting at the 
SAC, even in the presence of nocodazole 265. The addition of exogenous UBCH10 
protein to extracts of nocodazole-arrested mitotic cells increases CDC20 
autoubiquitination, disrupts MAD2- and BUBR1-bound CDC20 interactions, and 
activates APC/C 265. p31-Comet is another conformation-specific MAD2-binding protein 
that plays a role in SAC inactivation and resolution 267, 268. p31-Comet attaches to MAD1-
bound MAD2, preventing active conformer generation of MAD2 as C-MAD2, and 
reducing the rate of MAD2-bound CDC20 inhibitory complexes. p31-Comet, along with 
UBCH10, stimulates the autoubiquitination of CDC20 and disassembly of MAD2-bound 
CDC20 complexes, leading to SAC inactivation and APC/C-CDC20 activation 265, 267, 268. 
Meanwhile, USP44/protectin, a deubiquitinating enzyme, deubiquitinates CDC20 and 
maintains MAD2- and BUBR1-bound CDC20 interactions, contributing to SAC 
activation and APC/C-CDC20 inhibition 269. Collectively, the activation of SAC kinases 
and components, cellular concentrations of MAD2- and BUBR1-bound CDC20 
complexes as well as the expression level of UBCH10, p31-Comet and USP44/protectin 
all contribute to the delicate balance between 2 opposing dynamic processes that regulate 
the activation status of the SAC 265, 266, 269.  These processes are illustrated in Figure 7. 
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Figure 7. Model of APC/C-CDC20 regulation at the SAC (From Yu 68). 
 
1.4.3 Dismantling the SAC 
 SAC resolution and APC/C-CDC20 activation could be initiated by the loss of 
kinetochore localization of MAD1 and MAD2, and by the dissociation of MAD2- and 
BUBR1-bound CDC20 interactions. However, besides CDC20 autoubiquitination models 
and p31-Comet effects that inhibit the MAD2 conformation change described above, the 
exact mechanisms are poorly understood. A dynein motor protein-dependent ‘stripping’ 
mechanism has been proposed, where dynamic interaction between dynein motor protein 
along microtubules removes MAD2 as well as other outer kinetochore proteins from 
attached kinetochores and transports them to spindle poles, where they are released into 
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the mitotic cytosol  270-275. More recently, another SAC silencing and resolution pathway 
dependent on PP1 activity has been identified in yeast. These studies propose that, upon 
successful chromosome bi-orientation, PP1 dephosphorylates BUBR1 at kinetochores, 
which relieves APC/C-CDC20 inhibition, promoting entry into anaphase and cytokinesis 
276-278. Even though several pathways have been identified for the dismantling of spindle 
checkpoint signaling, challenges remain to better understand which pathway is the major 
physiological mode of SAC silencing and resolution and/or whether different pathways 
could be employed by cells either alone or together, depending on SAC amplitude and/or 
length.  
 
1.5 The mitotic exit signaling network 
 The final step of mitosis is cytokinesis, which controls the decision to physically 
divide a cell into 2 daughter cells that is often termed “mitotic exit”. In most animal cells, 
cytokinesis begins in anaphase and ends shortly after telophase completion. There are 4 
distinct stages of cytokinesis: initiation of the spindle midzone and cleavage furrow, 
contraction of the contractile ring, new membrane insertion, and completion by gap 
closure between the 2 daughter cells (reviewed in 279).  
 The molecular orchestration and reorganization that occur during cytokinesis are 
far from being completely understood. Absolutely required, ubiquitin-mediated 
proteolysis controls the passage of cells through mitosis. Specific substrates are degraded 
as cells progress into, and through, mitosis, APC/C being the major ubiquitin ligase 
involved in the process. APC/C-CDC20 mediates the ubiquitination of mitotic cyclins 
leading to the rapid debit of mitotic CDK1(CDC2) activity, simultaneously targeting 
securin to lose chromosome cohesion and allowing sister-chromatid segregation to 
opposite poles of the anaphase spindle. These are the first events that contribute to 
mitosis exit 180, 280, 281. Cytokinesis requires complete degradation of cyclin B1. By 
studying human cells engineered to express non-degradable cyclin B1, researchers have 
demonstrated that cyclin B1 level affects cytokinesis 192-194. In cells expressing a non-
degradable form of cyclinB1, a spindle midzone and cleavage furrow cannot be properly 
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formed 192-194 and chromosome passenger proteins remain at kinetochores, suggesting 
that cyclin B1 degradation is also required for translocation of various components from 
the kinetochores to the central spindle midzone 282. In Drosophila embryos, high levels of 
non-degradable cyclin B1 prevent chromosome passenger proteins, including Aurora B 
kinase and its INCEN-P partner, from leaving the kinetochore and binding to the central 
spindle midzone 282. Coupled to cyclin B1 destruction, CDK1(CDC2) activity declines at 
the onset of anaphase, and a series of CDK1(CDC2) substrates are rapidly 
dephosphorylated. Exit from mitosis is a complex transition, which converts proteins 
from a phosphorylated state to a dephosphorylated state, associated with cytoskeleton and 
microtubule remodeling. Figure 8 depicts the kinetics of CDK1(CDC2) kinase activity 
during mitosis and its progressive inhibition during cytokinesis 194.  
 
 
Figure 8. Kinetics of CDK1(CDC2) activity through mitotic progression (From Wolf et 
al. 194). 
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 After APC/C-CDC20 activation, CDC20 is replaced by the CDH1 subunit, 
expanding APC/C substrate specificity 283-289. CDC20 and CDH1 confer certain substrate 
specificity to APC/C. The WD40-repeat domain of CDH1 recognizes short peptide 
motifs within APC/C substrates, of which the most common are D- and KEN-boxes 285, 
288. APC/C-CDH1 becomes active during anaphase and retains its activity during 
cytokinesis and in G1 cells. APC/C-CDH1 continues to degrade cyclin B1 290 and is 
involved in the time control of cytokinesis 291. By timely targeting of specific substrates, 
APC/C-CDH1 is required for cytoskeleton and microtubule reorganization and for the 
recruitment of proteins at the spindle midzone 291-293. In a timely, regulated manner, 
APC/C-CDH1 commands the destruction of various kinases and components of the SAC, 
including Aurora A 294-297, MPS1 298, NEK2A 299, Aurora B 300, 301, BUB1 302, 
microtubule-associated proteins, such as NuSAP 303, SKAP2 304, TPX2 305 and, at the 
very end, PLK1 306 – to resume mitotic exit.  
 Assembly of the cleavage furrow and contractile ring consisting of actin filaments 
and Myosin-II is far from being understood in mammals and involves more than 120 
proteins in yeast (reviewed in 279). In mammalian cells, PLK1 and presumably PLK3 
activity, which is also found at the spindle midzone 307,  is required for assembly of the 
cleavage furrow and contractile ring 308. With Kinesin-6, PLK1 promotes the 
accumulation of active RhoA-GTP at the cleavage furrow, by phosphorylating RhoGAP 
that recruits RhoGEF which, in turn, activates RhoA-GTP 309. In association with the 
scaffold protein anilin, RhoA-GTPase flux then contributes to Myosin-II activation at the 
contractile ring 310, 311. Myosin-II is the driving force that constricts actin filaments at the 
contractile ring 279. 
 In addition to ubiquitin ligase activity, mitotic exit requires protein phosphatases. 
In budding yeast, the MEN controls post-anaphase CDK(CDC) activity to prevent 
premature cytokinesis. CDC14 is essential for timely, organized exit from mitosis in 
yeast 312-320. In yeast, CDC14 is associated with 2 signaling networks, CDC14 early 
anaphase release (FEAR) and the MEN, that are pivotal for triggering CDK inactivation 
and localize chromosomal passenger proteins to the spindle midzone 71, 318-320. Three 
CDC14 phosphatase homologs in human cells have been identified, CDC14A, B and C, 
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but whether they have a similar function in mitotic exit is still not known 321-323. In 
addition to CDC14, phosphatases PP1 and PP2A have been shown to play roles in mitotic 
exit in Xenopus egg extracts, budding yeast and, more recently, in human cells 277, 324-329. 
Indeed, Wu et al. demonstrated that PP1 activity is required to dephosphorylate 
CDK1(CDC2) substrates to allow mitotic exit 329.  
 
1.6 Bcl-xL function in apoptosis  
 Bcl-xL 330, a Bcl-2 family member, has anti-apoptotic activities and has been 
studied extensively because of its importance in the regulation of apoptosis, during 
development, tumorigenesis and cellular responses to stress, including anticancer 
therapies 27, 28, 330-354. A phenotype of mice deficient in the Bcl-x gene manifests abnormal 
development and death of fetal erythroid progenitors and neuronal cells, with the animals 
dying around embryonic day 14 displaying severe defects in erythropoiesis and neuronal 
development 332. Bcl-xL usually resides in the cytosol, on the cytoplasmic face of the 
outer mitochondrial membrane (OMM), endoplasmic reticulum and nuclear envelope 355-
357. A schematic view of the Bcl-2 family members is presented in Figure 9. 
 
Figure 9.  The Bcl-2 family members (From Danial 358) 
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 Bcl-xL contains BH1, BH2, BH3 and BH4 domains, a COOH-terminus 
hydrophobic transmembrane domain, and an unstructured loop domain, between BH4 
and BH3. The BH1, BH2 and BH3 domains create a hydrophobic pocket where the 
amphipathic α-helice of another BH3-containing protein can bind (Figure 1) 344, 359, 360. 
The BH3 domain, particularly among BH3-only proteins, mediates interaction between 
BH3-only proteins and Bcl-xL protein, thereby promoting apoptosis 361-366. The 3-
dimensional organization of Bcl-xL identifies a 60 amino acid loop lacking a defined 
structure 359. Compared to the full-length protein, Bcl-xL loop deletion mutant displays a 
similar or, in a few studies, an enhanced ability to inhibit apoptosis and does not present 
significant alterations in its ability to bind pro-apoptotic proteins, such as Bax, or prevent 
cytochrome c release and caspase activation 20, 367, 368.  
Two classical pathways of apoptosis, intrinsic and extrinsic, converge to caspase 
activation. The extrinsic pathway is initiated by a series of death receptors upon ligand 
activation, while the intrinsic pathway is triggered by various developmental cues or 
cytotoxic insults, including viral infections, replication stress, DNA damage and growth 
factor deprivation, strictly controlled by the Bcl-2 family of proteins (reviewed in 52, 357, 
369-371). Activation and heterodimerization of the pro-apoptotic family members Bax and 
Bak are crucial for inducing permeabilization of the OMM and subsequent release of 
apoptogenic molecules, including cytochrome c, which leads, with Apaf-1 and dATP, to 
caspase-9 activation 372-383. Anti-apoptotic proteins, such as Bcl-xL and Bcl-2, bind to 
and inhibit Bax and Bak activity. BH3-only proteins are potent mediators of cell death. 
BH3-only enabler or sensitizing proteins promote apoptosis by binding to, and inhibiting, 
pro-survival molecules, such as Bcl-2, Bcl-xL and Mcl-1, whereas BH3-only activator or 
activating proteins bind to and activate multidomain pro-apoptotic Bax and Bak proteins 
363, 384. Bax insertion and oligomerization into mitochondrial membranes require 
activation by a BH3-only activating protein, events that elicit OMM permeabilization; in 
contrast, the potency of anti-apoptotic proteins, such as Bcl-xL, to trap and inhibit these 
BH3-only activating proteins, prevents membrane permeabilization 366, 385-388. A 
schematic view of these interplays is illustrated in Figure 10. 
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Figure 10.  The mode of action of Bcl-2 family members. Anti-apoptotic proteins, such 
as Bcl-2 and Bcl-xL, maintain cell survival by inhibiting constitutively-expressed pro-
apoptotic Bax and Bak proteins. Subsets of the BH3-only proteins like Bad, promote 
apoptosis by binding to and inhibiting pro-survival proteins, such as Bcl-2 and Bcl-xL, 
whereas BH3-only activator, like Bim, Bid and Puma proteins bind to and activate 
multidomain pro-apoptotic Bax and Bak proteins. (From Adams and Cory 371). 
 
 23 
The unexpected pore-forming ability of Bcl-xL protein has also emerged from its 
3-dimensional structure. Structural similarities between Bcl-xL, particularly its α5- and 
α6-helices and the pore-forming domains of some toxins that act as channels, indicate 
that Bcl-2 members could also function by forming pores in intracellular organelles, 
including mitochondria (Figure 1) 340, 359, 385-388. Whether these channel activities function 
by themselves, or in association with other megachannels, such as components of 
mitochondrial permeability transition pores, or others, is still not completely elucidated 
387, 389-400. 
 
1.6.1 p53-dependent and -independent activation 
 Activation of BH3-only proteins as a consequence of replicative stress or after 
exposure to DNA-damaging and microtubule-poisoning agents has been studied 
extensively. The transcriptional activity of p53 in response to genotoxic agents 
contributes to its apoptotic activity 401. Bax itself was the first to be identified as a p53-
dependent apoptotic target 402, 403 and the BH3-only proteins Bid, Noxa and Puma were 
also described as p53-dependent target genes involved in irradiation and anticancer drug-
induced apoptosis 404-408. In addition, direct activation of multidomain pro-apoptotic 
proteins, such as Bax and Bak, by p53, and direct neutralization of multidomain anti-
apoptotic proteins, such as Bcl-2 and Bcl-xL by p53, were also reported 409-412. 
 Paradoxically, several observations have disclosed that cells lacking the ability to 
induce a cell cycle checkpoint, as a consequence of p53 disruption, could display 
hypersensitivity to DNA-damaging treatments and undergo apoptosis very rapidly, 
indicating the existence of p53-independent pathways of apoptosis 7, 9, 357, 413-424.  Indeed, 
many studies have now revealed that Bax and a multitude of BH3-only proteins, 
including Bim, Noxa, Puma, Bik and ITM2Bs, are activated in a p53-independent manner 
after DNA damage 357, 425-429. Its appears that many transcription factors activate these 
genes independently of p53, including p63, p73, E2F1 and FOXO3A  430-442. 
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1.7  Bcl-2 family members and the cell cycle  
 Recent studies have revealed links between some Bcl-2-like family members, cell 
cycle progression and cell cycle checkpoint regulation (Figure 11). First, Bcl-2 has been 
shown to slow entry from the quiescent G0 into the G1 phase of the cell cycle in multiple 
cell lineages from transgenic mice. In contrast, Bcl-2-/- knockout cells enter the S phase 
more quickly 31, 32. This effect of Bcl-2 on cell proliferation is genetically distinct from its 
function in apoptosis 31, 32. More recently, phosphorylated forms of Bcl-2 also have been 
co-localized in nuclear structures and on mitotic chromosomes, disclosing the importance 
of phosphorylation events for Bcl-2 protein location 443. Mcl-1, another Bcl-2 homologue 
known to function as an anti-apoptotic protein 444, inhibits cell cycle progression through 
the S phase of the cell cycle. The cell cycle regulatory function of Mcl-1 is partially 
mediated through its interaction with proliferating cell nuclear antigen, a cell cycle 
regulator that is crucial in DNA replication 40, 445. More recently, some have reported that 
a proteolytic fragment of Mcl-1 regulates cell proliferation via interaction with 
CDK1(CDC2) 42 and that Mcl-1 is essential in ATR-mediated CHK1 phosphorylation 45. 
Others have discerned the involvement of Bid, a BH3-only protein with pro-apoptotic 
activity, at the intra-S phase checkpoint under replicative stress and in response to DNA-
damaging agents. This function of Bid is mediated through its phosphorylation at Ser78 
and Ser61/64 by the DNA-damage signaling kinase ATM 43, 44.  
 
Figure 11. Schematic representation of the effects of Bcl-2, Mcl-1, Bid and Bcl-xL on 
cell cycle progression (From Schmitt et al. 159). 
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Microtubule inhibitors widely used in cancer chemotherapy induce mitotic arrest 
and apoptosis linked to Bcl-2, Bcl-xL and Mcl-1 phosphorylation 446-453.  Kharbanda et al. 
have reported that Bcl-xL is phosphorylated within the unstructured loop domain at 
Thr47 and on Thr115, adjacent to the α3-helix of Bcl-xL, in response to ionizing 
radiation 454. A few protein kinases have been proposed to phosphorylate Bcl-2 or Bcl-
xL, including the Ask1/Jun-N-terminal protein kinase 1 pathway, normally activated at 
G2/M transition 454-461, and PLK1 that is also involved in G2/M transition and during 
mitosis 453. The exact functions of these phosphorylation events are not yet understood. 
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2.  Rationale of the thesis 
2.1 Goal, hypothesis and specific objectives 
 A previous study in our laboratory showed that Bcl-xL stabilizes the G2 
checkpoint, an activity that resides within the flexible loop domain of Bcl-xL, a region 
that is not essential for its anti-apoptotic function 20. Our goal in this research program 
was to further understand the critical roles and molecular mechanisms by which Bcl-xL 
and its flexible loop domain interface with cell cycle progression and checkpoints. We 
hypothesize that Bcl-xL's functions in cell cycle progression and checkpoints are 
regulated by phosphorylation events within the Bcl-xL flexible loop domain that will 
influence: i) Bcl-xL location, ii) Bcl-xL protein/protein interactions with cell cycle 
checkpoint components, and iii) Bcl-xL activity in cell cycle progression and 
checkpoints. Toward this end, the 1st aim of the research program was to generate a 
series of single-point Bcl-xL cDNA phosphorylation mutants, including Thr41Ala, 
Ser43Ala, Thr47Ala, Ser49Ala, Ser56Ala, Ser62Ala and Thr115Ala, and express them in 
human cancer cell lines. The 2nd aim was to design experimental assays to measure the 
stability of DNA damage-induced G2 arrest and microtubule poisoning-induced SAC, 
and the kinetics of cytokinesis and mitotic exit, in cell lines expressing wild-type (wt) 
Bcl-xL, phosphorylation mutants and small interference RNA (siRNA) targeting Bcl-xL 
expression. The 3rd aim was to develop specific anti-phospho-Bcl-xL antibodies 
directed against phospho-Bcl-xL sites of interest. The 4th aim was to address the 
importance of these phosphorylation events for Bcl-xL location and function during cell 
cycle progression and checkpoints in wt synchronized cells or cells exposed to DNA-
damaging and microtubule-poisoning agents. The 5th aim was to identify the specific 
protein kinases involved in Bcl-xL phosphorylation at sites of interest. Finally, the 6th 
aim was to initiate studies by dissecting the molecular mechanisms behind Bcl-xL 
function during cell cycle progression and checkpoints.  
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2.2 Presentation of the appended manuscripts 
 In this thesis, I present my data in 3 manuscripts that have been submitted 
recently. The functional screening assays deployed in our studies revealed that cells 
expressing the phosphorylation mutants Bcl-xL(Ser49Ala) and Bcl-xL(Ser62Ala) behave 
differently than cells expressing wt Bcl-xL, in response to VP16, a DNA topoisomerase 
II inhibitor, and taxol, a microtubule poison, not in terms of apoptosis protection, but in 
terms of checkpoint stability and resolution. These first observations were the basis to 
further develop strategies and experimental approaches to understand the function of 
phospho-BclxL(Ser62) and (Ser49) during cell cycle progression and checkpoints. The 
first manuscript described the effect of phospho-Bcl-xL(Ser62) on the G2 checkpoint. 
The second manuscript described the effects of phospho-Bcl-xL(Ser62) during mitosis. 
Finally, in the third manuscript, the data for phospho-Bcl-xl(Ser49) at the G2 checkpoint 
and during mitosis are presented.  
 
2.3 Contribution of co-authors 
 Jianfang Wang (JW) performed more than 80-85% of all the works and 
experiments described in the 3 manuscripts. She designed, with the help of Richard 
Bertrand (RB), the experimental strategies and protocols, actively resolved technical 
problems that occured during these studies, and analysed the data. She wrote the first 
versions of the manuscripts and actively participated with RB in revision to the final 
versions. Myriam Beauchemin (MB), a technician in the laboratory, assisted JW for the 
generation and preparation of the constructs deployed in these studies, prepared and 
purified recombinant Bcl-xL protein and performed the in vitro kinase assays. MB was 
also involved in the validation of the specific phospho-antibodies produced in the course 
of these studies, and in the validation of siRNAs targeting Bcl-xL in the second 
manuscript. RB supervised the work, analysed the data with JW and MB and revised the 
manuscripts.   
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Abstract 
Accumulating evidence suggest that Bcl-xL, an anti-apoptotic member of the Bcl-2 
family, also functions in cell cycle progression and cell cycle checkpoints. Analysis of a 
series of phosphorylation mutants reveals that cells expressing Bcl-xL(Ser62Ala) mutant 
are less stable at the G2 checkpoint and enter mitosis more rapidly than cells expressing 
wild type Bcl-xL or Bcl-xL phosphorylation mutants, including Thr41Ala, Ser43Ala, 
Thr47Ala, Ser56Ala and Thr115Ala. Analysis of the dynamic phosphorylation and 
location of phospho-Bcl-xL(Ser62) in unperturbed, synchronized cells and during DNA 
damage-induced G2 arrest discloses that phospho-Bcl-xL(Ser62) translocates into 
nucleolar structures in VP16-exposed cells during G2 arrest. In a series of in vitro kinase 
assays, pharmacological inhibitors and specific siRNA experiments, we found that Polo 
kinase 1 and MAPK9/JNK2 are major protein kinases involved in Bcl-xL(Ser62) 
phosphorylation and accumulation into nucleolar structures during the G2 checkpoint. In 
nucleoli, phospho-Bcl-xL(Ser62) binds to and co-localizes with CDK1(CDC2), the key 
cyclin-dependent kinase required for entry into mitosis. These data indicate that, during 
G2 checkpoint, phospho-Bcl-xL(Ser62) stabilizes G2 arrest by timely trapping of 
CDK1(CDC2) in nucleolar structures to slow mitotic entry. It also highlights that DNA 
damage affects the dynamic composition of the nucleolus, which now emerges as a 
component of the DNA damage response. 
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Introduction 
 In mammals, development and tissue homeostasis require a carefully-orchestrated 
balance between cell proliferation, cell differentiation, cellular senescence and cell death. 
In recent years, several studies have reported that members of the Bcl-2 family, in 
addition to their central role in controlling apoptosis during development and cellular 
stress, also interface with the cell cycle, the DNA damage response, DNA repair 
pathways and premature senescence, effects that are generally distinct from their function 
in apoptosis (reviewed in (1, 2)).  
 Bcl-2 itself has been demonstrated to slow entry from the quiescent G0 to the G1 
phase of the cell cycle prior to DNA replication in multiple cell lineages and transgenic 
mice (3). In contrast, Bcl-2−/− knockout cells enter the S phase more quickly. This effect of 
Bcl-2 on cell proliferation is genetically distinct from its function in apoptosis (4). Mcl-1, 
another Bcl-2 homologue known to function as an anti-apoptotic protein inhibits cell-
cycle progression through the S phase of the cell cycle (5). More recently, others have 
reported that a proteolytic fragment of Mcl-1 regulates cell growth via interaction with 
CDK1(CDC2) (6) and that Mcl-1 plays an essential part in ATR-mediated CHK1 
phosphorylation (7). Others have discerned the involvement of Bid, a BH3-only Bcl-2 
family member with pro-apoptotic activity, at the intra-S phase checkpoint under 
replicative stress in response to DNA-damaging agents. This function of Bid is mediated 
through its phosphorylation by the DNA-damage signaling kinase ATM (8, 9).  
 Bcl-2 and/or Bcl-xL modulate the Rad51-dependent homologous recombination 
pathway as well as non-homologous end-joining and DNA damage mismatch repair 
activities, effects that are separable from their anti-apoptotic function (10-13). Bcl-xL also 
fulfills specific functions distinct from its function in apoptosis during the cell cycle (14, 
15). Indeed, we previously reported that, in addition to its mitochondrial effect, which 
delays apoptosis, Bcl-xL co-localizes in nucleolar structures and binds CDK1(CDC2) 
during the G2 cell-cycle checkpoint, and its over-expression stabilizes G2 arrest in 
surviving cells after DNA damage (15). Bcl-xL potently inhibits CDK1(CDC2) kinase 
activity, which is reversible by a synthetic peptide between the 41st to 61st amino acids 
within or near the described Thr47 and Ser62 phosphorylation sites within its flexible 
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loop domain. A mutant deleted of this region does not alter the anti-apoptotic function of 
Bcl-xL, but impedes its effect on CDK1(CDC2) activities and on G2 arrest after DNA 
damage (15).  
 To better understand the importance of the Bcl-xL flexible loop domain and 
putative phosphorylation events in regulating Bcl-xL location and function during the G2 
checkpoint, we generated a series of single-point Bcl-xL cDNA phosphorylation mutants, 
including Thr41Ala, Ser43Ala, Thr47Ala, Ser56Ala, Ser62Ala and Thr115Ala. Stably-
transfected cell populations were selected in human B lymphoma Namalwa and cervical 
carcinoma HeLa cells. In this study, we provide evidence that phospho-Bcl-xL(Ser62) is 
a key component in stabilizing DNA damage-induced cell cycle arrest.  
 
Results 
Effect of Bcl-xL and various Bcl-xL phosphorylation mutants on DNA damage-
induced G2 arrest 
 To examine the G2 cell-cycle arrest function of Bcl-xL, we generated various Bcl-
xL phosphorylation mutants, including Thr41Ala, Ser43Ala, Thr47Ala, Ser56Ala, 
Ser62Ala and Thr115Ala, then stably expressed them in Namalwa cells (Fig. 1A and 
Supplementary Fig. S1A).  A well-established, simple experimental procedure, referred 
to as mitotic trap assay (Fig. 1B) (16), evaluated the kinetics of G2 arrest after DNA 
damage, the kinetics of mitotic entry after G2 arrest, and the kinetics of cell death. In the 
mitotic trap assay, cells entering mitosis after G2 arrest, a direct indicator of G2 
checkpoint bypass or checkpoint recovery and adaptation, are trapped by adding 
nocadazole (0.35 µM) at 24-h intervals after VP16 treatment (10 µM/30 min in Namalwa 
cells) and monitored by flow cytometry with phospho-H3(Ser10) labeling and propidium 
iodide (PI) staining. Control Namalwa cells (Fig. 1C) or Namalwa cells stably transfected 
with empty vector (Fig. 1D) die rapidly after exposure to VP16.  In contrast, cells stably 
expressing HA-Bcl-xL and all phosphorylation mutants show strong inhibition of 
apoptosis (Fig. 1E-F and Supplementary Fig. S1E-K; green bars). More than 70% of cells 
over-expressing wt HA-Bcl-xL are arrested in G2, 24 h after VP16 treatment (Figure 1E; 
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grey bars).  However, some of them slowly escape from G2 and enter early mitosis, 48 to 
72 h after VP16 treatment (Figure 1E; red bars). The phosphorylation mutants, including 
HA-Bcl-xL(Thr41Ala), (Ser43Ala), (Thr47Ala), (Ser56Ala) and (Thr115Ala), present a 
similar phenotype compared to wt HA-Bcl-xL, protecting cells from apoptosis and 
allowing G2 arrest, with some cells escaping G2 arrest 48 and 72 h post-VP16 treatment 
(Supplementary Fig. S1F-K).  Strikingly, cells expressing the phosphorylation mutant 
HA-Bcl-xL(Ser62Ala) enter mitosis much more rapidly (Fig. 1F), revealing that Ser62 is 
important for Bcl-xL function at G2 arrest. In addition, expression of HA-Bcl-
xL(Ser62Ala) has an effect similar to HA-Bcl-xL in protecting cells from apoptosis (Fig. 
1E-F). Together, these observations suggest that Bcl-xL's function in cell cycle arrest is 
distinct from its function in apoptosis, with Ser62 as a key player. 
 
HA-Bcl-xL(Ser62) phosphorylation and location during DNA damage-induced G2 
arrest 
HA-Bcl-xL(Ser62) phosphorylation occurs simultaneously to phosphorylation/activation 
of key components of the DNA damage response and G2 checkpoint, including ATM, 
ATR, CHK1, CHK2, Aurora A, Polo kinase 1 (PLK1), MAPKAPK2, 
MAPK14/SAPKp38α, MAPK9/JNK2 and MAPK8 /JNK1 as well as CDK1(CDC2) 
phosphorylation/inactivation of (Fig. 2A), pointing to a temporal and functional link 
between these events. A previous study from our laboratory indicated that Bcl-xL co-
localized with CDK1(CDC2) in the nucleolus during the G2 checkpoint induced by 
camptothecin (CPT) and VP16 treatment in human cell lines (15). The nucleolus acts on 
cell-cycle progression and genomic stability by phased sequestration and the release of 
regulatory proteins, including p19/ARF, MDM2, CDC14, PP1, p53, CDK1(CDC2), 
telomerase and the DNA helicases WRN and BLM (reviewed in (17)). Indirect in cellular 
immunofluorescence microscopy was undertaken to monitor the re-distribution of wt 
HA-Bcl-xL and phosphorylation mutant HA-Bcl-xL(Ser62Ala). We observed that a pool 
of wt HA-Bcl-xL and phospho-Bcl-xL(Ser62) co-localized strongly with nucleolin, a 
marker of the nucleolus, 48 h-post VP16 exposure (Fig. 2B). In contrast, the 
phosphorylation mutant HA-Bcl-xL(Ser62Ala) showed no co-location with nucleolin 
(Fig. 2C). Total phospho-Bcl-xL(Ser62) in Namalwa cells, expressing the 
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phosphorylation mutant HA-Bcl-xL(Ser62Ala), was also considerably reduced. The 
percentage of wt HA-Bcl-xL and phosphorylation mutant HA-Bcl-xL(Ser62Ala) that co-
localized with nucleolin in Namalwa cells was quantified by image analysis (Fig. 2D). 
The percentages of total phospho-Bcl-xL(Ser62), including endogenous Bcl-xL and HA-
tagged expressed protein, are illustrated in Fig. 2E. Altogether, these results indicate that 
Ser62 is required for Bcl-xL translocation to nucleoli 48 h-post VP16 treatment, and that 
accumulation of phospho-Bcl-xL(Ser62) into nucleoli coincides with the stabilization of 
G2 arrest. The specificity of phospho-Bcl-xL(Ser62) antibodies is depicted in 
Supplementary Fig. S2. 
 
Endogenous Bcl-xL(Ser62) phosphorylation and location in unperturbed, 
synchronized cells and during DNA damage-induced G2 arrest 
 Because the above observations were made in HA-Bcl-xL-transfected and over-
expressed cells, we next explored the role of endogenous Bcl-xL in the cell cycle. We 
performed these experiments in human wt HeLa cells. Indeed, wt HeLa cells are less 
prone to apoptosis after VP16 treatment, and undergo G2 arrest, with some cells escaping 
G2 arrest 48 and 72 h-post VP16 treatment (Fig. 3A, left panel). Bcl-xL(Ser62) 
phosphorylation is also seen in wt HeLa cells exposed to VP16 and accumulates in 
enriched nuclear fractions (Fig. 3B).  In addition, HA-Bcl-xL transfection and over-
expression in HeLa cells stabilizes G2 arrest (Fig. 3A, right panel). When wt HeLa cells 
are synchronized by double thymidine block and released upon progression from S to G2, 
endogenous Bcl-xL is progressively modified with accumulation of Ser62 
phosphorylation (Fig. 3C). Phospho-Bcl-xL(Ser62) is found in cytosolic and nuclear 
extracts, with progressive accrual in nuclear extracts in late S and G2 (Fig. 3C), 
indicating that Bcl-xL phosphorylation on Ser62 occurs during normal cell cycle 
progression. We next investigated the subcellular location of endogenous phospho-Bcl-
xL(Ser62) in wt HeLa cells by indirect immunofluorescence staining, in asynchronized 
control and VP16-exposed cells and,  synchronized, untreated G2 cells (Fig. 3D-F). In wt 
HeLa cells exposed to VP16, phospho-Bcl-xL(Ser62) accumulated in nucleoli 24- and 48 
h-post VP16 exposure. Accumulation in nucleoli was more marked after VP16 treatment 
in comparison to synchronized, untreated G2 cells (Fig. 3D).  Phospho-Bcl-xL(Ser62) 
 34 
was also found in Cajal bodies with coilin, a specific Cajal body marker, but the location 
remained unchanged under the conditions tested (Fig. 3E).  Finally, phospho-Bcl-
xL(Ser62) did not locate in centrosomes (Fig. 3F). Taken together, these results indicate 
that endogenous Bcl-xL is phosphorylated on Ser62 during normal cell cycle progression 
and that phospho-Bcl-xL(Ser62) accumulates much more strongly in nucleoli during 
DNA damage-induced G2 checkpoint in wt HeLa cells. 
 
PLK1 and MAPK9/JNK2 are major protein kinases involved in Bcl-xL(Ser62) 
phosphorylation and accumulation in nucleoli during DNA damage-induced G2 
arrest 
 Various protein kinases have been postulated to phosphorylate Bcl-xL on Ser62 
under various experimental conditions including those driving activation of the mitotic 
spindle-assembly checkpoint (18-22). No study has yet documented Bcl-xL phosphorylation 
on Ser62 at the G2 checkpoint. Based on an in silico consensus site prediction search 
(Supplementary Table S5), and on known protein kinases activated during the DNA 
damage response and G2 checkpoint (Fig. 2A), we first tested a panel of protein kinases 
by in vitro kinase assays with recombinant human Bcl-xL protein as substrate. Among all 
the kinases tested, PLK1, MAPK9/JNK2, GSK3α, GSK3β, MAPK8/JNK1, MAPKAPK2 
and MAPK14/SAPKp38α were positive and able to phosphorylate recombinant Bcl-xL 
protein on Ser62 in in vitro kinase assays (Fig. 4A). The origin of the kinases, kinase 
assay description and enzyme-specific activities with control substrates are indicated in 
Supplementary Table S3 and Supplementary Fig. S3. Then, with specific 
pharmacological inhibitors and VP16-exposed cells, we observed that PLK, JNK and 
GSK3 inhibitors prevented Bcl-xL phosphorylation on Ser62 (Fig. 4B) in VP16-exposed 
cells. Deploying a series of specific siRNAs (Fig. 4C, and see supplementary Table S4 
and supplemenatry Fig. S4 for additional information and controls), western blotting of 
enriched nuclear extracts revealed that the most important kinases involved in Bcl-
xL(Ser62) phosphorylation in G2-arrested VP16-treated HeLa cells were PLK1, 
MAPK8/JNK1, MAPK9/JNK2 and, to a much lesser extent, GSK3β  (Fig. 4D).  Finally, 
to confirm these results and to monitor the effect of silencing the kinases on phospho-
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Bcl-xL(Ser62) accumulation in nucleoli in VP16-exposed cells, indirect in cellular 
immunofluorescence microscopy was undertaken and quantified (Fig. 4E). The data 
indicate that PLK1 and MAPK9/JNK2 are major protein kinases associated with 
progressive phospho-Bcl-xL(Ser62) accumulation in nucleolar structures in VP16-
exposed cells.  
 
Phospho-Bcl-xL(Ser62) meets CDK1(CDC2) in nucleolar structures during DNA 
damage-induced G2 arrest 
  In a series of reciprocal co-immunoprecipitation experiments, we previously 
showed that nuclear Bcl-xL binds to CDK1(CDC2) during the G2 checkpoint (15). Here, 
we repeated these experiments on enriched nuclear and enriched nucleolar extracts. In 
nuclear extracts, we observed that a pool of Bcl-xL protein co-immunoprecipitating with 
CDK1(CDC2) is phosphorylated on Ser62. The phosphorylation mutant Bcl-
xL(Ser62Ala) in nuclear extracts also co-immunoprecipitated with CDK1(CDC2), but to 
an apparently lesser extent (Fig. 5A). When co-immunoprecipitation experiments were 
performed on nucleolar extracts (Fig. 5B), we noted that phospho-Bcl-xL(Ser62) co-
immunoprecipitated with CDK1(CDC2), while the phosphorylation mutant Bcl-
xL(Ser62Ala) was not present in nucleolar fractions. Reciprocal co-immunoprecipitation 
was also undertaken (Fig. 5B). CDK1(CDC2) protein co-localized with nucleolin in 
VP16-exposed cells (Fig. 5C) as well as with phospho-Bcl-xL(Ser62) in nucleolar 
structures (Fig. 5D). Together, the data suggest that during G2 checkpoint, Bcl-xL 
phosphorylation on Ser62 promotes Bcl-xL translocation to nucleoli where it will meet an 
important pool of CDK1(CDC2), contributing to its trapping in nucleolar structures to 
timely avoid entry into mitosis (Fig. 5E).   
  
Discussion 
 Our study reveals Bcl-xL(Ser62) phosphorylation during the normal cell cycle and 
in DNA-damage-induced G2 arrest, and PLK1 and MAPK9/JNK2 are major protein 
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kinases responsible for Bcl-xL(Ser62) phosphorylation and progressive accumulation in 
nucleolar structures during the stabilization of DNA damage-induced G2 arrest. This 
function of phospho-Bcl-xL(Ser62) was clearly separable from Bcl-xL's known purpose 
in apoptosis, as the Bcl-xL(Ser62Ala) phosphorylation mutant retained its anti-apoptotic 
effect but lacked the G2-arrest stabilization function. This original role of phospho-Bcl-
xL(Ser62) is associated with its translocation into the nucleolus after DNA damage, 
where it will meet CDK1(CDC2). The dynamic complex processes that occur in the 
nucleolus are emerging. Besides their traditional function in ribosome biogenesis, 
nucleolar structures are now appearing as key centers that either provide local 
concentration of activities essential for nuclear and cellular processes, or exclude and 
timely trap nuclear factors that would otherwise interfere with proper nuclear and cellular 
functions (17). Indeed, the nucleolus acts on cell-cycle progression and genomic stability 
by phased sequestration and the release of regulatory proteins, including p19/ARF, 
MDM2, CDC14, PP1, p53, telomerase and the DNA helicases WRN and BLM (17). 
CDK1(CDC2) as well as Bcl-xL or Bcl-2 have also been reported previously in nucleolar 
structures (15, 23, 24). In the nucleolus, phospho-Bcl-xL(Ser62) binds to and co-localizes 
with CDK1(CDC2) in G2-arrested cells, indicating that its contributes to the temporal 
trapping of CDK1(CDC2), avoiding unwanted mitosis in the presence of DNA damage. It 
could also suggest that Bcl-xL(Ser62) protects nucleolar structures during DNA damage-
induced G2 arrest to avoid rapid nucleolar disassembly associated with mitosis onset. 
Phospho-Bcl-xL(Ser62) was also located in Cajal bodies. Although not investigated 
further in this study, Cajal bodies are known to encompass dynamic trafficking and 
fusion with nucleolar structures (17, 25). In the near future, it will certainly be of interest to 
further examine Cajal bodies/nucleoli interaction during the G2 checkpoint.  
  Entry into mitosis absolutely requires progressive accumulation of active cyclin 
B1/CDK1 (CDC2) complexes in the nucleus. Indeed, recent observations indicate that 
different levels of cyclin B1/CDK1(CDC2) kinase activity are timely organized to 
coordinate and trigger different mitotic events, the initial activation of cyclin 
B1/CDK1(CDC2) complexes occuring about 20 to 25 min before nucleolar disassembly 
and nuclear envelope breakdown (26). When cyclin B1/CDK1(CDC2) activity reaches a 
specific threshold, it triggers both nucleolar disassembly and nuclear envelope 
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breakdown. After these events, cyclin B1/CDK1(CDC2) rapidly reaches maximum 
activity to resume mitosis (26). Our data suggest that Bcl-xL(Ser62) phosphorylation is 
associated with its translocation to the nucleolus. In the nucleolus, phospho-Bcl-xL(Ser62) 
will meet CDK1(CDC2) during G2 checkpoint, playing a role in stabilizing G2 arrest by 
timely trapping of CDK1(CDC2) into nucleolar structures to avoid or slow down 
unwanted mitotic entry.  
 PLK1 activity is regulated both in time and space, and its many functions have 
been linked to cell entry into mitosis, centrosomes and microtubule-organizing centres, 
mitotic exit and cytokinesis (reviewed in (27)). Relatively little is known about its function 
during the S and G2 phases of the cell cycle. However, it has been reported recently that 
PLK1 accumulates in the nucleus during S and G2 phases revealing that PLK1 also has 
key functions during the S and G2 phases of the cell cycle (28). Among them, it has been 
shown that PLK1 interacts with many chromatin-bound components including those of 
the replicative helicase, Mcm complexes, suggesting a possible role during replication 
and/or in monitoring replicative stress (29). PLK1 also binds to and phosphorylates DNA 
topoisomerase IIα, promoting its activity (28). Our observation that PLK1 is one of the 
key protein kinases associated with Bcl-xL(Ser62) phosphorylation during the G2 
checkpoint illustrates additional functional roles for PLK1 along the cell cycle.  
 At G2/M transition, high PLK1 activation is promoted by BORA and Aurora A 
(30), and facilitates CDK1(CDC2)-cyclinB1 activation by promoting WEE1 
downregulation and regulating CDC25 phosphatase activities (31). PLK1 is an important 
target of the DNA damage response enabling cell-cycle arrest. In response to DNA 
damage, PLK1 ubiquitination, degradation and inactivation have been reported via a 
CDC14B/Cdh1 pathway. PLK1 also promotes checkpoint recovery after DNA damage 
(reviewed in (27)). However, mitotic entry in an unperturbed cell cycle can occur in the 
absence of PLK1, and PLK1 does not appear to act in an amplification loop with cyclin 
B1/CDK1 (CDC2) to trigger the early mitotic events (26).     
 Activation of various MAPK pathways during G2 and mitosis has also been 
documented. MAPK14/SAPKp38α directly activates MAPKAPK2, which is responsible 
for CDC25B/C phosphorylation and 14-3-3 protein binding in vitro in response to DNA 
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damage in mammalian cells (32). Thus, MAPKAPK2, in addition to CHK1 and CHK2, is 
involved in coordinating the DNA damage response of higher eukaryotic cells. 
MAPK8/JNK1 and MAPK9/JNK2 are also strongly expressed during the G2 and early 
M-phase, accumulating in the nucleus during G2, and play a role in proper mitosis (33). 
Inhibition or silencing of MAPK9/JNK2 only did not block entry of cells into mitosis but 
resulted in polyploidy, indicating that MAPK9/JNK2 also functions in maintaining 
genomic stability (34).  The MAPK9/JNK2 effect on Bcl-xL(Ser62) phosphorylation 
resulting in G2 checkpoint stabilization is consistent with a MAPK9/JNK2 - phospho-
Bcl-xL(Ser62) function in genomic stability.   
 Phospho-Bcl-xL(Ser62) during the normal cell cycle and DNA damage-induced 
G2 checkpoint has not yet been documented.  Phospho-Bcl-xL(Ser62) has been detected 
previously in cells treated with microtubule inhibitors, including nocodazole, paclitaxel, 
vinblastine and vincristine. Mitotic arrest induced by these compounds is associated with 
Bcl-2, Bcl-xL and Mcl-1 phosphorylation. Other studies have revealed that Bcl-2 and 
Mcl-1 phosphorylation is also tightly coupled with normal mitotic events (35, 36). Bcl-2 
phosphorylation multi-sites (Ser70, Ser87, Thr69) are located within the unstructured 
loop domain of the protein, a region generally not essential for its anti-apoptotic function. 
Multiple kinases have been proposed to phosphorylate Bcl-2 and/or Bcl-xL at Ser62 in 
microtubule inhibitor-exposed cells, but most studies have suggested that JNK, normally 
activated at G2/M, is the kinase responsible for Bcl-2 and Bcl-xL phosphorylation (19-22, 
37, 38).  
 In summary, our study reveals Bcl-xL(Ser62) phosphorylation during the normal 
cell cycle and in DNA damage-induced G2 arrest and, PLK1 and MAPK9/JNK2 are 
major kinases responsible for Bcl-xL(Ser62) phosphorylation and progressive 
accumulation in nucleolar structures during stabilization of DNA damage-induced G2 
arrest.  It highlights that DNA damage also affects the dynamic composition of a 
subnuclear domain, the nucleolus, which now emerges as an important piece of the DNA 
damage cell response. 
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Materials and methods 
Cell culture, cDNA construction and transfection. 
 Human Namalwa and HeLa cell lines were obtained from the American Type Culture 
Collection and grown at 37°C under 5% CO2 in RPMI-1640 medium and DMEM 
medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml 
penicillin and 100 µg/ml streptomycin, respectively. The phosphorylation mutant pCEP4-
HA-Bcl-xL and pCDNA3.1-HA-Bcl-xL vectors were generated by triple polymerase 
chain reactions (PCR) (15). All primers and details are provided in Supplementary Table 
S1. Transfected cells were grown under hygromycin B1 (pCEP4 vectors) or neomycin 
(pCDNA3.1 vectors) selection to obtain stable cell population prior to performing the 
experiments.  
 
Mitotic trap assay and cell synchronisation 
Mitotic trap assay has been described by Andreassen et al (16). Briefly cells entering 
mitosis after G2 arrest were trapped by adding nocadazole (0.35 µM) at 24-h intervals 
after VP16 treatment. At the indicated times, the kinetics of G2 arrest, mitotic entry and 
cell death were monitored in Coulter EpicsXL flow cytometers with phospho-H3(Ser10) 
labeling and PI staining. HeLa cells were synchronized by double-thymidine block (2 
mM) and release. 
 
Protein extraction, subcellular fractionation, immunoblotting and co-
immunoprecipitation 
To prepare total protein extracts, the cells were extracted with lysis buffer containing 20 
mM Hepes(KOH), pH 7.4, 120 mM NaCl, 1% Triton X-100, 2 mM 
phenylmethylsulfonyl fluoride (PMSF), a cocktail of protease inhibitors (CompleteTM, 
Roche Applied Science) and a cocktail of phosphatase inhibitors (PhosStopTM Roche 
Applied Science). Cytosolic and nuclear extracts were prepared with NE-PER Nuclear 
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and Cytoplasmic extraction reagents according to the manufacturer's protocol 
(ThermoScientific, Rockford IL). Nucleolar fractions were obtained from enriched nuclei 
according to a procedure adapted from published protocols (39). Briefly, purified nuclei 
were re-suspended in 3 ml of 0.34 M sucrose containing 0.5 mM MgCl2 and PhosStopTM, 
and then sonicated on ice for 6 x 6-s bursts with 10-s intervals between each burst, with a 
XL-2000 Microson (Misonix Inc., Farmingdale NY) at power setting 5. Nucleoli were 
then purified by layering the sonicated solution on a 3-ml 0.88M sucrose cushion 
containing 0.5 mM MgCl2 followed by centrifugation at 2,000 x g for 20 min. Nucleoli 
pellets were re-suspended in lysis buffer containing 20 mM Hepes(KOH), pH 7.4, 120 
mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 2 mM PMSF, a cocktail of protease 
and phosphatase inhibitors, incubated on ice for 30-min with insoluble materials 
discarded after centrifugation (10,000 x g; 20 min). For immunoprecipitation, samples 
were first pre-cleaned with a protein A- and G-Sepharose mixture and, after 
centrifugation, antibodies at 10 µg/ml concentration were incubated at 4°C for 4 h. All 
antibodies used in this study are listed in Supplementary Table S2.  
 
Protein kinase assays and protein kinase chemical inhibitors 
The kinases and kinase assays are described in Supplementary Table S3. Enzyme 
activities were tested on control substrates, and velocities were expressed as 
nmole/min/mg (data in Supplementary Fig. S3). Recombinant human Bcl-xL(ΔTM) 
protein was produced and purified, as described previously (15).  The protein kinase 
chemical inhibitors deployed in this study are listed in Supplementary Table S3.  
 
siRNA-mediated protein kinase inhibition 
HeLa cells were transfected with DharmaFECT-1 transfection reagent (ThermoScientific) 
according to the manufacturer’s instructions, with 100 nM of either control siRNA or 
siRNA targeting different kinases (Supplementary Table S4). The cells were treated 10 h-
post transfection with VP16 (10 µM) for 16 h, then washed twice with PBS, followed by 
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their incubation in drug-free medium for an additional 20 h prior to protein extraction and 
SDS-PAGE. 
 
Immunofluorescence microscopy 
Namalwa cells were spread by cytocentrifugation on glass slides and HeLa cells were 
seeded and grown directly on coverslips. Both cell types were fixed in methanol at -20°C 
for 30 min and rapidly immersed into ice-cold acetone for a few seconds. The slides were 
allowed to dry at room temperature and rehydrated in PBS. Nonspecific binding sites 
were blocked in PBS containing 5% FBS (blocking solution), then the slides were 
incubated sequentially with specific primary antibody (10 µg/ml in blocking solution), 
specific labeled-secondary antibody (10 µg/ml in blocking solution) followed by DAPI 
staining, also performed in blocking solution. All antibodies are listed in Supplementary 
Table S2. Images were generated with a Leica Microsystem mounted on a Leica 
DM6000B microscope and Leica DFC480 camera hooked up to a MacInctosh computer. 
All images were quantified with Clemex Vision software (Version 3.0.036, Clemex, 
Longueuil, QC, Canada), as described previously (40). 
 
Supplementary information:  Supplementary information for this article are available at 
the journal WEB site.   
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Figure 1 Effect of Bcl-xL and Bcl-xL(Ser62Ala) phosphorylation mutant on DNA 
damage-induced G2 arrest. (A) Expression level of HA-Bcl-xL and Bcl-xL(Ser62Ala) 
phosphorylation mutant in stably-transfected Namalwa cell populations. β-actin 
expression is shown as control. (B) Schematic view of the mitotic trap assay; VP16 was 
administered at 10 µM for 30 min; nocodazole treatments (0.35 µM) at the indicated 
intervals trapped cells entering mitosis.  (C-F) Kinetics of G2 arrest (grey bars), mitotic 
slippage (red bars) and cell death (green bars) in wt Namalwa cells and Namalwa cells 
expressing HA-Bcl-xL and Bcl-xL(Ser62Ala) phosphorylation mutant. Bars represent the 
means ± s.e.m. of n independent experiments. Data with additional HA-Bcl-xL 
phosphorylation mutants are in Supplementary Fig. S1. 
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Figure 2 
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Figure 2  HA-Bcl-xL(Ser62) phosphorylation and location during DNA damage-
induced G2 arrest. (A) Expression and phosphorylation kinetics of HA-Bcl-xL and key 
components of DNA damage responses after VP16 treatment (10 µM for 30 min).  (B)  
Co-location kinetics of HA-Bcl-xL and phospho-Bcl-xL(Ser62) with nucleolin in 
Namalwa cells expressing HA-Bcl-xL exposed to VP16 (10 µM for 30 min).  (C) Co-
location kinetics of HA-Bcl-xL(Ser62Ala) and phospho-Bcl-xL(Ser62) with nucleolin in 
Namalwa cells expressing the phosphorylation mutant HA-Bcl-xL(Ser62Ala) exposed to 
VP16 (10 µM for 30 min). (D) Percentage of HA-Bcl-xL and (E) phospho-Bcl-xL(Ser62) 
located in nucleoli in Namalwa cells expressing HA-Bcl-xL and HA-Bcl-xL(Ser62Ala) 
mutant exposed to VP16 (10 µM for 30 min). Bars represent the means ± s.e.m. from 
micrographs obtained in n independent experiments. 
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Figure 3 
 50 
 
Figure 3  Endogenous Bcl-xL(Ser62) phosphorylation and location in unperturbed 
synchronized cells and during DNA damage-induced G2 arrest. (A) wt HeLa cells and 
HeLa cells expressing HA-Bcl-xL were exposed to VP16 (10 µM,  16 h), and the kinetics 
of G2 arrest (grey bars), mitotic slippage (black bars) and cell death (white bars) were 
monitored by mitotic trap assay. Bars represent the means ± s.e.m. of 6 independent 
experiments. (B) Expression kinetics of endogenous Bcl-xL and phospho-Bcl-xL(Ser62) 
in wt Hela cells exposed to VP16 (10 µM,  16 h). Total protein extracts and proteins 
obtained from cytosolic and nuclear extracts are shown. Western blots are representative 
of 3 independent experiments.   (C) Kinetics of expression of endogenous Bcl-xL and 
phospho-Bcl-xL(Ser62) in synchronized wt Hela cells after double-thymidine block 
release. Expression levels in cytosolic and nuclear extracts are represented. β-actin and 
nucleolin expression is presented as control. Phase distributions analyzed by flow 
cytometry with phospho-H3(Ser10) labeling and PI staining are indicated. Western blots 
are representative of 2 independent experiments.  (D) Co-location kinetics of endogenous 
phospho-Bcl-xL(Ser62) with nucleolin (nucleolus marker), (E) coilin (Cajal body 
marker) and (F) γ-tubulin (centrosome marker) in wt Hela cells exposed to VP16 (10 µM, 
16 h). Percentage of phospho-Bcl-xL(Ser62) in nucleoli, Cajal bodies and centrosomes 
during VP16-induced G2 checkpoint and during normal G2 phase of the cell cycle in 
synchronized wt Hela cells (sG2) are indicated in the right panels. Bars represent the 
means ± s.e.m. from 12 micrographs obtained in 4 independent experiments. 
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Figure 4 
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Figure 4 PLK1 and MAPK9/JNK2 are major protein kinases involved in Bcl-
xL(Ser62) phosphorylation and accumulation in nucleoli during DNA damage-induced 
G2 arrest. (A) In vitro kinase assays of a panel of purified and active protein kinases with 
recombinant human Bcl-xL(ΔTM) protein as substrate. All enzyme activities were tested 
on control substrates (Supplemental Figure 2 ). Western blots are representative of 4 
independent experiments.  (B) Effects of specific protein kinase inhibitors on Bcl-xL 
phosphorylation on Ser62 in Namalwa cells exposed to VP16. Cells were first exposed to 
VP16 (10 µM, 30 min) and, 12 h-post treatment, kinase inhibitors were added for an 
additional 12 h: MAPKAPK2 inhibitor (KKALNRQLGVAA, 10 µM); PLK inhibitor 
(BI2536,  0.1 µM), p38 inhibitor (SB203580, 2.0 µM), JNK inhibitor (SP600125, 5.0 
µM), GSK3 inhibitor (SB216763, 10 µM). Western blots are representative of 4 
independent experiments. (C) Effects of specific siRNAs on silencing PLK1, 
MAPK8/JNK1, MAPK9/JNK2, MAPKAPK2, MAPK14/SAPKp38α, GSK3α and 
GSK3β expression in wt Hela cells. Schematic view of these experiments (C-E) is 
showed. Additional controls are illustrated in Supplementary Fig. S4. (D) Effects of 
silencing PLK1, MAPK8/JNK1, MAPK9/JNK2, MAPKAP2, MAPK14/SAPKp38α, 
GSK3α and GSK3β expression in wt HeLa cells on the phosphorylation level of 
endogenous Bcl-xL(Ser62) after VP16 treatment. Representative western blotting of 
nuclear extracts of 3 independent experiments. (E) Co-location of endogenous phospho-
Bcl-xL(Ser62) with nucleolin (nucleolus marker) in wt Hela cells exposed to VP16 where 
various protein kinases are silenced. Quantitation of micrographs is shown in the right 
panels. Green bars are total phospho-Bcl-xL(Ser62) staining in cells; red bars are total 
nucleoli staining in cells; orange bars are the phospho-Bcl-xL(ser62)/nucleoli staining 
ratio.  Data are presented relative to wt HeLa cells exposed to VP16, and symbols are: (-) 
cells treated with siRNA control and VP16,  (+) cells treated with specific siRNA 
targeting the given protein kinase and VP16. Bars represent the means ± s.e.m. from 20 
micrographs obtained in 3 independent experiments. 
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Figure 5 Phospho-Bcl-xL(Ser62) meets CDK1(CDC2) in nucleolar structures 
during DNA damage-induced G2 arrest. (A) Co-immunoprecipitation of HA-Bcl-xL, 
HA-Bcl-xL(Ser62Ala) and phospho-HA-Bcl-xL(Ser62) with CDK1(CDC2) from 
enriched nuclear extracts obtained from Namalwa cells expressing HA-Bcl-xL or HA-
Bcl-xL(Ser62Ala) mutant exposed to VP16 (10 µM for 30 min). IgG represents co-
immunoprecipitation experiments with control immunoglobulins and ( - ) indicates a 
nuclear extract obtained from Namalwa cells expressing HA-Bcl-xL 48 h-post VP16 
treatment loaded as a western blot control. Representative of 2 independent experiments. 
(B) Reciprocal co-immunoprecipitation of HA-Bcl-xL, HA-Bcl-xL(Ser62Ala) and 
phospho-Bcl-xL(Ser62) with CDK1(CDC2) from enriched nucleolar extracts purified 
from Namalwa cells expressing HA-Bcl-xL and HA-Bcl-xL(Ser62Ala) mutant exposed 
to VP16 (10 µM for 30 min). IgG, CDK and HA represent co-immunoprecipitation 
experiments with control immunoglobulins, CDK1(CDC2) and HA-epitope tag 
antibodies, respectively. ( - ) indicates nucleolar extracts obtained from Namalwa cells 
expressing HA-Bcl-xL before and after VP16 treatment loaded as western blot controls. 
(C) Co-location of CDK1(CDC2) with nucleolin and (D) CDK1(CDC2) with phospho-
Bcl-xL(Ser62) 36 h after the beginning of VP16 treatment (10 µM,  16 h) in wt HeLa 
cells. Micrographs are representative of 2 independent experiments. (E) Schematic view 
of a proposed model. 
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Supplementary Figure S1 Effect of Bcl-xL and various Bcl-xL phosphorylation 
mutants on DNA damage-induced G2 arrest. (A) Expression level of HA-Bcl-xL and 
various phosphorylation mutants in stably-transfected Namalwa cell populations. β-actin 
expression is shown as control. (B) Schematic view of the mitotic trap assay; VP16 was 
administered at 10 µM for 30 min; nocodazole treatments (0.35 µM) at the indicated 
intervals trapped cells entering mitosis.  (C-K) Kinetics of G2 arrest (grey bars), mitotic 
slippage (red bars) and cell death (green bars) in Namalwa cells expressing HA-Bcl-xL 
and various phosphorylation mutants. Bars represent the means ± s.e.m. of n independent 
experiments. 
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Supplementary Figure S2 Specificity of the phospho-Bcl-xL(ser62) antibodies.  (A) 
Expression of phospho-HA-Bcl-xL(Ser62) in Namalwa cells expressing expressing HA-
Bcl-xL and HA-Bcl-xL(Ser62Ala) mutant exposed to VP16 (10 µM for 30 min). HA-
Bcl-xL expression is shown as control. (B) Staining of phospho-Bcl-xL(Ser62) in wt 
HeLa cells exposed to control siRNA or siRNA targeting the expression of Bcl-xL. 
Nucleolin staining and Western blottings are shown as control.  
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Supplementary Figure S3  In vitro kinase assays. (A) Enzyme activities were 
tested on control substrates with recombinant purified kinases. Velocities are expressed 
as nmole/min/mg. Two independent experiments are shown. (B) Cdk1(cdc2) enzyme 
activities tested on histone H1 control substrate with cdk1(cdc2) kinase purified by 
immunoprecipitation. Two independent immunoprecipitation assays are shown. (C) In 
vitro kinase essay with [32P]-γATP and recombinant Bcl-xL as substrate. Autoradiography 
and Coomassie staining are shown. 
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Supplementary Figure S4 Specificity of the SiRNAs. (A) Effects of silencing 
MAPK8/JNK1 and MAPK9/JNK2 with different targeted sequences on the expression of   
PLK1, MAPK8/JNK1, MAPK9/JNK2, GSK3α and GSK3β expression in wt HeLa cells 
(HeLa control) and HeLa cells exposed to VP16 (+VP16). CRKL or β−actin expression 
is shown as control. (B) Effects of silencing PLK1, GSK3α and GSK3β on the 
expression of PLK1, MAPK8/JNK1, MAPK9/JNK2, GSK3α and GSK3β expression in 
wt HeLa cells (HeLa control) and HeLa cells exposed to VP16 (+VP16). β−actin 
expression is shown as control. (C) Effects of silencing PLK1 on the expression of 
PLK1 and PLK3 in wt HeLa cells (HeLa control) and HeLa cells exposed to VP16 
(+VP16). β−actin expression is shown as control. (D) Effects of silencing PLK1, 
MAPK8/JNK1 and MAPK9/JNK2, on the expression of PLK1, MAPK8/JNK1 and 
MAPK9/JNK2 in nuclear extracts obtained from HeLa cells exposed to VP16 (+VP16). 
Nucleolin expression is shown as control. 
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Supplemental TABLE S1    cDNA constructs 
 
 
HA-Bcl-xL (T41A)  
5'-end oligonucleotide (+) with Nhe1 + START ATG codon:  5'- gctagcccacc atg ggc cgc atc ttt ta 
3'-end oligonucleotide (-) with STOP TGA codon:   5'- ctcgag tca ttt ccg act gaa gag tga 
Overlapping oligonucleotide (+) containing T41A substitution:  5'- gcc cca gaa ggg gct gaa tcg gag atg 
Overlapping oligonucleotide (-) containing T41A substitution:  5- cat ctc cga ttc agc ccc ttc tgg ggc 
(from wt HA-Bcl-xL as template / subcloned Nhe1/ Xho1 in Cep4 vector) 
  
 
HA-Bcl-xL (S43A) 
5'-end oligonucleotide (+) with Nhe1 + START ATG codon:  5'- gctagcccacc atg ggc cgc atc ttt ta  
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgag tca tttc cga ctg aag agt ga 
Overlapping oligonucleotide (+) containing S43A substitution:  5'-gaa ggg act gaa gcg gag atg gag acc 
Overlapping oligonucleotide (-) containing S43A substitution:  5'-ggt ctc cat ctc cgc ttc agt ccc ttc 
(from wt HA-Bcl-xL as template / subcloned Nhe1/ Xho1 in Cep4 vector) 
 
 
HA-Bcl-xL (T47A) 
5'-end oligonucleotide (+) with Not1 + START ATG codon:  5'- gcggccgc atg tct cag agc aac cgg ga  
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgag tca tttc cga ctg aag agt ga 
Overlapping oligonucleotide (+) containing T47A substitution:  5'-tcg gag atg gag gcc ccc agt gcc atc  
Overlapping oligonucleotide (-) containing T47A substitution:  5'-gat ggc act ggg ggc ctc cat ctc cga  
(from wt Bcl-xL as templat / subcloned Not1/ XhoI  in Cep4-HA vector) 
 
 
HA-Bcl-xL (S56A) 
5'-end oligonucleotide (+) with Not1 + START ATG codon:  5'- gcggccgcatg tct cag agc aac cgg gag 
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgag tca tttc cga ctg aag agt ga 
Overlapping oligonucleotide (+) containing S56A substitution:  5'- aat ggc aac cca gcc tgg cac ctg gca 
Overlapping oligonucleotide (-) containing S56A substitution:  5'- tgc cag gtg cca ggc tgg gtt gcc att 
(from wt Bcl-xL as template / subcloned Not1/ XhoI  in Cep4-HA vector) 
 
 
HA-Bcl-xL (S62A) 
5'-end oligonulcleotide (+) with Not1 + START ATG codon:  5'- gcggccgcatg tct cag agc aac cgg gag 
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgag tca ttt ccg act gaa gag tga 
Overlapping oligonucleotide (+) containing S62A substitution:  5- cac ctg gca gac gcc ccc gcg gtg aat 
Overlapping oligonucleotide (-) containing S62A substitution:  5- att cac cgc ggg ggc gtc tgc cag gtg  
(from wt Bcl-xL as template / subcloned Not1/ XhoI  in Cep4-HA vector) 
 
 
HA-Bcl-xL (T115A) 
5'-end oligonulcleotide (+) with Not1 + START ATG codon:  5'- gcggccgcatg tct cag agc aac cgg gag 
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgag tca ttt ccg act gaa gag tga 
Overlapping oligonucleotide (+) containing T115A substitution:  5- cag ctc cac atc gcc cca ggg aca gca 
Overlapping oligonucleotide (-) containing T115A substitution:  5- tgc tgt ccc tgg ggc gat gtg gag ctg 
(from wt Bcl-xL as template / subcloned Not1/ XhoI  in Cep4-HA vector) 
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Supplemental TABLE S1 cDNA constructs. The phosphorylation mutant pCEP4-HA-
Bcl-xL and pCDNA3.1-HA-Bcl-xL vectors were generated by triple polymerase chain 
reactions (PCR) with wt pCEP4-HA-Bcl-xL vector as DNA template. The first fragments 
were amplified by Vent polymerase, with specific adapter primers containing restriction 
site sequences at the ATG start codon and anti-sense junction primers corresponding to 
the flanking sequences at each mutation site, as listed in Table S1. The second fragments 
were amplified by Vent polymerase, with sense junction primers corresponding to 
flanking sequences at each mutation site and adapter anti-sense primers containing 
restriction site sequences at the TGA stop codon. The 2 amplified fragments were gel-
purified, heat-denaturated, and slowly annealed on ice. After elongation by Taq 
polymerase for 10 min, the third PCR, with specific adapter primers containing sequences 
at the ATG start codon and TGA stop codon, was amplified. The amplified fragment was 
first cloned in pCR2.1Topo vector (Invitrogen Corporation), sequenced, and then sub-
cloned in the eukaryotic expression vectors pCEP4 and pCDNA3.1 (Invitrogen 
Corporation). For some constructs, the HA-tag sequences were not amplified by PCR; 
these amplified fragments were than sub-cloned in-frame into the pCEP4-HA vector. All 
primers are listed in Supplemental Table 1. Purified constructs were transfected in 
Namalwa cells by electroporation at 0.27 kV (Gene Pulser, BioRad, Hercules, CA) and in 
HeLa cells by Lipofectamine2000 transfection according to the manufacturer's protocol 
(Invitrogen Corporation). 
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Supplemental TABLE S2 
ANTIBODIES   ID   Species   Source 
Cyclin B1   clone GNS-1  mouse mAb  BD Biosciences 
Phospho-cdc2 Thr161  # 9114   rabbit pAb  Cell Signaling 
Phospho-cdc2 Tyr15  # 4539   rabbit pAb  Cell Signaling 
Cdc2/CDK1   # PC25   rabbit pAb  Calbiochem 
Cdc2/CDK1   clone 1/cdk1  mouse mAb  BD Biosciences 
ATM    clone D2E2  rabbit mAb  Cell Signaling 
Phospho ATM Ser1981  clone 10H11.E12 mouse mAb  Cell Signaling 
ATR    # 2790   rabbit pAb  Cell Signaling 
Phospho ATR Ser428  # 2853   rabbit pAb  Cell Signaling 
Chk1    # 2345   rabbit pAb  Cell Signaling 
Phospho Chk1 Ser317  # 2344   rabbit pAb  Cell Signaling 
Chk2    # 2662   rabbit pAb  Cell Signaling 
Phospho Chk2 Thr68  # 2661   rabbit pAb  Cell Signaling 
Plk1     clone 208G4  rabbit mAb  Cell Signaling 
Phospho Plk1 Thr210  clone K50483  mouse mAb  BD Biosciences  
Plk3    clone B37-2  mouse mAb  BD Biosciences 
Aurora A   clone 1G4  rabbit mAb  Cell Signaling 
Phospho Aurora A Thr288 clone C39D8  rabbit mAb  Cell Signaling 
MAPKAPK2   # 3042   rabbit pAB  Cell Signaling 
Phospho-MAPKAPK2 Thr334 clone 27B7  rabbit mAb  Cell Signaling 
p38α / MAPK14   clone L53F8  mouse mAb  Cell Signaling 
Phospho p38α Thr180/Tyr182 clone 28B10  mouse mAb  Cell Signaling 
JNK1/MAPK8   clone G151-333  mouse mAb  BD Biosciences 
JNK2/MAPK9   # 4672   rabbit pAb  Cell Signaling 
Phospho JNK Thr183/Tyr185 # 9251   rabbit pAb  Cell Signaling 
GSK3α    # 9338   rabbit pAb  Cell Signaling 
GSK3β    clone 27C10  rabbit mAb  Cell Signaling 
Bcl-xL    clone 2H12  mouse mAb  BD Biosciences 
Phospho-BclxL Ser62  custom   rabbit pAb  GenScript 
Phospho-BclxL Ser62  # 4428G  rabbit pAb  InVitrogen 
HA tag    clone 12CA5  mouse mAb  Roche Applied  
HA tag    # A00168  goat pAb  GenScript 
Coilin    Ab11822  mouse mAb  Abcam 
Nucleolin   clone 4E2  mouse mAb  GeneTex 
Actin    clone 4C40  mouse mAb  Sigma 
Phospho H3 (ser10) Alexa 488 # 9708   rabbit pAb  Cell Signaling 
Anti-Mouse IgG Alexa 488 # A11001  goat pAb  InVitroGen 
Anti-Rabbit IgG Alexa 488 # A11008  goat pAb  InVitroGen 
Anti-Mouse IgG Alexa 594 # A11005  goat pAb  InVitroGen 
Anti-Rabbit IgG Alexa 594 # A11012  goat pAb  InVitroGen 
Anti-Mouse IgG HP-linked # NA931V  sheep pAb  GE Healthcare 
Anti-Rabbit IgG HP-linked # NA934V  donkey pAb  GE Healthcare 
Normal Rabbit IgG  # sc-2027  rabbit IgG  Santa Cruz  
Normal Mouse IgG  # sc-2025  mouse IgG  Santa Cruz  
ProteinG Plus/ProteinA Agarose # IP05   ------------  Calbiochem 
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Supplemental TABLE S3 
Recombinant Enzyme Source  Control Substrate     Source             Buffer 
CHK1   Sigma-Aldrich  RXRX(L/A)S((R/F)  Cell Signaling A 
CHK2   Sigma-Aldrich  AMRLERQDSIFYPK  AnaSpec         A 
p38α /MAPK14  Cell Signaling ATF-2 (19-96)   Cell Signaling B 
JNK1/MAPK8  Cell Signaling         c-Jun (1-89)   Cell Signaling B+ 
JNK2/MAPK9  Cell Sciences  c-Jun (1-89)   Cell Signaling A 
MAPKAPK2  Cell Signaling KKKLNRTLSVA   AnaSpec  A+ 
PLK1   Cell Signaling RISDELMDATFADQEAK  AnaSpec  A 
PLK3   Cell Signaling RISDELMDATFADQEAK  AnaSpec  A 
Aurora A   Cell Signaling RRSLLE    Cell Signaling A 
Aurora B   Cell Signaling LRRLSLGLRRLSLGLR 
     RLSLGLRRLSLG    AnaSpec  A 
NEK2   Cell Signaling RFRRSRRMI   AnaSpec  A 
GSK3α   Cell Signaling RRAAEELDSRAGSPQL  AnaSpec  A 
GSK3β   Sigma-Aldrich GPHRSTPESRAAV  AnaSpec  A+ 
Immunoprecipitated Enzyme 
CDC2/CDK1  Namalwa cells  Histone H1    Sigma-Aldrich B+ 
 
Buffer A (5x): 25 mM MOPS pH 7.2 
  25 mM MgCl2 
  12.5 mM β-glycerol-2-phosphate 
  0.5 mM Na3VO4 
  5 mm EGTA 
  2 mM EDTA 
  0.25 mM dithiothreitol 
  500 µΜ ATP* 
  * 0.05 µCi/µl [32P]-γATP  
Buffer A+ (5x): buffer A  + 50 µg/ ml BSA 
 
Buffer B (5x): 125 mM TRIS pH 7.2   
  
  50 mM MgCl2    
  25 mM β-glycerol-2-phosphate 
  0.5 mM Na3VO4 
  10 mM dithiothreitol 
  500 µΜ ATP* 
  * 0.05 µCi/µl [32P]-γATP  
Buffer B+ (5x): buffer B + 50 µg/ ml BSA 
 
Target   INHIBITOR   Source   Concentration 
p38    SB 203580   Calbiochem     2 µM 
JNK   SP 600125   Sigma-Aldrich     5 µM 
MAPKAPK2  H-KKALNRQLGVAA-OH Calbiochem   10 µM 
PLK   BI 2536    Axon MedChem   0.1 µM  
Aurora    ZM 447439   Tocris BioScience  0.1 µM 
GSK3   SB 216763   Sigma-Aldrich    10 µM 
 
Supplemental Table S3.  Listing of the protein kinase assays and protein kinase 
inhibitors. Source, control substrates and reaction buffers are indicated.  
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Supplemental TABLE  S4 
 
 
Target   siRNA Target sequence    Source 
 
PLK 1    (1) 5' -AGAUUGUGCCUAAGUCUCU-3'  Mol Biol Cell 15:5623, 2004   
 
MAPK8/JNK1   (1) 5'-GCCCAGUAAUAUAGUAGUA-3'  Cell Cycle 7: 533, 2008  
    (2) 5'-GGCAUGGGCUACAAGGAAA-3'  Cell Cycle 7: 533, 2008  
 
MAPK9/JNK2   (1) 5'-AGCCAACUGUGAGGAAUUA-3'  Cell Cycle 7: 533, 2008  
     (2) 5'-UCGUGAACUUGUCCUCUUA-3'  Cell Cycle 7: 533, 2008   
 
MAPK14/ p38α        (1)         5'-GGAAUUCAAUGAUGUGUAU-3'  On-Target plus sequence /Dharmacon  
    (2) 5'-UCUCCGAGGUCUAAAGUAU-3'  On-Target plus sequence/ Dharmacon  
    (3) 5'-GUAAUCUAGCUGUGAAUGA-3'  On-Target plus sequence /Dharmacon 
      (4) 5'-GUCCAUCAUUCAUGCGAAA-3'  On-Target plus sequence /Dharmacon 
  
MAPKAPK2           (1)       5'-CGAAUGGGCCAGUAUGAAU-3'  On-Target plus sequence /Dharmacon 
    (2) 5'-GUUAUACACCGUACUAUGU-3'  On-Target plus sequence /Dharmacon 
    (3) 5'-GGCAUCAACGGCAAAGUUU-3'  On-Target plus sequence /Dharmacon 
      (4) 5'-CCACCAGCCACAACUCUUU-3'  On-Target plus sequence /Dharmacom  
 
GSK3α    (1) 5'-CAUCAAAGUGAUUGGCAAU-3'  SMART POOL /Dharmacon  
    (2) 5'-AGUUGACCAUCCCUAUCCU-3'  SMART POOL //Dharmacon 
    (3)  5'-CUGAUUACACCUCAUCCAU-3'  SMART POOL /Dharmacon  
      (4) 5'-UUCUCAUCCCUCCUCACUU-3'  SMART POOL /Dharmacom  
 
GSK3β    (1) 5'-GAUCAUUUGGUGUGGUAUA-3'  SMART POOL  /Dharmacon 
    (2) 5'-GCUAGAUCACUGUAACAUA'-3  SMART POOL /Dharmacon   
    (3) 5'-GUUCCGAAGUUUAGCCUAU-3'  SMART POOL /Dharmacon    
    (4) 5'-GCACCAGAGUUGAUCUUUG-3'  SMART POOL /Dharmacon 
 
 
NON-TARGETING        SMART POOL / Dharmacom  
  
 
 
 
 
  
    
Supplemental Table S4. Listing of the SiRNA targeted sequence deployed in this 
study. 
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Supplemental TABLE S5 
 
Bcl-xL    W-H-L-A-D-(pS62)-P-A-V-N 
 
 
Protein Kinase   Consensus motif 
 
CHK1    Φ-X-β-X-X-(pS/T) 
CHK2    R/F-R/Φ-L/I-L/R-R-X-X-(pS/T)-F/I-F/I/R  
Aurora A   R/K/N-R-X-(pS/T)- Φ 
MAPK8/JNK1   (pS/T)-P 
MAPK9/JNK2   (pS/T)-P 
MAPK14/SAPKp38α  (pS/T)-P 
Cdk1(cdc2)   (pS/T)-P-X-K/R 
GSK3    (pS/T)-X-X-X-S 
PLK-1    D/EX(pS/T)-Φ-X-D/E 
Nek-2    R/K-X-X-A/I-(pS/T)-R/K 
MAPKAPK2   Φ-X-R-X-X-(pS/T)- Φ 
 
 
Supplemental Table S5. These protein kinases were identified as putative protein 
kinase involved with Bcl-xL(Ser62) phosphorylation by in silico consensus site prediction 
search using either GPS2.0, NetPhosK, NetworKIN, or PhosphoELM softwares. 
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Abstract  
 
 Analysis of a series of phosphorylation mutants reveals that cells expressing Bcl-
xL(Ser62Ala) are more stable at a sustained spindle-assembly checkpoint (SAC) after 
exposure to taxol than cells expressing wild-type Bcl-xL or other phosphorylation 
mutants, an effect that appears to be independent of its anti-apoptotic activity. Bcl-
xL(Ser62) is strongly phosphorylated by PLK1 and MAPK14/SAPKp38α at 
prometaphase, metaphase and the anaphase boundary, while it is dephosphorylated at 
telophase and cytokinesis. Phospho-Bcl-xL(Ser62) localizes in centrosomes with γ-
tubulin, along the mitotic spindle with dynein motor protein and in cytosol with SAC 
signaling components.  In taxol-exposed cells, phospho-Bcl-xL(Ser62) binds to the 
CDC20/MAD2/BUBR1/BUB3 complex, while Bcl-xL(Ser62Ala) does not. These data 
indicate that during SAC, Bcl-xL(Ser62) phosphorylation accelerates SAC resolution and 
cell entry into anaphase, even in the presence of unattached or misaligned chromosomes. 
Silencing Bcl-xL expression also leads nocodazole-exposed cells to tetraploidy and 
binucleation, consistent with a Bcl-xL function in SAC and genomic stability. 
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Introduction 
 Mitosis involves proper alignment and accurate segregation of sister chromatids 
into two daughter cells to ensure precise inheritance of the genome. Failure of the process 
can lead to cell death or genetic instability, aneuploidy and diseases, including cancer 
(reviewed in (1-3)). After DNA replication and centrosome duplication, entry into mitosis 
absolutely requires progressive accumulation of active cyclin B1/CDK1 complexes in the 
nucleus that will initiate chromosome condensation, nuclear envelope breakdown, 
disassembly of the nuclear lamina and many forms of nuclear bodies, including Cajal 
bodies and nucleoli (4-7). Centrosomes become separated by the end of prophase, and, 
during prometaphase, highly dynamic mitotic microtubules form a bipolar spindle to 
which chromosomes must be bi-oriented and perfectly aligned by the end of metaphase.  
The spindle-assembly checkpoint (SAC) is the safety program that ensures the fidelity of 
chromosome bi-orientation and alignment, controlling entry into anaphase. It is 
constitutively active until proper microtubule attachment to and tension on kinetochores 
and individual sister chromatids at centromeric chromosomes (reviewed in (1-3)). 
Functionally, the SAC negatively regulates the ability of the limiting subunit CDC20 to 
activate the anaphase-promoting complex or cyclosome (APC/C), as APC/CCDC20, a large 
multiprotein E3 ubiquitin ligase consisting of at least 11 core subunits, that targets key 
mitotic substrates, including cyclin B and securin, provoking entry into anaphase and 
mitosis conclusion (8, 9).  
 The ability of CDC20 to activate APC/C, evoking entry into anaphase, is tightly 
regulated by several mechanisms, until all centromeric chromosomes have achieved 
bipolar kinetochore-microtubule attachment. During prometaphase/metaphase, when 
CDC20 is concentrated at kinetochores, the established view is that various mitotic 
checkpoint proteins, including BUB1, BUBR1, BUB3, MAD1 and MAD2, bind to 
kinetochores that lack attachment/tension, and generate a "stop anaphase signal" that 
diffuses into the mitotic cytosol (1-3, 8-11). This "stop anaphase signal" consists of a 
BUB3/BUBR1/MAD2 complex which diffuses into the mitotic cytosol, binds to CDC20 
and inhibits APC/C (12-19).  Direct phosphorylation of CDC20 by BUB1 and cyclin 
B1/CDK1 has also been reported, providing a direct catalytic mechanism that prevents 
CDC20 binding to APC/C during the SAC (20-22).   
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 In recent years, several studies have reported that members of the Bcl-2 family, in 
addition to their central role in controlling apoptosis during development and cellular 
stress, also play a part in the cell cycle and DNA repair pathways, effects that are 
generally distinct from their function in apoptosis and that influence genomic stability 
(reviewed in (23, 24)). Bcl-xL phosphorylation at Ser62 has been detected previously in a 
variety of cell lines treated with microtubule inhibitors, including nocodazole, paclitaxel, 
vinblastine, vincristine, colchicine and pironetin (25-33), but the exact function of Bcl-
xL(Ser62) phosphorylation during mitosis remains elusive. Bcl-xL(Ser62) is located 
within the unstructured loop domain of the protein, a region generally not essential for its 
anti-apoptotic function (34-36). However, studies have indicated that a deletion mutant of the 
loop domain displays an enhanced ability to inhibit apoptosis with no significant 
alterations in its ability to bind pro-apoptotic Bax (34). Some have suggested that Bcl-xL 
phosphorylation maintains its anti-apoptotic function (30), while others have reported that 
phosphorylation causes Bcl-xL to release bound Bax and promote apoptosis (31).  No 
study has investigated other possible Bcl-xL functions acting directly on mitosis 
regulation and progression. 
 To better understand the importance of Bcl-xL phosphorylation events within its 
flexible loop domain in regulating Bcl-xL location and function during mitosis, we 
generated a series of single-point Bcl-xL cDNA phosphorylation mutants, including 
Thr41Ala, Ser43Ala, Thr47Ala, Ser56Ala, Ser62Ala and Thr115Ala and selected stably-
transfected human cell populations. We also investigated Bcl-xL phosphorylation and 
location kinetics during mitosis and deployed siRNAs targeting Bcl-xL expression.  In 
this study, we provide evidence that phospho-Bcl-xL(Ser62) is a key component of 
mitosis progression at the SAC, which appears to be separate from its anti-apoptotic 
function.  
 
Results 
Effect of Bcl-xL and various Bcl-xL phosphorylation mutants on SAC stability and 
mitosis progression 
To examine the mitotic functions of Bcl-xL, we first generated various HA-tagged 
Bcl-xL phosphorylation mutants, including Thr41Ala, Ser43Ala, Thr47Ala, Ser56Ala, 
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Ser62Ala and Thr115Ala, then stably expressed them in Namalwa cells (Figure 1A and 
Supplemental Figure S1A). Simple experimental monitoring by flow cytometry with 
phospho-H3(Ser10) labeling and propidium iodide (PI) staining were used to evaluate the 
kinetics of early mitotic entry and stability (N4 DNA content, phospho-H3(Ser10)-
positive), mitotic exit (N4 DNA content, phospho-H3(Ser10)-negative), G1 entry (N2 
DNA content, phospho-H3(Ser10)-negative), and the kinetics of cell death (sub-G1 DNA 
content) in taxol-exposed cells. Control Namalwa cells (Figure 1B) or Namalwa cells 
stably transfected with empty vector (Figure 1C) died rapidly after taxol treatment (green 
bars).  In contrast, cells stably expressing HA-Bcl-xL and HA-Bcl-xL(Ser62Ala) mutant 
showed similar strong inhibition of apoptosis (Figure 1D-E; green bars). Up to 80% of 
cells over-expressing wild type (wt) HA-Bcl-xL and HA-Bcl-xL(Ser62Ala) mutants 
accumulated in early mitosis (N4 DNA/phospho-H3(Ser10)-positive; red bars) from 12- 
to 24-h taxol exposure. Interestingly, HA-Bcl-xL-expressing cells started to lose the 
phospho-H3(Ser10) marker by 36 h, whereas HA-Bcl-xL(Ser62Ala) mutant cells were 
still stable in early mitosis by 36 h (N4 DNA/phospho-H3(Ser10)-positive; red bars), 
gradually losing the phospho-H3(Ser10) marker only at 48 to 60 h after taxol treatment. 
The phosphorylation mutants, including HA-Bcl-xL(Thr41Ala), (Ser43Ala), (Thr47Ala), 
(Ser56Ala) and (Thr115Ala), did not present a phenotype similar to HA-Bcl-
xL(Ser62Ala) (Supplemental Figure S1B-I), revealing the specificity of the HA-Bcl-
xL(Ser62Ala) effect on mitosis regulation and progression.  Co-commitly, 
phosphorylation of HA-Bcl-xL(Ser62) appeared rapidly in taxol-exposed cells in parallel 
with phospho-histone H3(Ser10), but not on HA-Bcl-xL(Ser62Ala) mutant (Figure 1F). 
Together, these results indicated that Bcl-xL(Ser62) phosphorylation occurred at a SAC 
in taxol-exposed cells. Phospho-Bcl-xL(Ser62) also appeared to accelerate SAC 
resolution and cell entry into anaphase. Indeed, failure of this phosphorylation in cells 
expressing the HA-Bcl-xL(Ser62Ala) mutant maintained taxol-exposed cells at the SAC 
for a longer time period with no striking difference in apoptosis level. 
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Endogenous Bcl-xL(Ser62) phosphorylation and location in synchronized cells and 
in taxol-sustained SAC in wt HeLa cells 
Because the above observations were made in HA-Bcl-xL-transfected and over-
expressed cells, we next monitored and explored the role of endogenous phospho-Bcl-
xL(Ser62) during mitosis. First, wt HeLa cells were synchronized by double thymidine 
block and released upon progression to G2. The cells were then treated with nocodazole 
(0.35 µM, 4-h), and prometaphase/metaphase cells were collected by mitotic shake-off. A 
portion of these cells was released from nocodazole and by growth in the presence of 
MG-132 (25 µM), a proteasome inhibitor that prevents cyclinB1 and securin destruction, 
to obtain a cell population at the anaphase boundary. A second set was also released from 
nocodazole and by growth in the presence of blebbistatin (10 µM), a selective non-
muscle contractile motor myosin II inhibitor that prevents furrow ingression, to attain a 
cell population at telophase/cytokinesis. A schematic view of these experiments appears 
in Figure 2A. Western blotting disclosed that Bcl-xL was highly phosphorylated on Ser62 
at prometaphase, metaphase and the anaphase boundary, while it was rapidly 
dephosphorylated at telophase/cytokinesis (Figure 2A). Bcl-xL level remained stable 
along mitosis, and cyclinB1 and phospho-H3(Ser10) expression was also shown to be a 
specific early mitotic phase marker (Figure 2A). We next looked for the location of 
phospho-Bcl-xL(Ser62) in unperturbed, synchronized wt HeLa cells. In these 
experiments, wt HeLa cells were synchronized by double thymidine block and release 
upon progression to G2 and entry into mitosis. The cells were collected at 30-min 
intervals from 9 to 12 h after double thymidine block and release to acquire mitotic cells 
at all steps of mitosis. Phospho-Bcl-xL(Ser62) did not co-localize with kinetochore 
structural proteins, including CENPA and HEC1, the microtubule plus-end tracking-
associated protein CLIP170, but localized in centrosomes with γ-tubulin, in mitotic 
cytosol with the SAC signaling kinase PLK1, and in cytosol as well as along the 
microtubule spindle with the motor protein dynein (Figure 2B). Controls with Bcl-xL 
antibodies are illustrated in Supplemental Figure S2.  Similar observations were made in 
taxol-exposed wt HeLa cells. More than 50 to 60% of wt HeLa cells harbored N4 DNA 
content and phospho-H3(Ser10) positivity 24-h post-taxol exposure (Figure 3A) with 
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Bcl-xL phosphorylation on Ser62 (Figure 3B). The cells gradually lost Bcl-xL(Ser62) 
phosphorylation with the early mitotic and SAC phospho-H3(Ser10) marker.  In these 
cells 24 h post-taxol treatment, phospho-Bcl-xL(Ser62) had a similar location compared 
to the normal mitosis step at prometaphase and metaphase, with no co-location with 
kinetochore structural proteins, including CENPA and HEC1, and co-location in 
centrosomes with γ-tubulin, in mitotic cytosol with SAC signaling components, including 
PLK1, BUBR1 and MAD2, and the motor protein dynein (Figure 3C). A summary of 
microscopy analysis is presented in Tables 1A and 1B. 
 
The importance of Bcl-xL in SAC resolution and cell fate 
Because the above observations reveal a role of Bcl-xL in SAC and mitosis 
progression, we hypothesized that silencing Bcl-xL expression would have an impact on 
SAC stability and resolution. To perform these experiments, we used nocodazole which 
has less toxicity than taxol in wt HeLa cells. Two types of experiments were conducted. 
First, we monitored SAC resolution/adaptation under continuous nocodazole treatment in 
cells transfected with control siRNAs or siRNAs targetting Bcl-xL expression. A 
schematic illustration of these experiments appears in the upper left panel of Figure 4A, 
with Bcl-xL expression shown in the upper right panel (Figure 4A). When Bcl-xL 
expression was suppressed, the cells lost phospho-H3(Ser10) labeling more rapidly than 
cells expressing Bcl-xL (Figure 4A, red bars). Moreover, these cells did not enter into G1 
(Figure 4A, blue bars) and remained with N4 DNA content (Figure 4A, grey bars), 
indicating tetraploidy. Second, we monitored SAC resolution/recovery under conditions 
where cells were released from nocodazole treatment, and in cells transfected with 
control siRNA or siRNA targeting Bcl-xL expression. A schematic view of these 
experiments is shown in the upper left panel of Figure 4B, with Bcl-xL expression 
illustrated in the upper right panel (Figure 4B). When Bcl-xL expression was suppressed, 
the cells rapidly lost phospho-H3(Ser10) labeling compared to cells expressing Bcl-xL 
(Figure 4A, red bars). In addition, these cells did not enter into G1 as fast as cells 
expressing Bcl-xL (Figure 4B, blue bars), and more cells retained N4 DNA content 
(Figure 4B, grey bars) or died (Figure 4B, green bars). Finally, further observation of 
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tetraploid cells under the microscope revealed that they were binucleated (Figure 4C). 
 
PLK1 and MAPK14/SAPKp38α are major protein kinases involved in Bcl-
xL(Ser62) phosphorylation during mitosis 
Based on an in silico consensus site prediction search and on known protein 
kinases activated during mitosis, we first tested a panel of protein kinases by in vitro 
kinase assays with recombinant human Bcl-xL protein as substrate (Figure 5A). Among 
all the kinases tested, PLK1, MAPK8/JNK1, MAPK9/JNK2, MAPKAP2, 
MAPK14/SAPKp38α, GSK3α and GSK3β were positive and able to phosphorylate 
recombinant Bcl-xL protein on Ser62 in in vitro kinase assays (Figure 5A), while CHK1, 
PLK3, AuroraB, MPS1, CDK1(CDC2), BUB1, BUB3 and BUBR1 failed to 
phosphorylate recombinant Bcl-xL protein on Ser62 (Figure 5A). Enzyme-specific 
activities with control substrates are indicated in Supplemental Figure S3, and details of 
the kinase assays are given in Supplemental Table S1A. Then, with specific 
pharmacological inhibitors and nocodazole-exposed cells, we observed that PLK and 
MAPK14/SAPKp38α inhibitors prevented Bcl-xL phosphorylation on Ser62 in 
nocodazole-exposed cells (Figure 5B). A schematic illustration of these experiments, and 
Bcl-xL and phospho-H3(Ser10) expression appear in Figure 5B.  Deploying a series of 
specific siRNAs, Western blotting of cell extracts from cells collected by mitotic shake-
off revealed again that the most important kinases involved in Bcl-xL(Ser62) 
phosphorylation of wt HeLa cells were PLK1 and MAPK14/SAPKp38α (Figure 5C). 
These experiments and the expression level of phospho-Bcl-xL(Ser62), Bcl-xL, phospho-
H3(Ser10), PLK1, MAPK14/SAPKp38α, , MAPKAP2, MAPK8/JNK1, MAPK9/JNK2 
and β-actin are schematically illustrated in Figure 5C. Additional controls and siRNA 
experiments are reported in Supplemental Figure S4, with details in Supplemental Table 
S1B. The data indicate that PLK1 and MAPK14/SAPKp38α are major protein kinases 
associated with Bcl-xL(Ser62) phosphorylation during mitosis.  
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Interaction between phospho-Bcl-xL(Ser62) and the CDC20/MAD2/BUBR1/BUB3 
complex 
During SAC, a "stop anaphase signal" consisting of MAD2, BUBR1 and BUB3 
complex bound to CDC20 in mitotic cytosol negatively controls APC/C activity. In co-
immunoprecipitation experiments performed in transfected Namalwa cells, we observed 
that HA-Bcl-xL protein co-immunoprecipitated with MAD2, BUBR1, BUB3 and 
CDC20, but not BUB1, in unperturbed and taxol-exposed cells (24 h), while HA-Bcl-
xL(Ser62Ala) mutant was only bound to MAD2 and, to a much lesser extent, BUB3 
(Figure 6A). These interactions were lost as the cells gradually progressed into the later 
stage of mitosis 48 h post-taxol exposure (Figure 1D, red bars). A series of reciprocal co-
immunoprecipitations confirmed that MAD2, BUBR1 and CDC20 interact with phospho-
HA-Bcl-xL(Ser62) (Figure 6B). CDC27 (APC-3), a subunit of APC, did not co-
immunoprecipitate in these experiments. 
 
Discussion  
 Our study indicates that during SAC, PLK1 and MAPK14/p38α mediated Bcl-
xL(Ser62) phosphorylation, binding it to the inhibitory CDC20/MAD2/BUBR1/BUB3 
complex in a way that accelerates SAC resolution and leading cells to enter anaphase 
more rapidly, even in the presence of unattached or misaligned chromosomes. Silencing 
Bcl-xL expression also leads nocodazole-exposed cells to tetraploidy and binucleation, 
consistent with Bcl-xL function in genomic stability. Phospho-Bcl-xL(Ser62) also 
localizes in centrosomes with γ-tubulin and along the microtubule spindle with dynein 
motor protein, but its functions at these locations were not further addressed in this study. 
Importantly, phospho-Bcl-xL(Ser62) function in mitosis appears to be separable from 
Bcl-xL’s known role in apoptosis, as Bcl-xL(Ser62Ala) phosphorylation mutant keeps its 
anti-apoptotic effect but clearly shows different behavior during SAC resolution and 
mitotic progression. Figure 6C provides a schematic view of the proposed model. 
 Bcl-xL phosphorylation has been detected previously in mitotic cells treated with 
microtubule inhibitors and binders, including nocodazole, paclitaxel, vinblastine, 
vincristine, colchicine and pironetin, and a few protein kinases have been proposed to 
phosphorylate Bcl-xL at Ser62 in microtubule inhibitor-exposed cells. Most studies have 
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suggested that JNK, normally activated at G2/M, is the kinase responsible for Bcl-2 and 
Bcl-xL phosphorylation (25-33, 37). Unlike other studies which investigated single protein 
kinases, in this work we simultaneously probed more than 14 protein kinases in a 
combination of assays, including in vitro kinase assays, pharmacological inhibitors and 
siRNAs. Most importantly, siRNA analysis was performed in a highly-enriched mitotic 
cell population collected by mitotic shake-off, to eliminate and avoid contamination or 
unwanted effects of these protein kinases in the G2 cell population. Our systemic 
approach may explain difference between our study and others (25-33, 37). In our 
experiment, two major protein kinases, PLK1 and MAPK14/SAPKp38α, involved in Bcl-
xL(Ser62) phosphorylation during mitosis, have been identified.  PLK1 activity is known 
to be highly regulated in both time and space, and has key functions for cell entry into 
mitosis, SAC regulation, mitotic exit and cytokinesis (reviewed in (38, 39)). 
MAPK14/SAPKp38α  is another major protein kinase activated during mitosis (40), that 
plays key roles during SAC, at metaphase/anaphase transition (40-47). 
 The current model of SAC regulation, supported by many studies indicates that 
unattached kinetochores generate the formation of a "stop anaphase signal" containing the 
proteins MAD2, BUBR1 and BUB3 that diffuse into mitotic cytosol and sequester 
CDC20 to interfere with APC/C activity (1-3, 8-19). However, subsequent entry into 
anaphase required SAC resolution and APC/C activation by a mechanism that remains 
poorly understood. SAC resolution or mitotic slippage in the presence of unattached or 
misaligned chromosomes has often been observed with microtubule poisons (48-54), and 
SAC silencing or resolution at least required ubiquitination, deubiquitination and 
proteolysis (55-59).  Several findings in our study support a role of Bcl-xL in SAC 
resolution, even in the presence of unattached or misaligned chromosomes. First, cells 
overexpressing wt Bcl-xL or the phosphorylation mutant Bcl-xL(Ser62Ala) show 
differences in phospho-H3(Ser10) dephosphorylation kinetics while retaining N4 DNA 
content, a measure of SAC resolution in taxol-exposed cells. Second, phospho-Bcl-
xL(Ser62) phosphorylation and de-phosphorylation kinetics correlate with SAC/On and 
SAC/Off kinetics. Third, phospho-Bcl-xL(Ser62) binds to the CDC20/MAD2/BUBR1/ 
BUB3 inhibitory complex, while Bcl-xL(Ser62Ala) does not. Finally, silencing Bcl-xL 
expression also accelerates SAC resolution.  Our data do not exclude that, in addition to 
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Bcl-xL phosphorylation on Ser62, other events may also occur to regulate Bcl-xL 
function during mitosis. The formation of SAC inhibitory complex consisting of 
CDC20/MAD2/BUBR1/BUB3 is highly dynamic, and several intermediates have been 
resolved in a reconstituted cell-free system (19). In the near future, it will be of interest to 
use the reconstituted cell-free system with recombinant Bcl-xL protein and the 
combination of phosphorylation mutant and phosphorylation mimetic recombinant Bcl-
xL proteins to resolve their actions on the formation, stability and diassembly of the 
CDC20/MAD2/BUBR1/BUB3 inhibitory complex.  
 These data indicate that during SAC, Bcl-xL(Ser62) phosphorylation accelerates 
SAC resolution and cell entry into anaphase, even in the presence of unattached or 
misaligned chromosomes. Such Bcl-xL action will raise the occurrence of tetraploidy and 
binucleation, with a direct consequence on genomic stability. The association between 
anti-apoptotic Bcl-2 or Bcl-xL and genomic stability has previously been suggested in the 
context of DNA damage and DNA repair. Indeed, they have been shown to influence 
nucleotide excision repair (60), base excision repair (61), DNA mismatch repair (62), the 
Rad51-dependent homologous recombination pathway (63, 64), gene conversion (65) and the 
non-homologous end-joining pathway (66), providing significant effects on genomic 
stability. Bcl-xL also showed specific functions during the G2 checkpoint mediated by 
DNA damage, effects that are independent of its anti-apoptotic role, but which influence 
genomic stability  (36). Similarly, mice bearing a Bcl-xL transgene incur malignant 
conversion of benign tumors (67). To the best of our knowledge, this is the first 
observation to reveal that phospho-Bcl-xL(Ser62) is associated with genomic stability, 
influencing tetraploidy and binucleation as a consequence of its direct function on SAC 
resolution and mitosis progression. Our finding is in harmony with those observations of 
others which reveal that dysfunctional SAC has a dramatic effect on aneuploidy and 
tumorigenesis in mice (68).  
 
Materials and methods 
Cell culture, cDNA construction and cell analysis 
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  Human Namalwa and HeLa cell lines were obtained from the American Type 
Culture Collection and grown at 37°C under 5% CO2 in RPMI-1640 medium and DMEM 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin 
and 100 µg/ml streptomycin, respectively. The phosphorylation mutant pCEP4-HA-Bcl-
xL and pCDNA3.1-HA-Bcl-xL vector were generated by triple polymerase chain 
reactions. All primers and details are provided in Supplemental Table S1C. Transfected 
cells were grown under hygromycin B1 (pCEP4 vectors) or neomycin (pCDNA3.1 
vectors) selection to attain a stable cell population prior to performing the experiments. 
The kinetics of mitotic entry, cell cycle phase distribution and cell death were monitored 
in Coulter EpicsXL flow cytometers with phospho-H3(Ser10) labeling and PI staining.  
HeLa cells were synchronized by double-thymidine block (2 mM) and release. 
 
Protein extraction and immunoblotting  
To prepare total protein extracts, cells were extracted with lysis buffer containing 
20 mM Hepes(KOH), pH 7.4, 120 mM NaCl, 1% Triton X-100, 2 mM 
phenylmethylsulfonyl fluoride, a cocktail of protease inhibitors (CompleteTM, Roche 
Applied Science) and a cocktail of phosphatase inhibitors (PhosStopTM Roche Applied 
Science). For immunoprecipitation, the samples were first pre-cleaned with a protein A- 
and G-Sepharose mixture and, after centrifugation, antibodies at 10 µg/ml concentration 
were incubated at 4°C for 4 h. All antibodies used in this study are listed in Supplemental 
Table S1D.  
 
Immunofluorescence microscopy 
HeLa cells were seeded and grown directly on coverslips. The cells were fixed in 
methanol at -20°C for 30 min and rapidly immersed in ice-cold acetone for a few 
seconds. The slides were allowed to dry at room temperature and rehydrated in PBS. 
Nonspecific binding sites were blocked in PBS containing 5% FBS (blocking solution); 
then, the slides were incubated sequentially with specific primary antibody (10 µg/ml in 
blocking solution), specific labeled secondary antibody (10 µg/ml in blocking solution), 
followed by DAPI staining, also performed in blocking solution. All antibodies are listed 
in Supplemental Table S1E. Images were generated with a Leica Microsystem mounted 
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on a Leica DM6000B microscope and Leica DFC480 camera hooked up to a Macintosh 
computer. 
 
Protein kinase assays and protein kinase chemical inhibitors 
The kinases and kinase assays are described in Supplemental Table S1A. Enzyme 
activities were tested on control substrates, and velocities were expressed as 
nmole/min/mg (data in Supplemental Figure S3). Recombinant human Bcl-xL(ΔTM) 
protein was produced and purified, as described previously (36).  The protein kinase 
chemical inhibitors deployed in this study are listed in Supplemental Table S1A.  
 
siRNA-mediated protein kinase inhibition 
HeLa cells were transfected with DharmaFECT-1 transfection reagent 
(ThermoScientific) according to the manufacturer’s instructions, with 100 nM of either 
control siRNA or siRNA targeting different kinases (Supplemental Table S1C). The cells 
were treated 48 h post-transfection with taxol (0.1 µm) or nocodazole (0.35 µm), as 
indicated prior to protein extraction and SDS-PAGE. 
 
Online supplemental materials: Supplemental materials for this article, including 
supplemental figures and tables, are available at the Journal website.   
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TABLE 1A   Phase distribution versus labeling (number of cells) in synchronized  
  human wt HeLa cells  collected from 9 to 12 h after double thymidine  
  block-release 
 
P-Bcl-xL(S62) PROMETAPHASE METAPHASE ANAPHASE TELOPHASE CYOKINESIS TOTAL 
+ CENPA 17/22  (-) 17/17  (-) 11/11  (-) 10/10  (-) 16/16  (-) 76 
+ PLK1 45/45  (+) 46/46  (+) 21/21 (+) 12/19 (-) 14/14 (-) 145 
+ γ-Tubulin 21/21  (+) 19/19  (+) 15/15  (+) 08/10 (-) 15/15  (-) 80 
+ Clip-170 36/36  (-) 30/30  (-) 23/23  (-) 10/14  (-) 09/13  (-) 116 
+ Dynein 24/24  (+) 20/20  (+) 10/10  (+) 07/10  (-) 14/14 (-) 78 
+ HEC1  36/36  (-) 26/26  (-) 11/11  (-) 9/9  (-) 17/17  (-) 99 
              
Bcl-xL PROMETAPHASE METAPHASE ANAPHASE TELOPHASE CYOKINESIS TOTAL  
+ CENPA 32/32 (-) 19/19  (-) 10/10  (-) 09/09  (-) 12/12  (-) 82 
+ PLK1 55/55  (+) 28/29  (+) 21/21  (+) 08/12  (+) 14/14  (-) 131 
+ γ-Tubulin 28/28  (+) 22/22  (+) 11/11  (+) 12/12  (+) 14/18  (+) 91 
+ Clip-170 27/27  (-) 12/20  (-) 10/19  (-) 10/16  (-) 10/13  (-) 95 
+ Dynein 36/36  (+) 23/23 (+) 11/11  (+) 08/08  (+) 08/08  (+) 86 
+ HEC1  27/27  (-) 22/22 (-) 12/12 (-) 11/11  (-) 13/13  (-) 85 
              
TOTAL 389 293 175 140 167 1,164 
 
 
 
 
 
TABLE 1B   Phase distribution versus labeling (number of cells) in human wt HeLa  
  cells collected after taxol treatment (0.1 µm, 24 h) 
 
 
  Bcl-xL P-Bcl-xL(S62) TOTAL 
+  CENPA  94/94   (-) 91/102 (-) 196 
+HEC1 171/171 (-) 90/98  (-) 269 
+ Dynein  30/30   (+) 24/24  (+) 54 
+ γ-Tubulin  84/90   (+) 85/92  (+) 182 
+ PLK1 143/143 (+) 81/81  (+) 224 
+ BubRI  50/55  (+) 58/61  (+) 116 
+ MAD2 40/46 (+) 32/41 (+) 87 
       
TOTAL 629 499 1128 
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Figure 1 
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Figure 1 Effect of Bcl-xL and Bcl-xL(Ser62Ala) phosphorylation mutant on the 
stability of the SAC. (A) Expression level of HA-Bcl-xL and Bcl-xL(Ser62Ala) 
phosphorylation mutant in stably-transfected Namalwa cell populations. β-actin 
expression is shown as control. (B-E) Kinetics of G2/M cells (PI staining; grey bars), 
early mitotic cells (phospho-H3(Ser10) staining; red bars), dead cells (PI staining; green 
bars) and G1 cells (PI staining; blue bars) in wt Namalwa cells and Namalwa cells 
expressing empty vector, HA-Bcl-xL and HA-Bcl-xL(Ser62Ala) phosphorylation mutant 
during taxol treatment (0.1 µM). Bars represent the means ± s.e.m. of n independent 
experiments. (F) Expression and phosphorylation kinetics of HA-Bcl-xL(Ser62) and 
phospho-histone H3(Ser10) after taxol treatment (0.1 µM) in Namalwa cells expressing 
HA-Bcl-xL and Bcl-xL(Ser62Ala) phosphorylation mutant. Data on additional HA-Bcl-
xL phosphorylation mutants are reported in Supplemental Figure S1A-I, and additional 
controls for the specificity of phospho-Bcl-xL(Ser62) Ab are shown in Supplemental 
Figure S1J-K. 
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Figure 2 
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Figure 2  Bcl-xL(Ser62) phosphorylation and location in synchronized wt HeLa 
cells at mitosis. (A) Expression kinetics of Bcl-xL, phospho-Bcl-xL(Ser62), cyclin B1 
and phospho-H3(Ser10) in wt HeLa cells obtained at different steps of mitosis.  A 
schematic view of these experiments is illustrated on top. (B) Co-location of phospho-
Bcl-xL(Ser62) with CENPA, HEC1, CLIP170, PLK1, γ-tubulin and dynein motor protein 
at different steps of mitosis. Micrographs with Bcl-xL Ab labeling are shown in 
Supplemental Figure S2. Representative of a total of 1,164 mitotic cells (3 experiments). 
Summary in Table 1A. 
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Figure 3 Bcl-xL(Ser62) phosphorylation and location in taxol-exposed wt HeLa 
cells. (A) Kinetics of G2/M cells (PI staining; grey bars), early mitotic cells (phospho-
H3(Ser10) labeling; red bars), dead cells (PI staining; green bars) and G1 cells (PI 
staining; blue bars) of wt HeLa cells during taxol treatment. Bars represent the means ± 
s.e.m. of n independent experiments. (B) Expression kinetics of Bcl-xL, phospho-Bcl-
xL(Ser62) and phospho-H3(Ser10), in wt HeLa cells exposed to taxol. (C) Co-location of 
phospho-Bcl-xL(Ser62) with CENPA, HEC1, dynein motor protein, γ-tubulin, PLK1, 
BubR1 and Mad2 in wt HeLa cells exposed to taxol (0.1 µM; 24 h). Representative of a 
total of 1,128 cells (3 experiments). Summary in Table 1B. 
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Figure 4 
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Figure 4  Effect of silencing Bcl-xL expression on the stability and resolution of the 
SAC. wt HeLa cells were transfected with control siRNAs or siRNAs targeting Bcl-xL 48 
h prior to (A) continuous nocodazole treatment (SAC resolution/adaptation experiments), 
and (B) 24-h nocodazole treatment, followed by drug release (SAC resolution/recovery 
experiments). Schematic views of these experiments appear in the upper left panels, and 
Bcl-xL expression kinetics are reported in the upper right panels (A and B). β-actin 
expression is shown as control. The lower panels (A and B) present the kinetics of G2/M 
cells (PI staining; grey bars), early mitotic cells (phospho-H3(Ser10) labeling; red bars), 
dead cells (PI staining; green bars) and G1 cells (PI staining; blue bars) of HeLa cells 
transfected with control siRNAs or siRNAs targeting Bcl-xL, at the indicated times after 
nododazole treatment (0.35 µM). Bars represent the means ± s.e.m. of 4 independent 
experiments. (C) Light microscopy of HeLa cells 36 h post-nocodazole treatment.  
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Figure 5 
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Figure 5 PLK1 and MAPK14/SAPKp38α are major protein kinases involved in 
Bcl-xL(Ser62) phosphorylation at mitosis. (A) In vitro assays of a panel of purified and 
active protein kinases with recombinant human Bcl-xL(ΔTM) protein as substrate. All 
enzyme activities were tested on control substrates (Supplemental Figure S3). Western 
blots are representative of 2 independent experiments.  (B) Effects of specific protein 
kinase inhibitors on Bcl-xL phosphorylation on Ser62 in Namalwa cells exposed to taxol. 
The cells were first exposed to nocodazole (0.35 µM) and, 16 h post-treatment, kinase 
inhibitors were added for an additional 8 h: GSK3 inhibitor (SB216763, 10 µM); 
MAPKAPK2 inhibitor (KKALNRQLGVAA, 10 µM); SAPK/p38 inhibitor (SB203580, 
2.0 µM), JNK inhibitor (SP600125, 5.0 µM); PLK inhibitor (BI2536, 0.1 µM). Western 
blots representative of 3 independent experiments with either taxol or nocodazole. (C) 
Effects of specific siRNAs targeting PLK1, MAPKAPK2, MAPK14/SAPKp38α, 
MAPK8/JNK1 and MAPK9/JNK2 expression on Bcl-xL(Ser62) phosphorylation in 
nocodazole-exposed HeLa cells. A schematic view of these experiments is presented. 
Representative Western blotting of 3 independent experiments. *Nocodazole treatment 
was avoided in these cells.  
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Figure 6 Phospho-Bcl-xL(Ser62) interacts with SAC components. (A) Co-
immunoprecipitation of HA-Bcl-xL and HA-Bcl-xL(Ser62Ala) mutant protein with 
Mad2, Cdc20, BubR1, and Bub3 but not Bub1 in taxol-exposed (0.1 µM) Namalwa cells 
expressing either HA-Bcl-xL or HA-Bcl-xL(Ser62Ala) mutant protein. (B) Reciprocal 
co-immunoprecipitation of HA-Bcl-xL and phospho-Bcl-xL(Ser62) with Mad2, Cdc20, 
and BubR1, but not Cdc27 (APC-3) in taxol-exposed Namalwa cells (0.1 µM, 24 h). IgG 
represents co-immunoprecipitation experiments with control immunoglobulins. Extract 
means a mitotic protein extract obtained from Namalwa cells expressing HA-Bcl-xL after 
taxol treatment (0.1 µM, 24 h).  Representative of 4 independent experiments. (C) 
Schematic view of a proposed model. 
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Supplemental Figure S1 Effect of Bcl-xL and various phosphorylation mutants on 
the stability of the SAC. (A) Expression level of HA-Bcl-xL, HA-Bcl-xL(Th41Ala), Bcl-
xL(Ser43Ala), HA-Bcl-xL(Th47Ala), Bcl-xL(Ser56Ala), Bcl-xL(Ser62Ala) and HA-Bcl-
xL(Th115Ala) phosphorylation mutants in stably-transfected Namalwa cell populations. 
β-actin expression is shown as control. (B-I) Kinetics of G2/M cells (PI staining; grey 
bars), early mitotic cells (phospho-H3(Ser10) staining; red bars), dead cells (PI staining; 
green bars) and G1 cells (PI staining; blue bars) in wt Namalwa cells and Namalwa cells 
expressing HA-Bcl-xL, HA-Bcl-xL(Th41Ala), Bcl-xL(Ser43Ala), HA-Bcl-xL(Th47Ala), 
Bcl-xL(Ser56Ala), Bcl-xL(Ser62Ala) and HA-Bcl-xL(Th115Ala) phosphorylation 
mutants during taxol treatment (0.1 µM). Bars represent the means ± s.e.m. of n 
independent experiments. (J-K) Specificity of phospho-Bcl-xL(ser62) antibodies.  (J) 
Phospho-HA-Bcl-xL(Ser62) in Namalwa cells expressing HA-Bcl-xL and HA-Bcl-
xL(Ser62Ala) mutant exposed to VP16 (10 µM for 30 min). HA-Bcl-xL expression is 
shown as control. (K) Staining of phospho-Bcl-xL(Ser62) in wt HeLa cells exposed to 
control siRNA or siRNA targeting Bcl-xL expression. Western blottings are shown as 
control.  
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Supplemental Figure S2  Bcl-xL location in synchronized wt HeLa cells at mitosis. 
Co-location of Bcl-xL with CENPA, HEC1, CLIP170, PLK1, γ-tubulin and dynein motor 
protein at different steps of mitosis. Micrographs with phospho-Bcl-xL(Ser62) Ab 
labeling are shown in Figure 2. Representative of a total of 1,164 mitotic cells (3 
experiments). Summary in Table 1A. 
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Supplemental Figure S3 
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Supplemental Figure S3 In vitro kinase assays. (A) Enzyme activities were tested on 
control substrates with recombinant purified kinases. Velocities are expressed as 
nmole/min/mg. 2 independent experiments are reported. (B) BubR1, Bub1, Bub3 and 
Cdk1(cdc2) enzyme activities tested on histone H1 and myelin basic protein control 
substrates with kinases purified by immunoprecipitation. 2 independent 
immunoprecipitation assays are reported. (C) In vitro kinase assays with [32P]-γATP and 
recombinant Bcl-xL as substrates. Autoradiography and Coomassie staining are shown. 
 106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure S4 
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Supplemental Figure S4 Effects of specific siRNAs targeting CHK1, MPS1, Mad2, 
BubR1 and Bub1 expression on Bcl-xL(Ser62) phosphorylation in nocodazole-exposed 
HeLa cells. Silencing efficiency was monitored by Western blottings with corresponding 
antibodies.  Representative Western blottings of 2 to 3 independent experiments.  
Note: HeLa cells treated with siRNA targeting MPS1 fail to enter into mitosis (phospho-
H3(ser10) negative).  
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Supplemental TABLE S1-A 
Recombinant Enzyme Source  Control Substrate  Source           Buffer 
CHK1   Sigma-Aldrich  RXRX(L/A)S((R/F) Cell Signaling         A 
MAPK14/SAPK p38α  Cell Signaling ATF-2 (19-96)  Cell Signaling  B 
MAPK8/ JNK1  Cell Signaling        c-Jun (1-89)  Cell Signaling  B+ 
MAPK9/ JNK2  Cell Sciences  c-Jun (1-89)  Cell Signaling  A 
MAPKAPK2  Cell Signaling KKKLNRTLSVA  AnaSpec   A+ 
PLK1   Cell Signaling RISDELMDATFADQEAK AnaSpec   A 
PLK3   Cell Signaling RISDELMDATFADQEAK AnaSpec   A 
Aurora A   Cell Signaling RRSLLE    Cell Signaling  A 
Aurora B   Cell Signaling LRRLSLGLRRLSLGLRRL 
     SLGLRRLSLG     AnaSpec   A 
NEK2   Cell Signaling RFRRSRRMI  AnaSpec   A 
GSK3α   Cell Signaling RRAAEELDSRAGSPQL AnaSpec   A 
GSK3β   Sigma-Aldrich GPHRSTPESRAAV AnaSpec   A+ 
Mps1   Cell Signaling Myelin basic protein  Sigma-Aldrich  B 
Immunprecipitated Enzyme 
CDC2/CDK1  Namalwa cells Histone H1/ MBP   Sigma-Aldrich  B+ 
Bub1   Namalwa cells Histone H1/MBP  Sigma-Aldrich  B+ 
BubR1   Namalwa cells Histone H1/MBP  Sigma-Aldrich  B+ 
Bub3   Namalwa cells Histone H1/ MBP   Sigma-Aldrich  B+ 
 
Buffer A (5x): 25 mM MOPS pH 7.2 
  25 mM MgCl2 
  12.5 mM β-glycerol-2-phosphate 
  0.5 mM Na3VO4 
  5 mm EGTA 
  2 mM EDTA 
  0.25 mM dithiothreitol 
  500 µΜ ATP* 
  * 0.05 µCi/µl [32P]-γATP 
Buffer A+ (5x): buffer A  + 50 µg/ ml BSA 
 
Buffer B (5x): 125 mM TRIS pH 7.2    
  50 mM MgCl2    
  25 mM β-glycerol-2-phosphate 
  0.5 mM Na3VO4 
  10 mM dithiothreitol 
  500 µΜ ATP* 
  * 0.05 µCi/µl [32P]-γATP  
Buffer B+ (5x): buffer B + 50 µg/ ml BSA 
 
Target   INHIBITOR   Source   Concentration 
   
SAPKp38α   SB 203580   Calbiochem     2 µM 
JNK   SP 600125   Sigma-Aldrich     5 µM 
MAPKAPK2  H-KKALNRQLGVAA-OH  Calbiochem   10 µM 
PLK   BI 2536    Axon MedChem   0.1 µM  
Aurora    ZM 447439   Tocris BioScience   0.1 µM 
GSK3   SB 216763   Sigma-Aldrich    10 µM 
 
Supplemental Table S1-A. Listing of the protein kinase assays and protein kinase 
inhibitors. Source, control substrates and reaction buffers are indicated. 
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 Supplemental TABLE  S1-B 
 
 
 
Target   siRNA Target sequence   REFERENCE    
 
Bcl-xL    (2) 5'-GAAAUGACCAGACACUGAC-3'  On-Target plus sequence/ Dharmacom  
    (4)  5'-UUAGUGAUGUGGAAGAGAA-3'  On-Target plus sequence/ Dharmacom  
 
PLK 1    (1) 5' -AGAUUGUGCCUAAGUCUCU-3'  Mol Biol Cell 15:5623, 2004   
 
CHK1    (1) 5'-UCGUGAGCGUUUGUUGAAC-3'  J Biol Chem 278:14806, 2004   
 
Aurora A      (1) 5'-GGCAACCAGTGTACCTCAT-3'  Nature 455:119, 2008   
 
Aurora B      (1) 5'-AACGCGGCACUUCACAAUUGA-3'   Nat Cell Biol 7:93, 2004  
    (2) 5'-GGAAAGAAGGGAUCCCUAA-3'  Mol Biol Cell 17:2547, 2006 
 
Bub1    (1) 5'-GAGUGAUCACGAUUUCUAA-3'  J Cell Biol 185:5841, 2004  
    (2) 5'-GCCUGCCAACCCCUGGGAA-3'   J Cell Biol 178;283, 2007  
 
BubR1    (1) 5'-AACGGGCAUUUGAAUAUGAA-3'   Nat Cell Biol 7:93, 2004 
 
Mad2    (1) 5'-GGAAGAGUCGGGACCACAG-3'  Nat Cell Biol 7:93, 2004  
    (2) 5'-AAGUGGUGAGGUCCUGGAAAG-3'  Mol Cancer Res 7:371, 2009  
 
Mps1    (1) 5'-GACAGAUGAUUCAGUUGUA-3'  Cell 132:233, 2008   
 
MAPK8/ JNK1   (1) 5'-GCCCAGUAAUAUAGUAGUA-3'  Cell Cycle 7: 533, 2008  
    (2) 5'-GGCAUGGGCUACAAGGAAA-3'  Cell Cycle 7: 533, 2008  
 
MAPK9/ JNK2   (1) 5'-AGCCAACUGUGAGGAAUUA-3'  Cell Cycle 7: 533, 2008   
    (2) 5'-UCGUGAACUUGUCCUCUUA-3'  Cell Cycle 7: 533, 2008  
 
MAPK14 / p38α       (1)         5'-GGAAUUCAAUGAUGUGUAU-3'  On-Target plus sequence/ Dharmacom  
    (2) 5'-UCUCCGAGGUCUAAAGUAU-3'  On-Target plus sequence/ Dharmacom  
    (3) 5'-GUAAUCUAGCUGUGAAUGA-3'  On-Target plus sequence/ Dharmacom  
    (4) 5'-GUCCAUCAUUCAUGCGAAA-3'  On-Target plus sequence/ Dharmacom  
 
MAPKAPK2           (1)       5'-CGAAUGGGCCAGUAUGAAU-3'  On-Target plus sequence/ Dharmacom  
    (2) 5'-GUUAUACACCGUACUAUGU-3'  On-Target plus sequence/ Dharmacom  
    (3) 5'-GGCAUCAACGGCAAAGUUU-3'  On-Target plus sequence/ Dharmacom 
    (4) 5'-CCACCAGCCACAACUCUUU-3'  On-Target plus sequence/ Dharmacom 
 
GSK3α    (1) 5'-CAUCAAAGUGAUUGGCAAU-3'  SMART POOL/ Dharmacom   
    (2) 5'-AGUUGACCAUCCCUAUCCU-3'  SMART POOL / Dharmacom  
    (3)  5'-CUGAUUACACCUCAUCCAU-3'  SMART POOL / Dharmacom   
    (4) 5'-UUCUCAUCCCUCCUCACUU-3'  SMART POOL/ Dharmacom   
  
GSK3β    (1) 5'-GAUCAUUUGGUGUGGUAUA-3'  SMART POOL / Dharmacom   
    (2) 5'-GCUAGAUCACUGUAACAUA'-3  SMART POOL / Dharmacom 
    (3) 5'-GUUCCGAAGUUUAGCCUAU-3'  SMART POOL / Dharmacom  
    (4) 5'-GCACCAGAGUUGAUCUUUG-3'  SMART POOL / Dharmacom 
 
 
NON-TARGETING        SMART POOL / Dharmacom  
 
Supplemental Table S1-B.  Listing of the siRNA targeted sequences deployed in this 
study. 
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Supplemental TABLE S1-C    Oligonucleotides for cDNA constructs 
 
HA-Bcl-xL (T41A)  
5'-end oligonucleotide (+) with Nhe1 + START ATG codon:  5'- gctagcccaccatgggccgcatctttta 
3'-end oligonucleotide (-) with STOP TGA codon:   5'- ctcgagtcatttccgactgaagagtga 
oligonucleotide (+) containing T41A substitution:   5'- gccccagaaggggctgaatcggagatg 
oligonucleotide (-) containing T41A substitution:   5- catctccgattcagccccttctggggc 
(from wt HA-Bcl-xL as template / subcloned Nhe1/ Xho1 in Cep4 vector) 
  
HA-Bcl-xL (S43A) 
5'-end oligonucleotide (+) with Nhe1 + START ATG codon:  5'- gctagcccaccatgggccgcatctttta  
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgagtcatttcgactgaagagtga 
Overlapping oligonucleotide (+) containing S43A substitution: 5'-gaagggactgaagcggagatgagacc 
Overlapping oligonucleotide (-) containing S43A substitution: 5'-ggtctccatctccgcttcagtcccttc 
(from wt HA-Bcl-xL as template / subcloned Nhe1/ Xho1 in Cep4 vector) 
 
HA-Bcl-xL (T47A) 
5'-end oligonucleotide (+) with Not1 + START ATG codon:  5'- gcggccgcatgtctcagagcaaccgggag 
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgagtcatttccgactgaagagtga 
Overlapping oligonucleotide (+) containing T47A substitution: 5'-tcggagatggaggcccccagtgccatc  
Overlapping oligonucleotide (-) containing T47A substitution: 5'-gatggcactgggggcctccatctccga  
(from wt Bcl-xL as templat / subcloned Not1/ XhoI  in Cep4-HA vector) 
 
HA-Bcl-xL (S56A) 
5'-end oligonucleotide (+) with Not1 + START ATG codon:  5'- gcggccgcatgtctcagagcaaccgg gag 
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgagtcatttccgactgaagagtga 
Overlapping oligonucleotide (+) containing S56A substitution: 5'- aatggcaacccagcctggcacctggca 
Overlapping oligonucleotide (-) containing S56A substitution: 5'- tgccaggtgccaggctgggttgccatt 
(from wt Bcl-xL as template / subcloned Not1/ XhoI  in Cep4-HA vector) 
 
HA-Bcl-xL (S62A) 
5'-end oligonulcleotide (+) with Not1 + START ATG codon:  5'- gcggccgcatgtctcagagcaaccgggag 
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgagtcatttccgactgaagagtga 
Overlapping oligonucleotide (+) containing S62A substitution: 5'- cacctggcagacgcccccgcggtgaat 
Overlapping oligonucleotide (-) containing S62A substitution: 5- attcaccgcgggggcgtctgccaggtg  
(from wt Bcl-xL as template / subcloned Not1/ XhoI  in Cep4-HA vector) 
 
HA-Bcl-xL (T115A) 
5'-end oligonulcleotide (+) with Not1 + START ATG codon:  5'- gcggccgcatgtctcagagcaaccgggag 
3'-end oligonucleotide (-) with STOP TGA codon and XhoI:  5'- ctcgagtcatttccgactgaagagtga 
Overlapping oligonucleotide (+) containing T115A substitution: 5- cagctccacatcgccccagggacagca 
Overlapping oligonucleotide (-) containing T115A substitution: 5- tgctgtccctggggcgatgtggagctg 
(from wt Bcl-xL as template / subcloned Not1/ XhoI  in Cep4-HA vector) 
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Supplemental TABLE S1-C cDNA constructs. The phosphorylation mutant pCEP4-
HA-Bcl-xL and pCDNA3.1-HA-Bcl-xL vectors were generated by triple polymerase 
chain reactions (PCR) with wt pCEP4-HA-Bcl-xL vector as DNA template. The first 
fragments were amplified by Vent polymerase, with specific adapter primers containing 
restriction site sequences at the ATG start codon and anti-sense junction primers 
corresponding to the flanking sequences at each mutation site, as listed in Table S1. The 
second fragments were amplified by Vent polymerase, with sense junction primers 
corresponding to flanking sequences at each mutation site and adapter anti-sense primers 
containing restriction site sequences at the TGA stop codon. The 2 amplified fragments 
were gel-purified, heat-denaturated, and slowly annealed on ice. After elongation by Taq 
polymerase for 10 min, the third PCR, with specific adapter primers containing sequences 
at the ATG start codon and TGA stop codon, was amplified. The amplified fragment was 
first cloned in pCR2.1Topo vector (Invitrogen Corporation), sequenced, and then sub-
cloned in the eukaryotic expression vectors pCEP4 and pCDNA3.1 (Invitrogen 
Corporation). For some constructs, the HA-tag sequences were not amplified by PCR; 
these amplified fragments were than sub-cloned in-frame into the pCEP4-HA vector. All 
primers are listed in Supplemental Table 1. Purified constructs were transfected in 
Namalwa cells by electroporation at 0.27 kV (Gene Pulser, BioRad, Hercules, CA) and in 
HeLa cells by Lipofectamine2000 transfection according to the manufacturer's protocol 
(Invitrogen Corporation). 
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Supplemental TABLE S1-D 
ANTIBODIES   ID   Species   Source 
Cyclin B1   clone GNS-1  mouse mAb  BD Biosciences 
Cdc2/CDK1   # PC25   rabbit pAb  Calbiochem 
Cdc2/CDK1   clone 1/cdk1  mouse mAb  BD Biosciences 
Plk1     clone 208G4  rabbit mAb  Cell Signaling 
Plk3    clone B37-2  mouse mAb  BD Biosciences 
Aurora A   clone 1G4  rabbit mAb  Cell Signaling 
Aurora B   # 3094   rabbit mAb  Cell Signaling  
MAPKAPK2   # 3042   rabbit pAB  Cell Signaling 
MAPK14/SAPK p38α   clone L53F8  mouse mAb  Cell Signaling 
MAPK8/ JNK1   clone G151-333  mouse mAb  BD Biosciences 
MAPK9/ JNK2   # 4672   rabbit pAb  Cell Signaling 
GSK3α    # 9338   rabbit pAb  Cell Signaling 
GSK3β    clone 27C10  rabbit mAb  Cell Signaling 
MPS1/TKK   # 3255   rabbit pAb  Cell Signaling 
MPS1/TKK   clone BC032858  mouse mAb  Abcam 
Bub1    clone 14H5  mouse mAb  Upstate/ Millipore 
BubR1    # A300-386A  rabbit pAb  Bethyl  
BubR1    # 4116   rabbit pAb  Cell Signaling 
BubR1    clone9/BubR1  mouse mAb  BD Transduction  
Bub3    clone31/Bub3  mouse mAb  BD Transduction  
Bub3    # 3049   rabbit pAb  Cell Signaling 
Mad2    # A300-300A  rabbit pAb  Bethyl Lab 
Mad2    clone 48/Mad2  mouse mAb  BD Transduction  
cdc20    clone 41/p55cdc  mouse mAb  BD Transduction  
cdc20    # A301-179A  rabbit pAb  Bethyl Lab 
cdc20    # A301-180A  rabbit pAb  Bethyl  Lab 
CENP-A   # 07-574  rabbit pAb  Upstate/Millipore 
CENP-A   clone 3-19  mouse mAb  Assay Designs 
Dynein    clone 74.1  mouse mAb  Millipore 
HEC1    clone 9G3  mouse mAb  Abcam 
EB1    clone 5/ EB1  mouse mAb  BD Transduction  
Clip-170   custom   from Niels Galjart,  Rotterdam 
Bcl-xL    clone 2H12  mouse mAb  BD Biosciences 
Phospho-BclxL Ser62  custom   rabbit pAb  GenScript 
HA tag    clone 12CA5  mouse mAb  Roche Applied Sci 
HA tag    # A00168  goat pAb  GenScript 
γ-tubulin   clone GTU88  mouse mAb  Abcam 
α-tubulin   clone DM1A  mouse mAb  Sigma-Aldrich  
β-tubulin   clone DM1B  mouse mAb  Calbiochem  
β-Actin    clone 4C40  mouse mAb  Sigma 
Phospho H3(ser10)  # 06-570  rabbit pAb  Upstate/Millipore 
Phospho H3 ser10 Alexa 488 # 9708   rabbit pAb  Cell Signaling 
Anti-Mouse IgG Alexa 488 # A11001  goat pAb  InVitroGen 
Anti-Rabbit IgG Alexa 488 # A11008  goat pAb  InVitroGen 
Anti-Mouse IgG Alexa 594 # A11005  goat pAb  InVitroGen 
Anti-Rabbit IgG Alexa 594 #A11012  goat pAb  InVitroGen 
Anti-Mouse IgG HP-linked # NA931V  sheep pAb  GE Healthcare 
Anti-Rabbit IgG HP-linked # NA934V  donkey pAb  GE Healthcare 
Normal Rabbit IgG  # sc-2027  rabbit IgG  Santa Cruz Biotech 
Normal Mouse IgG  # sc-2025  mouse IgG  Santa Cruz Biotech 
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Abstract 
Functional analysis of a Bcl-xL phosphorylation mutant series has revealed that cells 
expressing Bcl-xL(Ser49Ala) mutant are less stable at G2 checkpoint after DNA damage 
and enter cytokinesis more slowly after microtubule poisoning than cells expressing wild-
type Bcl-xL. These effects of Bcl-xL(Ser49Ala) mutant seem to be separable from Bcl-
xL function in apoptosis. Bcl-xL(Ser49) phosphorylation is cell cycle-dependent. In 
synchronized cells, phospho-Bcl-xL(Ser49) appears during the S phase and G2, whereas 
it disappears rapidly in early mitosis during prometaphase, metaphase and early 
anaphase, and re-appears during telophase and cytokinesis. During DNA damage-induced 
G2 arrest, an important pool of phospho-Bcl-xL(Ser49) accumulates in centrosomes 
which act as essential decision centers for progression from G2 to mitosis. During 
telophase/cytokinesis, phospho-Bcl-xL(Ser49) is found with dynein motor protein. In a 
series of in vitro kinase assays, specific small interfering RNA and pharmacological 
inhibition experiments, polo kinase 3 (PLK3) was implicated in Bcl-xL(Ser49) 
phosphorylation. These data indicate that, during G2 checkpoint, phospho-Bcl-xL(Ser49) 
is another downstream target of PLK3, acting to stabilize G2 arrest. Bcl-xL 
phosphorylation at Ser49 also correlates with essential PLK3 activity and function, 
enabling cytokinesis and mitotic exit.  
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Introduction 
 
Bcl-xL (Bcl-2-related gene x, long isoform), a Bcl-2 (B cell leukemia/lymphoma 
protein-2) family member, is well-characterized for its function in apoptosis 1. Regulation 
of outer mitochondrial membrane permeabilization is the major way in which Bcl-xL 
protein exerts its anti-apoptosis regulatory and survival effect, which means preserving 
mitochondrial membrane integrity, mitochondrial transmembrane potential as well as 
ATP production, and preventing the release of apoptogenic factors in cytosol (reviewed 
in 2-4). Elucidation of Bcl-xL’s 3-dimensional structure has provided a first structural 
model in which α-helices located in BH1 (a Bcl-2 homology domain), BH2 and BH3 
domains create an elongated hydrophobic pocket domain where a BH3 amphipathic α-
helix of another Bcl-2-like protein can bind 5-7. Bcl-xL binds to pro-apoptotic family 
members through protein-protein interactions, forming a complex dynamic network of 
hetero-oligomers, depending on the cellular environment, stress condition and their 
subcellular localization 8-13. Heterodimerization between pro- and anti-apoptotic 
molecules controls cell fate, indicating that the relative concentration of one faction 
versus the other greatly influences the susceptibility of cells to death signals (reviewed in 
14, 15). BH3-only proteins are potent mediators of cell death. A subset, referred to as BH3-
only enabler or sensitizing proteins, promotes apoptosis by binding to and inhibiting pro-
survival molecules, such as Bcl-2, Bcl-xL and Mcl-1, whereas BH3-only activator or 
activating proteins bind to and activate multidomain pro-apoptotic Bax and Bak proteins 
10, 16. Bax insertion and oligomerization into membranes require activation, i.e. structural 
reorganization by a BH3-only activating protein, events that lead to outer mitochondrial 
membrane permeabilization; in contrast, the ability of anti-apoptotic proteins, such as 
Bcl-xL, to trap and inhibit these BH3-only activating proteins, prevents membrane 
permeabilization 17-20.   
The unexpected pore-forming ability of Bcl-xL protein has emerged from 
unfolding of its 3-dimensional structure. Structural similarities between Bcl-xL, 
particularly its α5- and α6-helices and the pore-forming domains of some bacterial toxins 
that act as channels for either ions or proteins, suggest that Bcl-2 members could function 
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by constituting pores in intracellular organelles, including mitochondria 5, 17-21. Whether 
these channel activities function by themselves, or in association with other 
megachannels, such as components of mitochondrial permeability transition pores, or 
others, is still not completely elucidated 3, 4, 19, 22-31. 
 Several studies have revealed that, in addition to their key role in controlling 
apoptosis, some Bcl-2 family members interface with the cell cycle, DNA damage 
responses and repair pathways, functions that are distinct from their role in apoptosis 
(reviewed in 32, 33). Indeed, Bcl-xL and/or Bcl-2 modulate the homologous recombination 
pathway as well as non-homologous end-joining and DNA damage mismatch repair 
activities, effects that are separable from their anti-apoptotic task 34-37. Bcl-xL also fulfills 
functions during the cell cycle 38-40. Bcl-xL phosphorylation at Ser62, within the 
unstructured loop domain of the protein, has been detected most often in cells treated 
with microtubule poisons, including nocodazole, paclitaxel, vinblastine, vincristine, 
colchicine and pironetin 41-49, and coupled, more recently, with specific G2 and mitotic 
events (Wang et al., 2011; manuscripts submitted). Similarly, Bcl-xL phosphorylation at 
Thr47 and Thr115 has been documented in response to genotoxic stress induced by 
ionizing radiation 50. 
 To search for potentially important phosphorylation site(s) regulating Bcl-xL's 
function during the cell cycle, we generated and monitored the effects of a series of 
single-point Bcl-xL phosphorylation mutants within its unstructured loop domain, a 
region generally not essential for its anti-apoptotic function 42, 51, 52. Taking a variety of 
experimental approaches with stably-transfected human cell populations and non-
transfected wild-type (wt) cells, we now provide evidence that Bcl-xL(Ser49) 
phosphorylation is a key element regulating Bcl-xL's functions at the G2 cell cycle 
checkpoint and entry into cytokinesis, influencing mitotic exit.  
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Results 
Effect of HA-Bcl-xL and HA-Bcl-xL(Ser49Ala) phosphorylation mutant on G2 
checkpoint stability and mitosis progression 
 First, human B lymphoma Namalwa cells were transfected with expression 
vectors encoding wt HA-Bcl-xL and HA-Bcl-xL(Ser49Ala) mutant, and stably-
transfected cell populations were selected. The protein expression levels are illustrated in 
Fig 1A (top right panel). A well-established experimental procedure, referred to as 
mitotic trap assay 53, evaluated the kinetics of G2 arrest after DNA damage, the kinetics 
of mitotic entry after G2 arrest, and the kinetics of cell death. In this assay, cells entering 
mitosis after G2 arrest are trapped by adding nocodazole (0.35 µM) at 24-h intervals after 
etoposide (VP16) treatment (10 µM/30 min in Namalwa cells) and monitored by flow 
cytometry with phospho-H3(Ser10) labeling as well as propidium iodide (PI) staining 
(Fig. 1A; top left panel). Control Namalwa cells or Namalwa cells stably transfected with 
empty vector die rapidly after exposure to VP16 (Fig 1A; green bars). In contrast, cell 
populations stably expressing wt HA-Bcl-xL and the phosphorylation mutant HA-Bcl-
xL(Ser49Ala) show strong inhibition of apoptosis (Fig. 1A; green bars). More than 70% 
of cells over-expressing wt HA-Bcl-xL are arrested in G2, 24 h after VP16 treatment (Fig 
1A, grey bars), while some cells slowly escape from G2 and enter early mitosis, 36 to 72 
h after VP16 (Fig. 1A; red bars). In contrast, cells expressing the phosphorylation mutant 
HA-Bcl-xL(Ser49Ala) enter mitosis much more rapidly, 36 to 72 h after VP16 (Fig. 1A; 
red bars), revealing that Ser49 is essential for Bcl-xL's function in G2 arrest. These 
observations also suggest that Bcl-xL's role in G2 arrest is distinct from its function in 
apoptosis. 
Similar experimental monitoring by flow cytometry with phospho-H3(Ser10) 
labeling and PI staining was undertaken to evaluate the kinetics of early mitotic entry and 
stability of the spindle-assembly checkpoint (N4 DNA content, phospho-H3(Ser10)-
positive), mitosis progression into cytokinesis (N4 DNA content, phospho-H3(Ser10)-
negative, after taxol treatment), G1 entry (N2 DNA content, phospho-H3(Ser10)-
negative), and cell death kinetics (sub-G1 DNA content) in taxol-exposed cells (Fig. 1B). 
Both Namalwa cells and Namalwa cells stably transfected with empty vector die rapidly 
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after taxol treatment, while cells stably expressing wt HA-Bcl-xL and the 
phosphorylation mutant HA-Bcl-xL(Ser49Ala) show strong inhibition of apoptosis (Fig. 
1B; green bars). Up to 80-85% of cells over-expressing wt HA-Bcl-xL and HA-Bcl-
xL(Ser49Ala) mutants accumulate in early mitosis (Fig. 1B; red bars) from 12- to 24-h 
taxol exposure. Interestingly, HA-Bcl-xL-expressing cells gradually start to lose the 
phospho-H3(Ser10) marker by 36 h, whereas most HA-Bcl-xL(Ser49Ala) mutant cells 
are still stable in early mitosis at 36 h, slowly losing the phospho-H3(Ser10) marker only 
at 48 to 60 h after taxol treatment (Fig. 1B; red bars). These results indicate that Bcl-
xL(Ser49) is required for spindle-assembly checkpoint resolution and/or entry into 
cytokinesis. Again, this effect of Bcl-xL(Ser49Ala) on mitosis progression in taxol-
exposed cells appears separable from its anti-apoptotic function.   
 
Bcl-xL(Ser49) phosphorylation and location during DNA damage-induced G2 arrest 
and in unpertubed, synchronized wt Hela cells 
 First, antibodies were produced to monitor Bcl-xL(Ser49) phosphorylation. The 
specificity of phospho-Bcl-xL(Ser49) antibodies is depicted in Supplementary Figure S1-
A. Experiments were then performed in human non-transfected wt HeLa cells, which 
undergo G2 arrest after VP16 treatment (10 µm; 16 h), with some cells escaping G2 
arrest 48 to 72 h post-VP16 treatment (Fig. 2A, right panel). Bcl-xL(Ser49) 
phosphorylation is observed in wt HeLa cells exposed to VP16 (Fig. 2A, left panel). 
When wt HeLa cells are synchronized by double thymidine block and released upon 
progression from S to G2, Bcl-xL is progressively phosphorylated on Ser49 (Fig. 2B, left 
panel), suggesting that Bcl-xL(Ser49) phosphorylation also occurs during normal cell 
cycle progression. Cell cycle phase distribution during these experiments is indicated in 
Fig. 2B, right panel. We next investigated the subcellular location of phospho-Bcl-
xL(Ser49) in wt HeLa cells by indirect immunofluorescence staining, in synchronized G2 
control and VP16-induced G2 arrest (Fig. 2C). In HeLa cells exposed to VP16, a pool of 
phospho-Bcl-xL(Ser49) accumulated in centrosomes with γ-tubulin 24 and 48 h post-
VP16 exposure (Fig. 2C). In contrast, no significant accumulation of phospho-Bcl-
xL(Ser49) in centrosomes was detected in synchronized, untreated G2 cells (Fig. 2C).  
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Phospho-Bcl-xL(Ser49) was not found in nuclear structures with colin, a specific Cajal 
body marker, and nucleolin, a specific nucleolus marker (Fig. 2C). Taken together, these 
results suggest that Bcl-xL is phosphorylated on Ser49 during normal cell cycle 
progression and that phospho-Bcl-xL(Ser49) accumulates much more strongly in 
centrosomes during DNA damage-induced G2 checkpoint in HeLa cells.  
 
Bcl-xL(Ser49) phosphorylation and location during mitosis progression  
We next monitored phospho-Bcl-xL(Ser49) during mitosis. First, wt HeLa cells 
were synchronized by double thymidine block and released upon progression to G2. They 
were then treated with nocodazole (0.35 µM, 4 h), and prometaphase/metaphase cells 
were collected by mitotic shake-off. A portion of these cells was released from 
nocodazole and growth in the presence of MG-132 (25 µM), a proteasome inhibitor that 
prevents cyclinB1 and securin destruction, to obtain a cell population at the anaphase 
boundary. A second set was also released from nocodazole and by growth in the presence 
of blebbistatin (10 µM), a selective non-muscle contractile motor myosin II inhibitor that 
averts furrow ingression, to attain a cell population at telophase/cytokinesis. A schematic 
view of these experiments appears in Fig. 3A (top panel). Western blotting revealed that 
Bcl-xL is timely dephosphorylated at Ser49 at prometaphase, metaphase and the 
anaphase boundary, while it is rapidly phosphorylated at telophase/cytokinesis (Fig. 3A). 
Total Bcl-xL level remained stable along mitosis. Interestingly, the Bcl-xL(Ser49) 
phosphorylation pattern was exactly opposite that of Bcl-xL(Ser62) (Fig. 3A), indicating 
differential function.  CyclinB1 and phospho-H3(Ser10) expression is shown as a specific 
early mitotic phase marker (Fig. 3A). The location of phospho-Bcl-xL(Ser49) in 
telophase/cytokinesis was then investigated. In these experiments, HeLa cells were 
synchronized by double thymidine block and release upon progression to G2 and entry 
into mitosis. They were collected at 30-min intervals from 9 to 12 h after double 
thymidine block and release to acquire mitotic cells at all steps of mitosis. In 
telophase/cytokinesis, phospho-Bcl-xL(Ser49) co-localizes strongly with the microtubule 
associated dynein motor protein (Fig. 3B). Phospho-Bcl-xL(Ser49) does not localize in 
centrosomes with γ-tubulin in telophase/cytokinesis (Fig. 3B). A summary of microscopy 
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analysis is presented in Supplemental Table S1. 
 
Polo kinase 3 (PLK3) is involved in Bcl-xL(Ser49) phosphorylation  
 To identify the putative protein kinase involved in Bcl-xL(Ser49) 
phosphorylation, a panel of protein kinases was first tested in in vitro kinase assays with 
recombinant human Bcl-xL protein as substrate. Among all the kinases tested, PLK3 was 
the only one able to phosphorylate recombinant Bcl-xL protein on Ser49 in in vitro 
kinase assays (Fig. 4A). Enzyme-specific activities with control substrates were carried 
on (not show) . The specificity of Ser49 phosphorylation by PLK3 was validated by mass 
spectrometry (Supplemental Figure S1-B). PLK3 participation in Bcl-xl(Ser49) 
phosphorylation during DNA damage-induced G2 arrest was validated by using 2 
specific small interfering RNAs (siRNAs) targeting PLK3 mRNA. A schematic 
illustration of these experiments appears in Fig. 4B.   
With siRNAs targeting PLK3 mRNA, several attempts were made to confirm its 
involvement in Bcl-xL(Ser49) phosphorylation at telophase/cytokinesis (data not 
reported). Interfering with PLK3 expression does not allow cells to enter cytokinesis, an 
effect reported previously 54-57. Trying to circumvent it, we adopted a protocol similar to 
that described in Fig. 3, where synchronized cells at G2 are first allowed to accumulate at 
metaphase with nocodazole, then released in the presence of blebbistatin to enrich the cell 
population at telophase/cytokinesis. A fraction of the cells were released from nocodazole 
by blebbistatin and BI-2536, a PLK inhibitor. The experiments are illustrated 
schematically in Fig. 4B. Inhibiting PLK activities in these cells prevented Bcl-xL(Ser49) 
phosphorylation. However, they failed to enter telophase/cytokinesis as cyclin B1 and 
phospho-H3(Ser10) expression remained significantly high. Together, these experiments 
confirmed that cytokinesis requires PLK3 activity. Quenching its expression with 
siRNAs or suppressing its activity in a timely manner in synchronized cells after 
nocodazole release causes cytokinesis defects, which also correlate with failure to 
phosphorylate Bcl-xL(Ser49).  
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Discussion 
 This study reveals a new phosphorylation site within Bcl-xL – Bcl-xL(Ser49) – 
that undergoes dynamic phosphorylation/dephosphorylation events during cell cycle 
progression. Phospho-Bcl-xL(Ser49) is essential in at least 2 key events of the cell cycle, 
G2 checkpoint and progression to telophase/cytokinesis during mitosis. A pool of 
phospho-Bcl-xL(Ser49) strongly localizes at centrosomes with γ-tubulin during the G2 
checkpoint induced by DNA damage and with the microtubule associated dynein motor 
protein during telophase/cytokinesis. PLK3, which has known essential functions during 
cell cycle progression, is a key kinase involved in Bcl-xL(Ser49) phosphorylation. 
Importantly, phospho-Bcl-xL(Ser49) functions during G2 checkpoint and, in mitosis, it 
appears to be separable from Bcl-xL’s known role in apoptosis, as Bcl-xL(Ser49Ala) 
phosphorylation mutant retains its anti-apoptotic effect but clearly shows different cell 
cycle behavior in DNA damage-induced G2 arrest and taxol-mediated mitotic actions.  
 Bcl-xL phosphorylation at Ser62 is well-documented and generally associated 
with microtubule poisoning 41-49. Phospho-Bcl-xL(Ser62) functions have remained 
elusive until recently. We have recently observed that it undergoes differential location 
during G2 and spindle-assembly checkpoints (Wang et al., 2011; manuscripts submitted). 
A pool of phospho-Bcl-xL(Ser 62) is located in Cajal bodies in interphase and a pool  
accumulates with CDK1(CDC2) in nucleoli during G2 checkpoint, whereas its interacts 
with the inhibitory CDC20/MAD2/BUBR1/BUB3 complex during spindle-assembly 
checkpoints (Wang et al., 2011; manuscripts submitted). Interestingly, in this study, we 
noted a differential pattern of expression and location for phospho-Bcl-xL(Ser49) 
compared to phospho-Bcl-xL(Ser62). Phospho-Bcl-xL(Ser49) accumulates in 
centrosomes during G2 checkpoint, is rapidly dephosphorylated at early mitotic phases 
and is re-phosphorylated during telophase/cytokinesis. These dynamic changes of 
location and phosphorylation/dephosphorylation events strongly indicate differential 
functions. Although the exact molecular mechanisms were not fully addressed here, 
functional changes in cell cycle progression and cell behavior in response to VP16 and 
taxol treatment are documented, with cells expressing the Bcl-xL(Ser49Ala) 
phosphorylation mutant.  
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 PLK3 activity and function have been reviewed recently 58.  Observed in 
centrosomes and nucleoli during interphase 56, 59, PLK3 is found at spindle poles and 
midbody during cytokinesis 55, 56. PLK3 activity increases rapidly after DNA damage in 
an ATM-dependent manner, and is involved in G2 arrest by phosphorylating and 
inhibiting CDC25C phosphatase 60-63. Its exact functions during mitosis remain unclear, 
but overexpression of PLK3's polo box domain, but not the kinase domain, causes mitotic 
arrest and cytokinesis defects 54-56. Similarly, cells harbouring PLK3 knockdown by small 
hairpin RNA presented incomplete cytokinesis, which produced multinucleated cells 57. 
PLK3 strongly phosphorylated Bcl-xL(Ser49) in in vitro kinase assays. RNA interference 
experiments conducted during G2 arrest confirmed that PLK3 is the key enzyme in Bcl-
xL(Ser49) phosphorylation. During cytokinesis, our results are strongly indicative of 
PLK3’s involvement, having demonstrated correlations between PLK3 expression and 
activity, failure to enter cytokinesis and to phosphorylate Bcl-xL at Ser49. The functional 
outcome of phospho-Bcl-xL(Ser49) on the stability of G2 checkpoint and kinetics of 
cytokinesis also correlates with PLK3 functions during G2 arrest and cytokinesis, 
suggesting that Bcl-xL is a downstream target of PLK3 and part of the network mediating 
PLK3’s effect. 
 In summary, our data disclose a yet uncharacterized phosphorylation site within 
Bcl-xL. Bcl-xL(Ser49) is phosphorylated during normal cell cycle progression and 
checkpoints. Interfering with Bcl-xL(Ser49) phosphorylation destabilizes DNA damage-
induced G2 arrest and slows entry into cytokinesis, but has no effect on the kinetics of 
VP16- and taxol-induced apoptosis. Our data also indicate that PLK3 is involved in Bcl-
xL(Ser49) phosphorylation at G2 checkpoint and cytokinesis. Additional work is 
underway to dissect the molecular mechanisms of phospho-Bcl-xL(Ser49) action. 
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Materials and methods 
Cell culture, cDNA construction and cell analysis 
  Human Namalwa and HeLa cell lines were obtained from the American Type 
Culture Collection and grown at 37°C under 5% CO2 in RPMI-1640 medium and DMEM 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin 
and 100 µg/ml streptomycin, respectively. The phosphorylation mutant pCEP4-HA-Bcl-
xL(Ser49Ala) was generated by triple polymerase chain reactions (PCR) with wt pCEP4-
HA-Bcl-xL vector as DNA template. Briefly, the first fragments were amplified by Vent 
polymerase, with specific adapter primers containing restriction site sequences at the 
ATG start codon and anti-sense junction primers circumscribing the mutated codon with 
flanking sequences. The second fragments were amplified by Vent polymerase, with 
sense junction primers containing the mutated codon, with flanking sequences and 
adapter anti-sense primers comprising restriction site sequences at the TGA stop codon. 
The 2 amplified fragments were gel-purified, heat-denaturated, and slowly annealed on 
ice. After elongation by Taq polymerase for 10 min, a third PCR, with specific adapter 
primers containing sequences at the ATG start codon and TGA stop codon, was 
amplified. The amplified fragment was first cloned in pCR2.1Topo vector (Invitrogen 
Corporation), sequenced, and then sub-cloned in the eukaryotic expression vector pCEP4 
(Invitrogen Corporation). Purified constructs were transfected in Namalwa cells by 
electroporation at 0.27 kV (Gene Pulser, BioRad, Hercules, CA), and cells were grown 
under hygromycin B1 selection to attain a stable cell population prior to performing the 
experiments. The kinetics of mitotic entry, cell cycle phase distribution and cell death 
were monitored in Coulter EpicsXL flow cytometers with phospho-H3(Ser10) labeling 
and PI staining.  HeLa cells were synchronized by double-thymidine block (2 mM) and 
release. 
 
Protein extraction and immunoblotting  
To prepare protein extracts, cells were lysed in buffer containing 20 mM 
Hepes(KOH), pH 7.4, 120 mM NaCl, 1% Triton X-100, 2 mM phenylmethylsulfonyl 
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fluoride, a cocktail of protease inhibitors (CompleteTM, Roche Applied Science) and a 
cocktail of phosphatase inhibitors (PhosStopTM, Roche Applied Science). The antibodies 
tested in this study are listed in Supplemental Table S2. Bcl-xL(Ser49) antibodies were 
prepared and purified by GeneScript, using the phosphopeptide-KLH conjugate 
CTESEMETP(pS)AING as immunogen. The affinity and specificity of the preparations 
were first analyzed with ELISA, deploying coated phosphopeptide and non-
phosphopeptide as antigens.   
 
Immunofluorescence microscopy 
HeLa cells, seeded and grown directly on coverslips, were fixed in methanol at -
20°C for 30 min and rapidly immersed in ice-cold acetone for a few seconds. The slides 
were allowed to dry at room temperature and rehydrated in PBS. Nonspecific binding 
sites were blocked in PBS containing 5% FBS (blocking solution); then, the slides were 
incubated sequentially with specific primary antibody (10 µg/ml in blocking solution), 
specific labeled secondary antibody (10 µg/ml in blocking solution), followed by DAPI 
staining, also performed in blocking solution. Images were generated with a Leica 
Microsystem mounted on a Leica DM6000B microscope and Leica DFC480 camera 
hooked up to a Macintosh computer. 
 
Protein kinase assays and protein kinase chemical inhibitors 
The kinases and kinase assays are described in Supplemental Table S3. Enzyme 
activities were tested on control substrates, and velocities were expressed as 
nmole/min/mg (data not showed). Recombinant human Bcl-xL(ΔTM) protein was 
produced and purified, as described previously 40. BI-2536 was obtained from Axon 
MedChem Corp. 
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siRNA-mediated protein kinase inhibition 
HeLa cells were transfected with DharmaFECT-1 transfection reagent 
(ThermoScientific) according to the manufacturer’s instructions, with 100 nM of either 
control siRNA (non-targeting Smart Pool) or siRNA #3 and #4 targeting PLK3 mRNA 
obtained from Dharmacon,ThermoScientific.  
 
Online supplemental materials: Supplemental materials for this article, including 
supplemental figures and tables, are available on the journal website.   
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Figure 1 
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Figure 1 Effect of Bcl-xL and Bcl-xL(Ser49Ala) phosphorylation mutant on G2 
checkpoint resolution and entry into cytokinesis. A) G2 checkpoint experiments are 
illustrated schematically in the top left panel. The expression levels of HA-Bcl-xL, HA-
Bcl-xL(Ser49Ala) phosphorylation mutant and β-actin in stably-transfected Namalwa cell 
populations are shown in the top right panel. Kinetics of G2 cells (N4 DNA content, 
phospho-H3(Ser10)-negative; grey bars), early mitotic cells (N4 DNA content, phospho-
H3(Ser10)-positive) and dead cells (sub-G1 cells; green bars) in wt Namalwa cells and 
Namalwa cells expressing empty vector, HA-Bcl-xL and HA-Bcl-xL(Ser49Ala) 
phosphorylation mutant after VP16 treatment. Bars represent the means ± s.e.m. of n 
independent experiments. B) Taxol experiments are illustrated schematically in the top 
left. Kinetics of early mitotic cells (N4 DNA content, phospho-H3(Ser10)-positive), late 
mitotic cells (or G2 at time 0) (N4 DNA content, phospho-H3(Ser10)-negative), dead 
cells (sub-G1 cells; green bars) and G1 cells (N2 DNA content; blue bars) in wt Namalwa 
cells and Namalwa cells expressing empty vector, HA-Bcl-xL and HA-Bcl-xL(Ser49Ala) 
phosphorylation mutant during taxol treatment (0.1 µM). Bars represent the means ± 
s.e.m. of n independent experiments.  
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Figure 2 Bcl-xL(Ser49) phosphorylation and location during DNA damage-induced G2 
arrest and in unpertubed, synchronized wt Hela cells at interphase. A) Expression kinetics 
of phospho-Bcl-xL(Ser49), Bcl-xL and β-actin in wt HeLa cells treated with VP16. These 
experiments are illustrated schematically at the top. Kinetics of G2 cells (N4 DNA 
content, phospho-H3(Ser10)-negative; grey bars), early mitotic cells (N4 DNA content, 
phospho-H3(Ser10)-positive; red bars) and dead cells (sub-G1 cells; green bars) in wt 
HeLa cells treated with VP16 appear on the right histogram. Bars represent the means ± 
s.e.m. of n independent experiments. B) Expression kinetics of phospho-Bcl-xL(Ser49), 
Bcl-xL and β-actin in synchronized HeLa cells after double-thymidine block release. Cell 
cycle phase distribution during these experiments is illustrated in the right histogram. C) 
Co-location of phospho-Bcl-xL(Ser49) with colin (Cajal body markers), nucleolin 
(nucleolus marker) and γ-tubulin (centrosome marker) in synchronized G2 cells and 
during VP16-induced DNA damage and G2 arrest. The percentages of phospho-Bcl-
xL(Ser49) in nucleoli, Cajal bodies and centrosomes during VP16-induced G2 
checkpoint and during normal G2 phase of the cell cycle in synchronized wt Hela cells 
(sG2) are indicated in the right histogram. Bars represent the means ± s.e.m. from 
micrographs obtained in 4 independent experiments. 
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Figure 3 
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Figure 3 Bcl-xL(Ser49) phosphorylation and location during mitosis progression. A) 
Expression kinetics of phospho-Bcl-xL(Ser49), phospho-Bcl-xL(Ser62), Bcl-xL, 
phospho-H3(Ser10) and cyclin B1 in wt HeLa cells obtained at different steps of mitosis. 
The design of these experiments is illustrated at the top. B) Co-location of phospho-Bcl-
xL(Ser49) only with dynein motor protein in telophase/cytokinesis. Representative of a 
total of 624 cells obtained from 3 experiments. Details in Supplemental Table S1. 
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Figure 4 
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Figure 4 PLK3 is involved in Bcl-xL(Ser49) phosphorylation. A) In vitro assays of a 
panel of purified and active protein kinases with recombinant human Bcl-xL(ΔTM) 
protein as substrate. All enzyme activities were tested on control substrates in 
Supplemental Figure S2, and validation by mass spectrometry appears in Supplemental 
Figure S3. Western blots are representative of 3 independent experiments. B) Effects of 2 
specific siRNAs targeting PLK3 mRNA on the expression kinetics of phospho-Bcl-
xL(Ser49), Bcl-xL and PLK3 in wt HeLa cells exposed to VP16. The design of these 
experiments is presented on the left. C) Effects of a PLK inhibitor (BI-2536, 0.1 µm) on 
phospho-Bcl-xL(Ser49), Bcl-xL, PLK1 and PLK3 expression in synchronized wt HeLa 
cells released from nocodazole in the presence of blebbistatin to obtain enriched 
telophase/cytokinesis. The design of these experiments is presented at the top. Western 
blots are representative of 2 independent experiments. 
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Supplementary Figure S1  
A) Specificity of the phospho-Bcl-xL(ser49) antibodies.  Expression of phospho-HA-Bcl-
xL(Ser49) in Namalwa cells expressing expressing wt HA-Bcl-xL and HA-Bcl-
xL(Ser49Ala) mutant exposed to VP16 (10 µM for 30 min). HA-Bcl-xL expression is 
shown as control. In the right panels, antibodies were first incubated with excess 
phophorylated peptide (CTESEMETP(pS)AING) prior to Western blotting.  
 
B) Tandem mass spectra of phospho(Ser49) analysed using Mascot (Matrix Science, 
London, UK; version Mascot). Mascot was searched with a fragment ion mass tolerance 
of 0.50 Da and a parent ion tolerance of 2.0 Da. Scaffold (version Scaffold_3_00_02, 
Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and 
protein identifications. Peptide identifications were accepted if they could be established 
at greater than 95.0% probability. Validation of phosphate positions were conducted 
using Ascore. On that spectrum, Ascore score is of 42.65 
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SUPPLEMENTAL TABLE S1   Phase distribution versus labeling (number of cells) 
  in synchronized human wt HeLa cells collected from 9 to 12 h after double 
  thymidine block-release 
 
 
Phospho-
Bcl-xL 
(S49) PROMETAPHASE METAPHASE ANAPHASE TELOPHASE CYOKINESIS TOTAL 
+  CENPA 28/28  (-) 12/12  (-) 10/10  (-) 12/12  (-) 18/18  (-) 80 
+ PLK1 41/41  (-) 32/32  (-) 30/30  (-) 25/31  (-) 23/23  (-) 157 
+ γ-Tubulin 20/28  (-) 23/23  (-) 13/13  (-) 10/16  (-) 12/15  (-) 95 
+ Clip-170 30/30  (-) 22/22  (-) 19/19  (-) 10/14  (-) 18/21  (-) 106 
+ Dynein 35/35 (-) 21/21 (-) 11/11 (-) 10/10 (+) 08/11  (+) 88 
+ HEC1 36/36  (-) 25/25 (-) 09/09  (-) 09/13  (-) 12/15  (-) 98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table S1 
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Supplemental TABLE S2 
 
ANTIBODIES   ID   Species   Source 
Cdc2/CDK1   # PC25   rabbit pAb  Calbiochem 
Cdc2/CDK1   clone 1/cdk1  mouse mAb  BD Biosciences 
Plk1     clone 208G4  rabbit mAb  Cell Signaling 
Plk3    clone B37-2  mouse mAb  BD Biosciences 
Aurora A   clone 1G4  rabbit mAb  Cell Signaling 
Aurora B   # 3094   rabbit mAb  Cell Signaling  
MAPKAPK2   # 3042   rabbit pAB  Cell Signaling 
MAPK14/SAPK p38α   clone L53F8  mouse mAb  Cell Signaling 
MAPK8/ JNK1   clone G151-333  mouse mAb  BD Biosciences 
MAPK9/ JNK2   # 4672   rabbit pAb  Cell Signaling 
MPS1/TKK   # 3255   rabbit pAb  Cell Signaling 
MPS1/TKK   clone BC032858  mouse mAb  Abcam 
Bub1    clone 14H5  mouse mAb  Upstate/ Millipore 
BubR1    # A300-386A  rabbit pAb  Bethyl  
BubR1    # 4116   rabbit pAb  Cell Signaling 
BubR1    clone9/BubR1  mouse mAb  BD Transduction  
Bub3    clone31/Bub3  mouse mAb  BD Transduction  
Bub3    # 3049   rabbit pAb  Cell Signaling 
Mad2    # A300-300A  rabbit pAb  Bethyl Lab 
Mad2    clone 48/Mad2  mouse mAb  BD Transduction  
cdc20    clone 41/p55cdc  mouse mAb  BD Transduction  
cdc20    # A301-179A  rabbit pAb  Bethyl Lab 
cdc20    # A301-180A  rabbit pAb  Bethyl  Lab 
CENP-A   # 07-574  rabbit pAb  Upstate/Millipore 
CENP-A   clone 3-19  mouse mAb  Assay Designs 
Dynein    clone 74.1  mouse mAb  Millipore 
HEC1    clone 9G3  mouse mAb  Abcam 
EB1    clone 5/ EB1  mouse mAb  BD Transduction  
Clip-170   custom   from Niels Galjart,  Rotterdam 
Bcl-xL    clone 2H12  mouse mAb  BD Biosciences 
Phospho-BclxL Ser49  custom   rabbit pAb  GenScript 
HA tag    clone 12CA5  mouse mAb  Roche Applied Sci 
HA tag    # A00168  goat pAb  GenScript 
γ-tubulin   clone GTU88  mouse mAb  Abcam 
α-tubulin   clone DM1A  mouse mAb  Sigma-Aldrich  
β-tubulin   clone DM1B  mouse mAb  Calbiochem  
β-Actin    clone 4C40  mouse mAb  Sigma 
Phospho H3(ser10)  # 06-570  rabbit pAb  Upstate/Millipore 
Phospho H3 ser10 Alexa 488 # 9708   rabbit pAb  Cell Signaling 
Anti-Mouse IgG Alexa 488 # A11001  goat pAb  InVitroGen 
Anti-Rabbit IgG Alexa 488 # A11008  goat pAb  InVitroGen 
Anti-Mouse IgG Alexa 594 # A11005  goat pAb  InVitroGen 
Anti-Rabbit IgG Alexa 594 #A11012  goat pAb  InVitroGen 
Anti-Mouse IgG HP-linked # NA931V  sheep pAb  GE Healthcare 
Anti-Rabbit IgG HP-linked # NA934V  donkey pAb  GE Healthcare 
Normal Rabbit IgG  # sc-2027  rabbit IgG  Santa Cruz Biotech 
Normal Mouse IgG  # sc-2025  mouse IgG  Santa Cruz Biotech 
 
Supplemental Table S2 
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Supplemental TABLE S3 
Recombinant Enzyme Source  Control Substrate  Source           Buffer 
CHK1   Sigma-Aldrich  RXRX(L/A)S((R/F) Cell Signaling         A 
MAPK14/SAPK p38α  Cell Signaling ATF-2 (19-96)  Cell Signaling  B 
MAPK8/ JNK1  Cell Signaling        c-Jun (1-89)  Cell Signaling  B+ 
MAPK9/ JNK2  Cell Sciences  c-Jun (1-89)  Cell Signaling  A 
MAPKAPK2  Cell Signaling KKKLNRTLSVA  AnaSpec   A+ 
PLK1   Cell Signaling RISDELMDATFADQEAK AnaSpec   A 
PLK3   Cell Signaling RISDELMDATFADQEAK AnaSpec   A 
Aurora A   Cell Signaling RRSLLE    Cell Signaling  A 
Aurora B   Cell Signaling LRRLSLGLRRLSLGLRRL 
     SLGLRRLSLG     AnaSpec   A 
NEK2   Cell Signaling RFRRSRRMI  AnaSpec   A 
GSK3α   Cell Signaling RRAAEELDSRAGSPQL AnaSpec   A 
GSK3β   Sigma-Aldrich GPHRSTPESRAAV AnaSpec   A+ 
Mps1   Cell Signaling Myelin basic protein  Sigma-Aldrich  B 
Immunprecipitated Enzyme 
CDC2/CDK1  Namalwa cells Histone H1/ MBP   Sigma-Aldrich  B+ 
Bub1   Namalwa cells Histone H1/MBP  Sigma-Aldrich  B+ 
BubR1   Namalwa cells Histone H1/MBP  Sigma-Aldrich  B+ 
Bub3   Namalwa cells Histone H1/ MBP   Sigma-Aldrich  B+ 
 
Buffer A (5x): 25 mM MOPS pH 7.2 
  25 mM MgCl2 
  12.5 mM β-glycerol-2-phosphate 
  0.5 mM Na3VO4 
  5 mm EGTA 
  2 mM EDTA 
  0.25 mM dithiothreitol 
  500 µΜ ATP* 
  * 0.05 µCi/µl [32P]-γATP 
Buffer A+ (5x): buffer A  + 50 µg/ ml BSA 
 
Buffer B (5x): 125 mM TRIS pH 7.2    
  50 mM MgCl2    
  25 mM β-glycerol-2-phosphate 
  0.5 mM Na3VO4 
  10 mM dithiothreitol 
  500 µΜ ATP* 
  * 0.05 µCi/µl [32P]-γATP  
Buffer B+ (5x): buffer B + 50 µg/ ml BSA 
 
 
 
Supplemental Table S3. Listing of the protein kinase assays  
 
 
 
Supplemental Table S3 
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6. Discussion 
  In these studies, we investigated the functional importance of phosphorylation 
events within Bcl-xL’s unstructured flexible loop domain during G2 and the SAC as well 
as for cytokinesis and mitotic exit in a series of Bcl-xL phosphorylation mutants, 
including Thr41Ala, Ser43Ala, Thr47Ala, Ser49Ala, Ser56Ala, Ser62Ala and Thr115Ala. 
Our results demonstrate that Bcl-xL Ser49 and Ser62 undergo differential 
phosphorylation/dephosphorylation events during cell cycle progression, in association 
with the G2 checkpoint, the SAC, cytokinesis and mitotic exit. 
  
6.1 Bcl-xL and its unstructured flexible loop domain  
 The unstructured Bcl-xL loop domain, which has various flexible and unstable 
conformations in space, first emerged from Bcl-xL’s 3-dimensional structure 359. Then, 
sequence homology alignment revealed that among all Bcl-2 family members, only Bcl-2 
and Bcl-xL contain such a flexible loop domain 367. It was postulated to be the target for 
post-translational modifications that would affect Bcl-xL function 367. Studies with Bcl-xL 
loop domain deletion mutants indicated that this protein domain was not essential for the 
anti-apoptotic function of Bcl-xL against irradiation- and DNA topoisomerase I and II 
inhibitor-induced OMM permeabilization, cytochrome c release, caspase activation and 
apoptosis 20, 367, 368. Liu et al. reported that the flexible loop domain was somehow 
involved in Bcl-xL’s binding to Bim, and changed shape upon Bcl-xL-Bim interaction 462. 
They also suggested that the engagement of Bim makes the Bcl-xL flexible loop domain 
more susceptible to proteolysis 462. Other studies indicated that Bcl-xL(Ser62), located 
within the flexible loop domain, undergoes phosphorylation when cells are exposed to 
microtubule poisons 449, 451-453, 461, 463-466, a post-translational modification that 
paradoxically has been claimed to maintain or impair the anti-apoptotic effect of Bcl-xL 
452, 465. No experiments have yet directly addressed the effect of Bcl-xL(Ser62) 
phosphorylation on cell cycle progression and checkpoints. We are the first to uncover 
Bcl-xL(Ser49) phosphorylation. Indeed, our investigations of Bcl-xL(Ser49) represent the 
first observation that Bcl-xL undergoes cell cycle-dependent phosphorylation on Ser49.  
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 Among all the phosphorylation mutants deployed in these studies, only Bcl-xL 
Ser49Ala and Ser62Ala showed phenotypic functional effects on the stability of the G2 
checkpoint and the SAC and on the kinetics of cytokinesis and mitotic exit. With flow 
cytometry assays, we designed experimental protocols to screen the effects conferred by 
these mutants, monitoring the stability of VP16-induced G2 arrest and microtubule 
poisoning-induced SAC as well as the kinetics of cytokinesis and mitotic exit. 
Simultaneously, these screening assays also monitored the kinetics of cell death. They let 
us distinguish between the cell death and cell cycle functional effects of Bcl-xL 
phosphorylation mutants, and clearly revealed that the cell cycle effects of the Bcl-xL 
phosphorylation mutants Ser49Ala and Ser62Ala are separable from Bcl-xL's function in 
cell death. In synchronized and untreated cells and in drug-exposed cells, Bcl-xL is 
phosphorylated on Ser62 and Ser49 at various phases of the cell cycle, at diverse locations 
in cells, and binds differently to cell checkpoint components, indicating dissimilar 
functions of Bcl-xL Ser62 and Ser49 phosphorylation/dephosphorylation events during 
cell cycle progression and checkpoints.  
 Together, our studies reveal that the unstructured flexible loop domain, that is only 
present in Bcl-xL and Bcl-2 among all Bcl-2 family members 367, has an unique role in 
regulating Bcl-xL's functions on cell cycle progression and checkpoints. Bcl-xL post-
translational modifications within its unstructured flexible loop domain, as postulated in 
1997 by Chang at al. 367, are part of the complex signaling networks that control cell cycle 
progression and checkpoints. Our studies shed some light on the unstructured flexible loop 
domain mystery. 
 
6.2 Bcl-xL phosphorylation and the cell cycle 
6.2.1 Bcl-xL and the MAPK family 
 A few studies have mentioned the relationship between Bcl-xL and JNKs, 
normally activated at G2/M, in taxol-induced Bcl-xL phosphorylation at Ser62 and 
apoptosis 451, 460, whereas Kharbanda et al. suggested that JNKs were associated with Bcl-
xL Thr47 and Thr115 phosphorylation in response to ionizing radiation 454. These 
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investigations were conducted with pharmacological inhibitors but without RNA 
interference. In our studies, we deployed 3 different approaches, including in vitro kinase 
assays, pharmacological inhibitors and siRNA to dissect which kinases are involved in 
Bcl-xL(Ser62) phosphorylation during the G2 checkpoint and the SAC. Our experiments 
implicated both MAPK8/JNK1 and MAPK9/JNK2 in Bcl-xL(Ser62) phosphorylation 
during the G2 checkpoint, but only MAPK9/JNK2 activity was associated with the 
nucleolar localization of phospho-Bcl-xL(Ser62) during the G2 checkpoint. None of them 
was linked with Bcl-xL phosphorylation at the SAC. MAPK8/JNK1 and MAPK9/JNK2 
are known to be strongly expressed during G2, accumulating in the nucleus, and playing 
a role in proper mitosis entry 467-469.  
 During the SAC, we observed that MAPK14/SAPKp38α phosphorylates Bcl-
xL(Ser62). Our experiments were conducted on highly-enriched mitotic cell populations 
collected by mitotic shake-off, to eliminate and avoid contamination or unwanted effects 
of protein kinases involved in the G2 cell population. The importance of 
MAPK14/SAPKp38α during mitosis and the SAC has been well documented in previous 
studies 99, 470-477. Interestingly, Yen and Yang reported that MAPK14/SAPKp38α signals 
CDC20 ubiquitination and proteolysis during the SAC and that it is also necessary for the 
formation of MAD2-bound CDC20 complex 475. As we discerned that phospho-Bcl-
xL(Ser62) binds to the BUBR1-MAD2-BUB3-CDC20- inhibitory complex, we are 
tempted to suggest that, in addition to the MAPK14/SAPKp38α effect on MAD-2-bound 
complex 475, MAPK14/SAPKp38α also influences the dynamics of BUBR1-bound 
complexes via Bcl-xL(Ser62) phosphorylation. MAPK14/SAPKp38α activity, through its 
direct activation of MAPKAPK2, is also required for proper spindle assembly at 
metaphase 476. Consistently, MAPK14/SAPKp38α activity is involved in the timely, 
stable attachment of kinetochores to spindle microtubules, but not in mitotic process 
fidelity 477. It is also suggested that MAPK14/SAPKp38α promotes checkpoint 
satisfaction; in the absence of MAPK14/SAPKp38α activity, the duration of mitosis is 
prolonged by about 40% in non-transformed human RPE-1, 80% in PtK2, and 25% in 
mouse cells 477. This is a similar effect that we noted in cells expressing the 
phosphorylation mutant Bcl-xL(Ser62Ala), with prolonged duration of the SAC. 
Together, MAPK14/SAPKp38α activity was associated with checkpoint satisfaction 477 
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and, in our studies, Bcl-xL(Ser62) phosphorylation was also linked with checkpoint 
satisfaction, facilitating metaphase-to-anaphase transition. MAPK14/SAPKp38α and 
phospho-Bcl-xL(Ser62) appear to work in the same direction for SAC resolution. 
   
6.2.2 Bcl-xL and the polo kinase family 
 PLK1, a serine/threonine protein kinase highly regulated in time and space, is 
involved in multiple key events during G2/M transition and mitosis, playing roles in  
centrosome maturation, spindle assembly, chromosome segregation, cytokinesis and 
mitotic exit (reviewed in 136, 478). Recently, in a series of in vitro experiments, Tamura et 
al. postulated that PLK1 could phosphorylate Bcl-xL at least on 13 residues, including 
Ser23, Ser28, Thr35, Ser43, Ser49, Ser56, Thr69, Ser72, Ser74, Thr109, Ser122 and 
Thr190, but not Ser62 453. They also suggested that Bcl-xL(Ser62) was phosphorylated 
after pironetin treatment by a JNK-related kinase, but not PLK1 453. This contradicts the 
results of our studies. In our experiments, we found that silencing PLK1 reduced the level 
of phospho-Bcl-xL(Ser62) at the G2 checkpoint induced by DNA damage, and in the 
early phase of mitosis, the latter investigation being performed on highly-enriched mitotic 
cells collected by mitotic shake-off without drug treatment. Because silencing PLK1 
resulted mostly in cells arrested in G2, the mitotic shake-off protocol was essential to 
collect cells in early mitosis. Proper control included the monitoring of phospho-histone 
H3(Ser10) in these samples. In the experiments by Tamura et al., in cells treated with 
pironetin and siRNA targeting PLK1, no control of mitotic cells was included, suggesting 
that their preparations could be contaminated by a high level of G2 cells. Indeed, we did 
observe that both MAPK8/JNK1 and MAPK9/JNK2 were involved in Bcl-xL(Ser62) 
phosphorylation during DNA damage-induced G2 arrest. We did not monitor the effect 
of PLK1 on Bcl-xL(ser62) during normal synchronized and unperturbed cell cycle 
progression at G2.  It is possible that PLK1-mediated phosphorylation of Bcl-xL during 
G2 only occurs during DNA damage.  
 The functions of PLK3, a PLK family member, are much less known (reviewed in 
479). In the interphase, PLK3 has been observed in centrosomes and nucleoli 307, 480. 
During mitosis, it is found at spindle poles and midbody during cytokinesis 307, 481. PLK3 
activity increases rapidly after DNA damage in an ATM-dependent manner, and is 
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involved in G2 arrest by phosphorylating and inhibiting CDC25C phosphatase 145, 482-484. 
Overexpression of PLK3's polo box domain-only, which acts as a dominant negative 
form of PLK3, causes mitotic arrest and cytokinesis defects 307, 481, 485. Similarly, cells 
treated with siRNA targeting PLK3 presented incomplete cytokinesis and produced 
multinucleated cells 486. In our in vitro kinase screening, PLK3 was the only protein 
kinase that strongly phosphorylated Bcl-xL in Ser49, experiments that were confirmed by 
mass spectrometry. siRNA targeting, during G2 arrest, confirmed that PLK3 is the key 
enzyme in Bcl-xL(Ser49) phosphorylation. This is in agreement with the known function 
of PLK3 as a negative regulator of G2/M transition, participating in the G2 checkpoint, 
by phosphorylating and inhibiting CDC25C phosphatase 145. During cytokinesis, our 
results are not only correlative but also strongly indicative of PLK3’s involvement, 
having demonstrated correlations between PLK3 expression and activity, failure to enter 
cytokinesis and to phosphorylate Bcl-xL at Ser49. Our study is the first to reveal that Bcl-
xL is phosphorylated on Ser49 during cell cycle progression and cytokinesis. 
 
 
6.2.3 Bcl-xL and CDK1(CDC2) kinase 
 Several contradictions arose between what we observed and a recent publication 
on Bcl-xL and CDK1(CDC2) 466. The authors reported that cyclin B1/CDK1(CDC2) 
kinase is responsible for mitotic arrest-induced Bcl-xL/Bcl-2 phosphorylation. They used 
protein purification and mass spectrometry to identify the major vinblastine-induced 
phosphorylation site in Bcl-xL as Ser62, in the flexible loop domain between BH3 and 
BH4 domains. Then, they showed that vinblastine-induced Bcl-xL/Bcl-2 phosphorylation 
was inhibited in the presence of a CDK1(CDC2) inhibitor. With in vitro kinase assay, 
they also determined that recombinant CDK1(CDC2) could phosphorylate Bcl-
xL(Ser62). In our in vitro kinase assays, active cyclin/CDK1(CDC2) obtained by 
immunoprecipitation was unable to phosphorylate Bcl-xL at Ser62, while active on other 
natural substrates, either histone H1 or basic myelin protein. In their experiments, 
Terrano et al. performed in vitro kinase assays for 5 hours 466. In our studies, in vitro 
kinase assays were run for 30 minutes, a standard protocol employed regularly by 
investigators that probably reflects enzyme kinetics more adequately. Indeed, in cells, 
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cyclin B1/CDK1(CDC2) kinase activity is organized timely, its initial activation 
occurring only 20 to 25 minutes before mitosis onset 120, 121. It is possible that Terrano et 
al. might have detected "star activity" or unspecific activity of their recombinant enzyme 
by conducting their kinase assays for 5 hours. Highly-sensitive controls with radioactive 
32P-ATP as phosphate donor were also deployed in our assays, and other kinases, 
including MAPK8/JNK1, MAPK9/JNK2 and PLK1, exerted a strong effect on Bcl-xL 
phosphorylation within the 30-minute assays, demonstrating much stronger affinity. A 
second conflict is that we routinely encountered recombinant Bcl-xL inhibition of cyclin 
B1/CDK1(CDC2) activity in vitro with 30-minute kinase assays 20. In their experiments 
with CDK1(CDC2) inhibitor, no controls were added to indicate that the cells were 
actually in mitosis. Given the importance of CDK1(CDC2) for G2-to-mitosis transition, 
their cells were probably in G2. We believe that our experiments were conducted with 
more appropriate controls. 
 
 
6.3 Phospho-Bcl-xL(Ser62) and (Ser49) location 
 
6.3.1 Phospho-Bcl-xL(Ser49) and (Ser62) and centrosomes 
 Centrosomes play fundamental roles in organizing the interphase cytoskeleton and 
bipolar mitotic spindle. More recently, centrosomes were revealed as important 
organization centers that integrate cell cycle arrest and DNA repair signaling networks in 
response to genotoxic stress 487. We found that a pool of phospho-Bcl-xL(Ser49) co-
localizes with γ-tubulin at centrosomes after DNA damage in G2-arrested cells. In 
contrast, a pool of phospho-Bcl-xL(Ser62) segregates to centrosomes in early mitosis. 
Although not further exploited in our studies, these observations indicate a function of 
phospho-Bcl-xL(Ser49) and (Ser62) in centrosomes. One important aspect of centrosome 
biology is the control of cyclin B1/CDK1(CDC2) activity for entry into mitosis. Indeed, 
centrosomal activation of cyclin B1/CDCk1(CDC2) precedes its translocation to the 
nucleus, where the accumulation of active cyclin B1/CDK1(CDC2) complexes drives 
cells into mitosis 137. The phosphatase CDC25B activates cyclin B1/CDK1(CDC2) 
complexes at centrosomes, and regulates centrosomal microtubule nucleation at G2/M 
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transition 488-490. Consistent with these observations, Aurora A and PLK1 have also been 
localized at centrosomes 491, 492. In the late G2 phase, Aurora A, first activated at 
centrosomes, is required for initial recruitment and activation of cyclin B1/CDK1(CDC2) 
at centrosomes, and entry into mitosis 492. CHK1 has also been found to prevent the 
premature initiation of mitosis by inhibiting centrosome-associated cyclin 
B1/CDK1(CDC2) through CDC25B phosphatase at centrosomes 118, 493. 
 
6.3.2 Phospho-Bcl-xL(Ser62) and nucleoli  
 The nucleolus, a central hub, coordinates the stress response. Although it was 
primarily associated with ribosome biogenesis, the nucleolus has now been shown to be 
multifunctional and also regulates cell-cycle progression as well as stress signaling, 
including DNA damage responses 494. The nucleolus acts primarily by phased 
sequestration and the release of regulatory proteins, including the tumor suppressor p53, 
p19/ARF and Mdm2 proteins, CDC14 and PP1 phosphatases, DNA telomerase and the 
DNA helicases Wagner and Bloom 495. CDK1(CDC2) as well as Bcl-xL and Bcl-2 have 
also been reported previously in nucleolar structures 20, 443, 496. Phospho-Bcl-xL(Ser62) 
expression dramatically increases in nucleoli during the G2 checkpoint induced by DNA 
damage, whereas that of the Bcl-xL(Ser62Ala) mutant protein does not. Phospho-Bcl-
xL(Ser62) co-locates and binds to CDK1(CDC2) in nucleoli. These results indicate that 
phospho-Bcl-xL(Ser62) could timely trap CDK1(CDC2) in nucleoli, thereby preventing 
the release and activation of a CDK1(CDC2) pool during G2 arrest.  
 
6.3.3 Phospho-Bcl-xL(Ser62) and Cajal bodies 
 First identified in human neurons in 1903 by the Spanish neuro-cytologist 
Santiago Ramon, Cajal bodies have since been described in many other organisms and 
cell types 497. They are primarily involved in distinct cellular pathways, including small 
ribonucleoprotein biogenesis as well as histone mRNA processing 498. In addition, Cajal 
bodies are linked to the regulation of cell-cycle progression, and their number and 
composition vary throughout the cell cycle, disappearing, like other interphasic nuclear 
structures, at early mitosis with nuclear membranes 499. They are also intimately linked 
with the nucleolus, and encompass dynamic trafficking and fusion with nucleolar 
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structures, although the regulation of these processes are not yet understood 495, 499, 500. 
Phospho-Bcl-xL(Ser62) has been observed in Cajal bodies in interphasic cells in our 
studies, and further experiments, including fluorescence time-lapse microscopy imaging 
in living cells, will be required to further investigate the dynamic relationship and 
trafficking, if any, between thems and nucleoli during the G2 checkpoint.  
 
 6.3.4 Phospho-Bcl-xL(Ser49) and (Ser62) and microtubules 
 Dynein motor protein plays key roles at almost every step in mitotic spindle 
assembly and function, providing outward force to separate spindle poles during 
anaphase and cytokinesis 271, 272, 275, 501-510. Both phospho-Bcl-xL(Ser49) and Ser(62) 
timely co-localize with dynein at different steps of mitosis. Given the large amount of 
dynein proteins along the spindle, it is unclear if any functional mechanisms couple 
phospho-Bcl-xL(Ser49) and Ser(62) with dynein motor activity. Additional experiments 
are required with other microtubule and spindle markers to dissect these interactions. 
Interestingly, the BH3-only protein Bim is well-known to interact with the dynein light 
chain LC8 and is thereby sequestered in microtubule-associated dynein motor complexes 
in cells 511-513. Bim function at this location is clearly unknown. Considering the high 
affinity between Bcl-xL and Bim and the observations reported by Liu et al. that the 
flexible loop domain is somehow involved in Bcl-xL’s binding to Bim 462, it would be of 
interest to further characterize Bcl-xL-Bim interaction at the level of dynein motor 
protein complexes during mitosis. It would be the first demonstration of an interaction 
between 2 Bcl-2 family members, anti- and pro-apoptotic proteins, with functions 
uncoupled from apoptosis.  
 
6.4 Bcl-xL, cell survival and genomic stability 
 By default, anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, maintain cell 
survival and normal cell homeostasis by inhibiting constitutively-expressed pro-apoptotic 
Bax and Bak proteins 332, 514-518. Mice deficient in the Bcl-x gene manifests abnormal 
development and death of fetal erythroid progenitors and neuronal cells, with the animals 
dying around embryonic day 14 displaying severe defects in development 332. In response 
to cancer radiotherapeutic and chemotherapeutic agents, anti-apoptotic protein like Bcl-
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xL stands out among the most crucial regulators of apoptosis and promotes drug 
resistance and treatment failure 21-30.  During development and in response to various 
cellular stresses, eukaryotic cells must also inhibit anti-apoptotic proteins and activate 
pro-apoptotic proteins to eliminate unwanted cells and undergo apoptosis. This is 
achieved by BH3-only proteins. Subsets of these proteins, BH3-only enabler or 
sensitizing proteins, promote apoptosis by binding to and inhibiting pro-survival proteins, 
such as Bcl-2 and Bcl-xL, whereas BH3-only activator or activating proteins bind to and 
activate multidomain pro-apoptotic Bax and Bak proteins 363, 384. The process eliminates 
unwanted and damaged cells and maintains genomic stability.  
 Apoptosis is a barrier to cancer development and, as a whole biological system, acts 
with tumor suppressive activities 78, 82. However, dysregulation of apoptosis by means of 
anti-apoptotic protein overexpression showed oncogenic properties. Indeed, the Bcl-2 
gene itself was first identified at the chromosomal breakpoint of t(14:18)-bearing B cell 
lymphomas, and found to act as a new class of oncogenes that function to prevent 
apoptosis and sustain cell survival instead of promoting cellular proliferation, and that 
synergize with classical oncogenes for tumor development 519-527. More recent 
observations, that Bcl-2 and/or Bcl-xL modulate the Rad51-dependent homologous 
recombination pathway as well as non-homologous end-joining and DNA damage 
mismatch repair activities 48-51, are consistent with tumor suppressive activities.  
 Our studies show that Bcl-xL plays a role during the G2 checkpoint and the SAC, 
functions that appear independent of Bcl-xL known function on apoptosis. By stabilizing 
the G2 checkpoint after DNA damage, Bcl-xL could either allow more times for DNA 
repair and promote cell survival, or facilitate the establishment of premature senescence. 
These effects of Bcl-xL could have dramatic consequences on cell responses to 
radiotherapy and chemotherapy. During mitosis, by facilitating the progression of 
mitosis, acceleration of SAC resolution and mitotic exit, Bcl-xL could increase genomic 
instability in presence of unattached kinetochores. In addition, we also reported that 
silencing Bcl-xL expression leads nocodazole-exposed cells to tetraploidy and 
binucleation. These observations are consistent with the tumor suppressive activity of 
Bcl-xL, to maintain genomic stability. Our work is also "in line" with modern cell 
biology studies indicating, more and more, that gene expression is only the beginning. 
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Post-translation modifications, location and protein-protein interactions govern the 
various cellular functions of a given protein.  Additional works will be required to clearly 
evaluate the consequences of Bcl-xL expression, phosphorylation and location on cell 
cycle progression and checkpoints, particularly in cell responses to radiotherapy and 
chemotherapy. 
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7. Conclusion 
 
 Our studies uncovered novel Bcl-xL functions during cell cycle progression and 
checkpoints. Major findings are summarized in Figure 12. 
Figure 12. Schematic illustration of major findings in these studies 
 
 
7.1 Major findings  
 The 1st appended manuscript reports that Bcl-xL undergoes Ser62 
phosphorylation during the normal cell cycle and in DNA-damage-induced G2 arrest. 
PLK1 and MAPK9/JNK2 are responsible for Bcl-xL(Ser62) phosphorylation and 
progressive accumulation in nucleolar structures during the stabilization of DNA 
damage-induced G2 arrest. This function of phospho-Bcl-xL(Ser62) was clearly 
separable from Bcl-xL's known purpose in apoptosis, as the Bcl-xL(Ser62Ala) 
phosphorylation mutant retained its anti-apoptotic effect but lacked the G2-arrest 
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stabilization function. Phosphorylation of Bcl-xL(Ser62) is associated with its 
translocation into the nucleolus after DNA damage, where it will meet CDK1(CDC2). It 
is suggested that phospho-Bcl-xL(Ser62) participates in the G2 checkpoint by trapping 
CDK1(CDC2) in nucleolar structures. 
 The 2nd appended manuscript indicates that during the SAC, PLK1 and 
MAPK14/p38α mediate Bcl-xL(Ser62) phosphorylation, binding it to the inhibitory 
CDC20/MAD2/BUBR1/BUB3 complex in a way that accelerates SAC resolution. 
Silencing Bcl-xL expression also leads nocodazole-exposed cells to tetraploidy and 
binucleation, consistent with Bcl-xL function in genomic stability. Phospho-Bcl-
xL(Ser62) also localizes in centrosomes with γ-tubulin and along the microtubule spindle 
with dynein motor protein, but its functions at these locations were not further addressed 
in this study. Again, phospho-Bcl-xL(Ser62) function in mitosis appears to be separable 
from Bcl-xL’s known role in apoptosis. 
 The 3rd appended manuscript discloses a yet uncharacterized phosphorylation site 
within Bcl-xL. Bcl-xL(Ser49) is phosphorylated during normal cell cycle progression and 
checkpoints. Interfering with Bcl-xL(Ser49) phosphorylation destabilizes DNA damage-
induced G2 arrest and slows entry into cytokinesis, but has no effect on the kinetics of 
VP16- and taxol-induced apoptosis. Our data indicate that PLK3 is involved in Bcl-
xL(Ser49) phosphorylation at the G2 checkpoint and cytokinesis.  
 
7.2 Future directions 
 These studies yield many future directions to further understand the role and 
functional importance of phospho-Bcl-xL(Ser49) and (Ser62) during cell cycle 
progression. Dynamic protein location and interaction with components of cell cycle 
checkpoints and microtubules during mitosis will be addressed by time-lapse 
fluorescence microscopy imaging in living cells and with Forster resonance energy 
transfer monitoring 385. To achieve this goal, wt Bcl-xL, Bcl-xL(Ser49Ala), Bcl-
xL(Ser49Asp), Bcl-xL(Ser62Ala), Bcl-xL(Ser62Asp) and the dual mutants Bcl-
xL(Ser49Ala/Ser62Ala) and Bcl-xL(Ser49Asp/Ser62Asp) will be generated in a 
lentivirus expression system coupled with a fluorescence tag and expressed in cells. First, 
we will monitor their dynamic movement and location in synchronized cells and cells 
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exposed to DNA-damaging agents and microtubule poisons. To confirm interactions with 
CDK1(CDC2), BUBRI-MAD2-BUB3-CDC20 complex and dynein motor protein 
complex, these will be expressed with another fluorescent tag, and co-localization 
monitored by time-lapse fluorescence microscopy in living cells and with Forster 
resonance energy transfer, again in synchronized cells and cells exposed to DNA-
damaging agents and microtubule poisons 385. 
 To further dissect Bcl-xL interaction with BUBR1-bound complexes, we will 
deploy a cell-free system recently described by Kulukian et al. to study the kinetics of 
formation of these complexes 262. Briefly, in this cell-free system, kinetochore-mediated 
SAC signaling is reconstructed by adding sequentially, one by one, purified components 
of the SAC and then measuring the ubiquitin-ligase activity of APC/C-CDC20 on 
purified cyclin B1. By incorporating recombinant wt Bcl-xL, Bcl-xL(Ser49Ala), Bcl-
xL(Ser49Asp), Bcl-xL(Ser62Ala), Bcl-xL(Ser62Asp) and the dual mutants Bcl-
xL(Ser49Ala/Ser62Ala) and Bcl-xL(Ser49Asp/Ser62Asp) to this system, we will 
hopefully dissect the molecular interactions between Bcl-xL with MAD2- and BUBR1-
bound complexes and their effects on APC/C-CDC20 activity. 
 Two approaches will be taken to further investigate the involvement of wt Bcl-xL 
and various mutants in genomic stability: BJ normal foreskin fibroblast cells, and C. 
elegans, an in vivo model 528. BJ normal foreskin fibroblast cells have a reported normal 
diploid karyotype at population doubling 61 but an abnormal karyotype at population 
doubling 82 529. We will infect these cells with our constructs coding for wt Bcl-xL as 
well as all mutants and, in parallel, silence the expression of endogenous Bcl-xL protein 
to eliminate background. To do so, we will deploy a targeted sequence located in the 3'-
end of the non-coding region of Bcl-xL mRNA, as described in the second manuscript. 
Infection will be evoked around doubling time 40. Then, at 5 doubling time intervals, we 
will analyze cell karyotypes. Our hypothesis is that cells expressing Bcl-xL(Ser62Ala) 
and (Ser49Ala) mutants  will rapidly show abnormal karyotypes. 
 In C. elegans, we will use Ced 9 mutant animals and re-introduce wt Bcl-xL as 
well as all Bcl-xL mutants. We expect that all Bcl-xL constructs will reverse the Ced 9 
mutant phenotypes as all Bcl-xL constructs, including the mutants, should retain their 
anti-apoptotic function. However, it is expected that the Bcl-xL(Ser62Ala) and 
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(Ser49Ala) mutants might confer some genomic instability in C. elegans. In the long-
term, mice models could be developed as well.  
 Finally, postulating that Bcl-xL Ser49 and Ser62 are important for genomic 
stability, an in silico search could be performed to investigate if any sequencing already 
done on clinical tumor specimens could be informative for the presence of mutations 
within these residues. Alternately and/or in parallel, high-throughput sequencing of Bcl-
xL could be undertaken on tumor tissue banks already existing in Canada. These 
investigations will indicate if Bcl-xL Ser49 and Ser62 mutations occur in human tumors 
and, eventually, correlation with treatment outcome could be addressed.  
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